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Abstract 
Prior to the licensing and introduction of rotavirus vaccines in 2006, rotavirus was 
the most common cause of severe acute gastroenteritis (AGE) in children <5 years of 
age, with the majority of disease burden occurring in children under two years of age. 
In the UK rotavirus was estimated to result in 80,000 general practice (GP) 
consultations in children <5 years of age each year, together with 45% of 
hospitalisations and 20% of emergency department (ED) attendances for AGE. 
The UK introduced rotavirus vaccination into the routine childhood immunisation 
programme in July 2013. Whilst rotavirus vaccine impact on severe disease has been 
well described, uncovering vaccine impact on gastrointestinal (GI) disease outcomes 
across primary and secondary care is of public health importance; particularly 
understanding the extent of indirect effect or ‘herd’ protection. It is also important to 
ensure vaccine uptake and impact is equitable. As incidence of AGE is highest in the 
most socioeconomically deprived populations and vaccine uptake is often lower, 
measuring vaccine impact in relation to socioeconomic deprivation is critical. These 
themes were addressed through a series of inter-linked studies, for three years post-
vaccine introduction (July 2013 to June 2016), in Merseyside, UK. 
In Merseyside, uptake of first-dose of rotavirus vaccine was 91.4%, and 86.7% for 
completion of the two dose schedule. Whilst, the risk of non-vaccination was higher 
in the most socioeconomically deprived populations.  
At a large acute paediatric hospital, after two seasons post-rotavirus vaccine 
introduction, laboratory confirmed rotavirus gastroenteritis (RVGE) hospitalisations 
reduced by 84% in vaccine-eligible children <2 years of age and 69% in vaccine 
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ineligible children 2-4 years of age. Reductions in both hospital- and community-
acquired RVGE was comparable (83%). 
Interrupted time-series analysis of multiple routine healthcare datasets for three 
seasons post-vaccine introduction showed that among children <5 years of age, the 
incidence of RVGE and AGE hospitalisations decreased by 80% and 44%, 
respectively, ED attendances fell by 23%, walk-in-centre attendances by 32% and 
GP consultations by 13%. Vaccine impact was greatest during the rotavirus-season 
and for vaccine eligible age groups. The rate of hospitalisations averted was higher 
among infants in the most deprived communities compared to the least deprived. In 
adults aged 65 years or older, AGE hospitalisations fell by 25%.  
Analysis of a GP birth cohort of children born between May 2010 and June 2016, 
demonstrated an overall rotavirus vaccine effectiveness (VE) of 11% against AGE. 
However, when using established methods to estimate direct and indirect VE, 
estimates were improbable, suggesting unmeasured confounding, and flawed 
comparator populations. A novel method using propensity score analysis was 
developed to deal with these issues through balancing comparator populations. 
Applying the alternative method produced epidemiologically and biologically 
plausible direct (8-11%) and indirect (1-4%) estimates of VE against GP 
consultations for AGE.  
In summary, rotavirus vaccination reduced healthcare use for multiple GI disease 
outcomes across the healthcare system. Effects were greatest in infants, for specific 
rotavirus outcomes, for severe disease, and in the rotavirus season. Furthermore the 
reduction of GI disease in older populations suggests ‘herd’ protection. Prioritising 
vaccine uptake in the most socioeconomically deprived communities is likely to give 
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the greatest health benefit in terms of reducing population disease burden. Finally, a 
novel approach for measuring VE has been developed to mitigate against 
unmeasured confounding. This methodology will be valuable for studies using 
routine healthcare data to measure the broader public health impact of vaccines using 
syndromic non-specific endpoints.  
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1 Introduction: rotavirus and rotavirus infection 
1.1 Rotavirus biology and classification 
Rotaviruses were first identified in humans in 1973 by Bishop and colleagues in the 
duodenal mucosa of children with gastroenteritis (1). These virus particles identified 
by Bishop were  linked to earlier descriptions of viruses identified as causing severe 
diarrhoea in animals (1–3). They were named rotaviruses due to their wheel like 
structure and icosahedral shape with rotational symmetries (like an old fashioned 
football) seen under electron microscopy (4).  
Rotavirus is a double-stranded segmented RNA virus, with a non-enveloped capsid. 
The capsid consists of three layers: the inner core, composed of the viral protein 
(VP) VP2, which contains the viral genome and VP3 and VP1; the middle capsid 
formed by VP6; and the outer capsid containing VP7 and VP4, which form the viral 
spikes. The middle capsid antigen (VP6) defines eight groups of rotavirus (A-H). In 
humans the majority of rotavirus disease is caused by group A rotaviruses (2,5), 
which are further classified by the sequence diversity of genes encoding their outer 
capsid. The VP7 is a glycoprotein that determines G-types and the VP4 is protease 
sensitive protein that determines P types, both of these proteins elicit type-specific 
neutralising antibody responses (2,5). Furthermore, whole genome sequencing has 
allowed rotavirus strains to be classified according to genotype constellations based 
on all 11 genome segments (6,7). For this whole genome classification, the genetic 
backbone constellation (defined by nine gene segments excluding VP7 and VP4) can 
be used to define genotype constellations (6,7). Among human group A rotaviruses 
there are two common genotype constellations: Wa-like and DS-1 like (6,7).  
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The segmented structure of the rotavirus genome means it is possible for rotaviruses 
to reassort during infections with multiple strains, and because VP7 and VP4 can 
segregate independently different G- and P- type combinations can co-circulate (8,9). 
This exchange of genetic material can lead to emerging novel strains, including 
zoonotic strains from reassortment between animal and human rotavirus strains (10). 
 
Figure 1-1 Simplified diagram of the location of the rotavirus structural 
proteins and overall virus structure  [Source Graham Colm English Wikipedia] 
1.2 Transmission and symptoms  
Transmission of rotavirus is by the faecal-oral route and can be person to person, via 
contact with contaminated surfaces, water and food. Because rotavirus is robust and 
has a low infectious dose (10-100 virus particles) it is highly transmissible (11,12). 
Rotavirus infection has a short incubation period, typically between 24 and 48 hours 
(13), followed by a rapid onset of symptoms of diarrhoea, vomiting and dehydration. 
Although acute gastroenteritis (AGE) is the most common set of symptoms 
associated with rotavirus, afebrile and febrile benign convulsions and other 
neurological conditions have been described (14). The severity of symptoms is 
variable and depends on a wide variety of host pathogen factors. If symptoms go 
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untreated infection can result in death, with young children living in low income 
countries at highest risk.   
1.3 Diagnosis of rotavirus infection 
There are a number of ways to diagnose rotavirus infection; symptoms alone cannot 
be used because of shared commonality with other pathogens and non-
communicable diseases. However, rotaviruses can be easily detected using standard 
laboratory procedures, with varying degrees of specificity and sensitivity. Faecal 
specimens are normally used and because of the high viral load during symptomatic 
infection, visualisation of viral particles is possible using electron microscopy (2). 
However, laboratory detection of rotavirus gastroenteritis (RVGE) in humans using 
electron microscopy has low sensitivity. This technique was replaced with antigen 
based assays, such as enzyme-linked immunosorbent assay (ELISA) using 
antibodies against the inner capsid antigen VP6 (15). This method is recommended 
by the World Health Organization (WHO) and correlates well with clinical disease 
but commercial ELISA kits generally can only detect group A rotaviruses (16). 
Diagnostic testing protocols for rotavirus differ between countries / regions and must 
therefore be considered when describing disease (17,18). 
Molecular techniques such as, reverse transcription-quantitative polymerase chain 
reaction (qRT-PCR) can be used to detect rotavirus in stool samples and distinguish 
between rotavirus groups. Furthermore qRT-PCR can be used to identify G and P 
types using standardised methodologies (17,18). The sensitivity of qRT-PCR 
compared to ELISA means that it can detect rotavirus shedding in faecal samples 
from asymptomatic individuals (16,19,20). Due to the good correlation between 
ELISA and clinical disease it has been used to identify cut-offs for qRT-PCR 
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equivalent to clinical disease (21,22). These cut-offs have become more important as 
molecular techniques are used more frequently in diagnostic laboratories. 
1.4 Rotavirus epidemiology 
1.4.1 Infections and susceptibility 
During a person’s life they experience repeat rotavirus infections often as 
asymptomatic episodes. Rotavirus has normally infected the majority of children by 
3-5 years of age (5). Severe symptomatic infection normally follows primary or early 
exposure to rotavirus, a level of protection is then provided against subsequent 
infections (23). A prospective birth cohort study from Mexico showed that 96% of 
children under 2 years had experienced a primary rotavirus infection. Also, showing 
that following primary infection the host / child has reduced susceptibility to 
secondary infections and that subsequent infections are more likely to be caused by 
different genotypes to that causing primary infection (24). The nature of host 
susceptibility helps to drive the age distribution of symptomatic cases with the 
majority occurring in children 4-24 months of age (2,5,25). Older children having 
already had multiple infections and therefore reduced susceptibility. Thus, by late 
childhood and adulthood, severity and frequency of clinical disease has declined; 
with the proportion of asymptomatic infections relative to symptomatic infections 
increasing (5,24). However, epidemiology of rotavirus infections in older children 
and adults is heavily affected by case presentation to healthcare establishments and 
testing protocols (26).  
1.4.2 Global rotavirus disease burden in children under 5 years 
Prior to licensing and routine use of rotavirus vaccination, rotavirus was the leading 
cause of AGE in children under the age of five years. Rotavirus was estimated to be 
responsible for 450,000 deaths globally (Figure 1-2); with over 90% of deaths 
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occurring in developing countries (27,28). Whilst mortality from rotavirus infections 
is low in high income countries they do cause substantial severe morbidity and 
burden on healthcare resources (29,30). Using a range of country specific incident 
rates from 1986-2000 it was estimated that in high income countries that rotavirus 
causes 223,000 (range 142,000–358,000) hospitalisations and 7,122,000 (range 
2,123,000–17,881,000) episodes of RVGE  requiring only home care per year (28). 
Rotavirus is also an important cause of nosocomial (healthcare-acquired) diarrhoea 
in children under 5 years of age. In Europe rotavirus was estimated to be responsible 
for 31-87% of paediatric nosocomial diarrhoea (31). 
In the USA rotavirus has been estimated to cost over $300 million to the healthcare 
system and nearly $1 billion in society costs (e.g. loss of earnings, childcare) (32).  
 
Figure 1-2 Estimated rotavirus disease burden in children <5 years of age, prior 
to rotavirus vaccine introduction  (28) 
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1.4.3 Seasonality 
Seasonality of rotavirus infections is very variable by geographical region. There has 
been speculation that genotype diversity, geographical location, climate and country 
development level all affect seasonality. However, there is no evidence that there is 
one unifying factor that explains why some regions have seasons and others 
experience year round disease (33). In Western Europe there is strong seasonality of 
disease in the Northern Hemisphere during the winter / spring months (Figure 1-3). 
There is some indication that rotavirus infections spread in Europe from South to 
North and West to East, with similar patterns described in the US (18,34–36). A 
recent review of global studies established that high income countries experience 
disease patterns which were more likely to be seasonal (33). 
 
Figure 1-3 Rotavirus seasonality in European countries participating in 
EuroRotaNet rotavirus surveillance network; prior to routine rotavirus vaccine 
introduction, September 2006 to August 2013 [EuroRotaNet data (17)] 
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1.4.4 Epidemiology in adults 
While the epidemiology and disease burden of RVGE in infants and young children 
is well described, the burden of rotavirus disease in older children and adults is less 
well understood. Whilst nearly all adults would have been infected by rotavirus 
across their life, rotavirus infections in adults are normally milder than in young 
children resulting in less clinical presentation (37–39). Furthermore the rates of 
infection and clinical presentation with symptoms is variable by geographical area 
and a country’s level of development (40). In the early 1980s a small hospital based 
study in the UK investigated the aetiology of acute diarrhoea hospitalisations in 73 
adults and identified that 4% were caused by rotavirus (41). Similarly rotavirus was 
identified in 3% of adults with diarrhoea presenting at a Swedish infectious disease 
clinic (42), and 5% of adults admitted to hospital with diarrhoea in Thailand (43). A 
hospital based surveillance study in Bangladesh also identified rotavirus in 4% of 
≥60 year olds with diarrhoeal disease (44). There have however, been studies in 
adults in which rotavirus is detected more frequently. Another small study conducted 
in Australia in 74 adults with acute diarrhoea identified rotavirus as the second most 
common pathogen (17%) and a Mexican study identified rotavirus in 64% of adults 
with moderate to severe AGE (45,46).  
Whilst most studies have been in the hospital setting focusing on moderate to severe 
RVGE, there is limited research on RVGE in adults in the community setting. A 
prospective surveillance study conducted in the UK showed that in those aged 5 
years and older, rotavirus was detected in approximately 4% of primary care 
consultations and 3% of community episodes for infectious intestinal disease (30,47).  
Several studies have also indicated that whilst endemic rotavirus season is driven by 
young children, adult disease is less season-specific, instead, occurring all year 
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(36,40). Although, rotavirus infection does occur in adult settings, such as long-term 
care facilities (48), the highest risk of rotavirus infection in adults appears to be in 
adults in contact with children with rotavirus infection (37–39). These findings 
suggest exposure to rotavirus is likely to vary dramatically over a person’s life and 
that young adults without dependents would be at the lowest risk of exposure to 
rotavirus.  
1.5 Prevention of rotavirus gastroenteritis 
Rotavirus can spread easily and infects nearly all children in early life, although 
good cleanliness and hand washing are good practice, routine handwashing in the 
home is ineffective at reducing rotavirus transmission (49–51). Whilst programmes 
which improve sanitation, hygiene and water supply in low-income countries is 
estimated to reduce diarrhoeal disease incidence by approximately 30%, the 
comparable rates of rotavirus disease (not severity) in low- and high-income 
countries (despite better sanitation in high-income countries), indicate that these 
improvements have minimal impact on rotavirus transmission (50,52–54). Therefore, 
vaccination against rotavirus currently represents the most effective preventative 
measure against rotavirus disease (49,51,54).  
1.5.1 A brief history of rotavirus vaccines 
Research into the development of vaccines against RVGE began in the late 1970’s. 
Using animal models it was demonstrated that previous infections with animal 
strains protected an animal from infection with human rotaviruses (55). Therefore it 
was supposed that live attenuated (reduced virulence) animal strains when given to 
humans orally could copy the immunity conferred by natural infection and prevent 
severe disease (14,54). This led to the development of live attenuated animal 
reassortment vaccines; however, field trials indicated variable efficacy (56–58). 
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Because of the broad diversity of rotaviruses any vaccine needs to show good cross-
protection against the predominant genotypes. Therefore, to achieve better cross-
protection, multivalent human - animal reassortment vaccines and live attenuated 
human rotavirus vaccines have been developed (5).  
The first licensed rotavirus vaccine was RotaShield® (Wyeth Laboratories) and it 
began use in the US in 1998. However, RotaShield® was withdrawn from use in 
1999 following associated incidences of intussusception (59). Intussusception is 
when one segment of the intestine folds into another section of the intestine and can 
result in an obstruction, whilst intussusception can occur in non-vaccinated infants 
and can be remedied using medical procedures, it is potentially fatal (60). 
Although RotaShield® remained licenced it was removed from use. Subsequently, 
since 2006, two major vaccines have been licensed for use; a three dose pentavalent 
human-bovine reassortment vaccine (RV5, RotaTeq®, Merck & Co., Inc.) and two 
dose live attenuated monovalent vaccine (RV1, Rotarix®, GlaxoSmithKline 
Biologicals, Belgium) (54) (Table 1-1).  
Clinical trials have shown both to be highly effective. In high-income countries with 
low mortality rates the vaccine efficacy in the first two years of follow-up is over 
80% against severe (defined using a score cut-off from either a Clark or Vesikari 
Clinical Severity Scoring System) rotavirus disease (61–63). But as income declines 
and mortality increases the efficacy of the vaccines decrease, with reported efficacy 
of ~39-49% in countries with high mortality rates (61,64,65). Although the efficacy 
is lower in high mortality countries the absolute benefit is substantial due to the 
higher baseline burden of disease (66). Currently no one factor has been identified as 
being responsible for the lower efficacy of the vaccines in high mortality countries. 
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There has been speculation that this is due to lower systemic immune response to 
both natural infection and rotavirus vaccination (67). Indeed two recent nested-case 
control studies of Ghanaian and Pakistani infants has suggested that the composition 
of the gut microbiome correlates with the immunogenicity of rotavirus vaccines and 
could be contributing to the reduced efficacy in developing countries (68,69).  
A further consideration is whether these rotavirus vaccines can induce heterotypic 
immunity. This is crucial, because of the variety of rotavirus strains circulating co-
currently, which may be heterotypic to the G and P types contained in the vaccine. 
Efficacy studies have indicated that both RotaTeq® and Rotarix® provide heterotypic 
protection, although this may be to a reduced degree for strains with G or P types 
which do not match the vaccine strain (54,70,71). Reassuringly a recent meta-
analysis of the strain specific effectiveness of rotavirus vaccines also suggest that 
both vaccines exert similar protection against homotypic and heterotypic rotavirus 
strains (72). However, an important component of the long-term evaluation of 
rotavirus vaccine programmes will be the continued surveillance of rotavirus strain 
distributions to identify possible vaccine induced changes in rotavirus strain 
distributions and any emerging new strains.  
As of April 2017 over 90 countries had introduced rotavirus vaccination into 
national immunisation programmes worldwide and many more have rotavirus 
vaccine available at state level or via private healthcare insurance (Figure 1-4) (73). 
Since the first introduction of the current era of rotavirus vaccines in 2006, 
observational and ecological studies have been conducted to assess the effect of 
rotavirus vaccines in the ‘real world’. The next section provides an overview of 
methodologies that are being employed to assess the effect of rotavirus vaccines 
after introduction into public health programmes. 
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Table 1-1 Details of two licensed rotavirus vaccines.(16) 
 Rotarix® 
GlaxoSmithKline Biologicals 
RotaTeq® 
Merck & Co 
Indication For the active immunisation of infants aged ≥6 weeks against RVGE 
Composition Live attenuated monovalent human 
rotavirus strain  
G1P[8] 
Live attenuated pentavalent  bovine 
(WC3)-human reassortant strains 
G1P[5]; G2P[5]; G3P[5]; G4P[5]; 
G6P[8] 
Form Orally administered in liquid formulation 
Administration  Two doses 
 First dose from 6 weeks of age 
 Minimum of 4 weeks between 
doses 
 Schedule should be completed by 
24 weeks of age 
 Three doses 
 First dose between 6 and 12 
weeks of age 
 Minimum of 4 weeks between 
doses 
 Schedule should be completed 
by 26 weeks of age 
 
 
 
Figure 1-4 Countries that have introduced rotavirus vaccine 
 [Source: IVAC, accessed 20th February 2018]  
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1.6 Methodologies for measuring population vaccine effectiveness and 
impact 
Vaccines can have an effect at both the individual (direct protection) and population 
level (indirect protection) (74). Vaccine efficacy represents the direct effect of 
vaccination in individuals receiving vaccine under rigorously controlled conditions 
(75). This is normally measured in pre-licensure clinical trials. Whereas, vaccine 
effectiveness (VE) is for measuring vaccine performance in a population after 
vaccine introduction (76–78). Observational studies are the principal study design 
used for calculating VE (79). These studies are informative to public health as they 
measure both the effect on the individual and the population (74,77). The types of 
population effect include the indirect, total and overall effect. The indirect effect is 
the herd protection conferred by the vaccine on the unvaccinated (76); the total effect 
is a combination of the direct effect and indirect on vaccinated individuals (77,79); 
and the overall effect is a population weighted combination of the indirect effect on 
unvaccinated individuals and the total effect in vaccinated individuals. This overall 
effect allows health authorities to evaluate the population impact of a vaccine 
programme including calculation of vaccine cost-effectiveness (80,81).  
To measure the direct effect studies normally require one population in which the 
vaccine is available and then a comparison of the measured outcome in those that 
have received the vaccine with those that have not (77,79,80). In order to measure 
the indirect, total and overall effects of vaccination two populations are required, one 
with and one without vaccination. These populations are normally separate in time 
and / or space (Figure 1-5) (77). The epidemiological study designs employed for 
measuring VE predominately include: case-control, cohort, screening, outbreak, and 
ecological. Each design has biases and pros and cons, and the type of effect which 
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can be measured principally depends on the study design and the populations being 
compared (Table 1-2) (77). There are also serological studies, such as correlates of 
protection, which focus on a measurable biological response such as antibody titres 
(82–84). If this response is correlated to disease then they can be used for vaccine 
evaluations. The sections below describe the most common epidemiological study 
designs for assessing VE and population impact.  
 
Figure 1-5 Types of vaccine effect and comparison populations  [VE is the Vaccine 
effectiveness, where Ω is the attack rate (the proportion of cases in a defined population); f is proportion of the 
population vaccinated; t is time.] (74,77,85) 
Table 1-2 Study design and effect type 
Study type Effect type 
Direct Indirect Total Overall 
Cohort Yes Yes Yes Yes 
Outbreak Yes No No No 
Case-control Yes No No No 
Screening No No No Yes 
Ecological No No No Yes 
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Cohort studies 
These are normally conducted by comparing the incidence of an outcome / disease in 
a cohort of vaccinated and unvaccinated persons over a period of observation, either 
prospectively or retrospectively (83,84). Prospective studies are utilised less 
frequently to measure VE due to cost, time and subject dropout (82). However, they 
have been used to measure the long-term effectiveness of varicella vaccination in 
children, influenza VE in older adults and to assess VE of catch-up vaccine 
campaigns during disease outbreaks (86–88). A prospective cohort study can be 
affected by a number of potential biases. Some of these biases fall under a broad 
grouping of selection bias; error introduced when the population under study do not 
accurately represent the general or target population, resulting in reduced external 
validity (89,90). Types of selection bias include: loss to follow-up bias (attrition 
bias), when those who drop out of the study differ systematically from those that are 
not lost; non-response bias, when those who enrol in the study are different from 
those who did not. The healthy entry / healthy worker bias is an example of non-
response bias, when the study includes individuals at baseline that would be likely to 
be more healthy than the general population (90–92).  
Other biases that are commonly present in cohort studies are information bias and 
confounding. Response bias is a type of information bias, which could occur if 
participants systematically under report behaviour or health issues that may affect 
the chance of outcome, an example of this may be underreporting alcohol use (90). 
Confounding can occur when a variable has an association with both exposure 
(vaccination) and outcome (disease). For example, healthcare seeking behaviour / 
healthcare access can be an important confounder in some observational studies. 
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Confounding, information bias and selection bias need to be appropriately controlled 
for in study design or in the study analyses (89,91). 
In retrospective cohort studies that involve primary data collection the chance of bias 
is increased compared to a prospective study, through recall bias (83).  
A version of the cohort study commonly used to measure VE is those using pre-
established healthcare databases which include information on exposure 
(vaccination) and outcome (disease) (85,93–95). It is important in these studies that 
chance of exposure to the outcome is equal between groups or that adequate 
statistical approaches are applied to mitigate for any inequality (96). Often 
differences in health-seeking behaviour between vaccinated or unvaccinated 
individuals can lead to under ascertainment of the outcome and bias in VE estimates 
(82,97).  Unlike case-control studies cohort studies avoid bias associated with 
selecting inappropriate controls and also often allow the calculation of all four effect 
types (82,85), although the accuracy of these estimates can be variable depending on 
the occurrence of cofounders in comparator populations (85). In cohort studies 
typically there is a time element so that survival, relative incidence rates or relative 
hazards can be calculated for vaccinated versus unvaccinated groups. Therefore 
cohort studies will normally measure VE through the formula: E = (1 − RR) × 100 , 
where RR is the relative risk; or, VE = (1 − HR) × 100, where HR is the hazard 
ratio. 
Case-control studies 
Case-control studies are the most common study used in ‘real world’ VE studies 
(80,83,84,98). However, only the direct effect of a vaccine programme can be 
calculated in this design. They recruit based on the endpoint (cases of disease) and 
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establish a control comparator of individuals who have not experienced the outcome 
of interest (79,83,84). It is important that the end-point is specific because non-
specific endpoints can change over time and setting (99). Vaccine status is 
established retrospectively for both groups, normally along with baseline 
characteristics and confounders that may be adjusted for in analyses. These methods 
can be relatively cheap and rapid, but can be problematic if a vaccine programme is: 
highly effective with a large herd effect resulting in a lack of cases; and / or vaccine 
uptake is so low or high that unvaccinated population are likely to have a different 
disease risk to the general population independent of vaccination; and / or vaccine 
uptake is so high most cases are vaccinated so that a larger sample size is needed to 
detect a significant difference in vaccination status between cases and controls. 
Therefore, to increase power and reduce sample size, case-control studies are best 
implemented when vaccine coverage is between 20-80% (100).This may be easiest 
to achieve if the study is conducted as soon as possible after the start date of the 
vaccine programme (99).  
It is also important that cases and controls have an equal risk of exposure and that 
vaccine status is collected in the same robust way from both cases and controls 
(83,97). Often a matched case-control design is utilised using factors such as age, 
sex and geography (99). This is usually for convenience, improving efficiency and 
/or precision or for control in the analysis of unquantifiable social, environment or 
biological factors  (101). However, it is a common misconception that matching 
reduces confounding and it may actually increase the chance of confounding if the 
factors matched are not present in the overall population (101).  
The use of test negative-controls is common in case-control studies. Test negative-
controls are controls, which have the same symptoms as the cases but were negative 
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for the pathogen of interest. It is often logistically advantageous, cost-effective and 
provides a high-degree of comparability between controls and cases because both 
controls and cases are from the same single source (99). It can help to minimise 
selection bias because cases and controls are assumed to have similar health-seeking 
behaviour  reducing outcome ascertainment bias (97). A limitation of the test-
negative design is that there is an assumption that the vaccine under study has no 
effect on disease incidence in the controls. In case-control studies VE is 
predominately measured using a rate difference with the Odds Ratio (OR) in the 
formula: 𝑉𝐸 = (1 − 𝑂𝑅) × 100.  
Screening studies 
The screening method is a variation on the case-control and cohort methodologies, in 
this design the entire population or a sample of the population is used as a reference 
(102–105). In screening studies the number of cases with the outcome of interest is 
required as is the number of cases vaccinated; the comparator is then the vaccine 
uptake in the reference population (84,102). This is less resource intensive than 
retrospective case-control studies and primary data collection cohort studies. Whilst 
the screening method has a role to play in measuring VE it is limited. The method is 
designed to be a rapid preliminary assessment of VE when attack rate data is 
unavailable. As the screening method uses secondary data analysis it is subject to the 
associated biases and relies on accurate measurement of vaccine coverage. 
Furthermore, when herd immunity is provided by a vaccine, and population 
incidence declines in the unvaccinated, the screening method will underestimate VE 
(102). Therefore, the appropriateness of using the screening method is dependent on 
the target vaccine, data quality, and the population; and may need to be followed up 
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with more robust observation methodologies. To measure VE using the screening 
study design the following formula is therefore used: 𝑉𝐸 = (
𝑃𝐶𝑉
1−𝑃𝐶𝑉
) × (
1−𝑃𝑃𝑉
𝑃𝑃𝑉
) ×
100, where PCV is the proportion of cases vaccinated and PPV is the proportion of 
the total reference population vaccinated. 
Outbreak studies 
These studies are best conducted after a disease outbreak in a defined population 
setting such as a school, establishment or city (106–108). In outbreak studies 
measurement of VE is during a defined time-period and setting, using data on 
whether people became infected and / or developed disease in a defined population. 
Relative risk based on cumulative incidence or relative attack rates (the number of 
cases in a specific population dived by population under study) will be used to 
calculate VE: VE = (1 − RR) × 100 , where RR is the relative risk. 
Ecological – population vaccine impact 
These studies normally measure a disease over time e.g. “before and after” vaccine 
introduction. In these types of studies good quality surveillance data is required for a 
number of year’s pre and post-vaccine introduction, any temporal or seasonal trend 
must be taken in to account when assessing a change in disease burden. Temporal 
ecological studies remove the concerns of confounding through health status and 
health seeking behaviour associated with exposure (vaccination) because they do not 
compare the disease incidence in the vaccinated with that in the unvaccinated (97). 
However, in these studies there is the issue that any change or no change in disease 
incidence could be a result of the vaccine or some other factor, natural or otherwise 
(e.g. change in healthcare provision, data quality). Also, within this design there is 
the possibility of reducing some of this cofounding if the vaccine programme has 
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been introduced in phases, group by group (83). In this case a stepped wedge design 
can be utilised; groups of vaccinated and those yet to be vaccinated are compared, 
this could involve random or programmatic selection of groups (84,109). 
Confounding would be reduced as the groups under comparison should have similar 
base-line characteristics (83).  
A common study design for measuring population vaccine impact in the ‘real world’ 
is the interrupted time-series (ITS) (110–113). In the context of vaccine evaluations 
the ITS methodology would follow a disease outcome, over time, prior to an 
intervention (vaccination) to establish a baseline trend and seasonality, then under a 
hypothetical situation where vaccine introduction did not take place the 
counterfactual trend is predicted for the post-vaccine period and compared to the 
actual post-vaccine trend (110). A percentage change can then be calculated from 
this comparison. There is further complexity to the ITS design depending on how the 
vaccine is introduced, for instance, vaccine uptake that reaches a steady state almost 
instantly as a one off step / level change or gradual introduction could be analysed as 
multiple steps (111).  
In reality many published studies which assess vaccine impact are limited in the 
robustness of the analyses by the available data. Often a more crude “before and 
after” approach is used; in which mean / median incidence from the pre-vaccine 
period is compared to the post-vaccine introduction years, with little or no 
adjustment for trend or seasonality (114). Nevertheless, ecological study designs 
using both ITS and simple “before and after” methods have been used to evaluate the 
population impact of a number of vaccines including pneumococcal conjugate (115–
119), varicella (120), influenza (121,122), and rotavirus (112–114,123). 
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In summary, whilst there are variations on all these study designs, such as the case-
cohort, cohort and case-control studies contribute the majority of VE studies 
assessing individual level vaccine effects. Whereas studies aiming to assess vaccine 
impact at the population level will usually utilise an ecological design with varying 
degrees of rigour. 
1.7 Impact of rotavirus vaccination in high income countries 
Since licensing of Rotarix® and RotaTeq® in 2006, the global mortality from 
rotavirus diarrhoea in children <5 years of age has decreased substantially; from an 
estimated 528,000 in 2000 to 215,000 in 2013 (124). While the majority of this 
reduction has resulted from vaccine introduction in low-middle income countries 
(124), many high-income countries have also introduced rotavirus vaccination. 
Belgium and the USA introduced rotavirus vaccination in 2006, followed by Austria 
and Australia in 2007, Finland in 2009 and Israel in 2010. There are also a number 
of countries that have introduced the vaccine privately or regionally, such as in 
Germany, Greece, Italy, and Spain. More recently countries such as, Germany, 
Ireland and Norway, have introduced country wide vaccination. Chapter 3 in this 
thesis provides a systematic review and meta-analyses of observational case-control 
and cohort studies measuring rotavirus VE, whereas studies assessing the overall 
public health impact of rotavirus vaccination through ecological study design are 
described below.  
The majority of rotavirus impact studies have been retrospective using routine 
healthcare databases to assess a change in disease burden post-vaccine introduction 
relative to a pre-vaccine baseline. There have also been a few prospective 
surveillance studies. A number of rotavirus specific outcome measures have been 
reported, predominately RVGE hospitalisations, RVGE laboratory detections and 
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less frequently, RVGE ED visits and RVGE outpatient / GP visits. There have also 
been reports on less-specific disease outcomes such as AGE hospitalisation, AGE 
ED visits and AGE outpatient attendances, as well as, diarrhoeal disease outpatient / 
GP visits. As the US was one of the first countries to introduce rotavirus vaccination 
the majority of published impact studies have been conducted in the US.  
Impact on RVGE and AGE hospitalisations 
In the US RotaTeq® was first recommended in 2006 for routine childhood 
vaccination, this recommendation was expanded to include Rotarix® in 2008. 
Vaccination coverage is variable by state ranging from ~55% to 85% in 2013 for 19-
35 month olds (125). Impact studies covering seasons 2008, 2009 and 2010 showed 
reductions of between 55% and over 80% in RVGE hospitalisations in children <5 
years of age and reductions in all-cause AGE hospitalisations of between 29% and 
50% (126–133). These included studies of: national and state level health databases; 
a sub-national active surveillance study from the New Vaccine Surveillance Network 
of rotavirus diarrhoea; an insurance claims database study; and, local hospital based 
studies of laboratory confirmed rotavirus (126–133). The largest reductions in these 
studies were in vaccine eligible infants <12 months of age and 1 year olds, with a 
number of these studies also showing evidence of herd protection among 
unvaccinated groups (132,133). Additionally, data from the national healthcare 
database, from hospitals in 42 states, showed significant reductions in both RVGE 
coded discharges and all-cause AGE hospitalisations in 2008, 2009 and 2010 among 
5-14 year olds and 15-24 years (134,135). These reductions were highest during the 
winter / spring peak rotavirus season strengthening the evidence for an indirect effect 
of rotavirus vaccination.  
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Australia introduced rotavirus vaccination in specific states / territories that had high 
RVGE disease burden in 2006, followed by full inclusion in the national 
immunisation programme in 2007. Both Rotarix® and RotaTeq® are used in 
Australia, dependent on the state / territory choice. National vaccine uptake reached 
over 80% in 2007 and 2008 (136). In a national healthcare database study RVGE 
hospitalisations in children under 5 years of age reduced by 67% and 45% in 
2007/08 and 2008/09, respectively (136). There was also a 38% decline in non-
rotavirus coded AGE hospitalisations in 2009/10 (137). A one site paediatric hospital 
study of RVGE hospitalisations in children aged  under 5 years of age showed 
similar reductions of over 65% in 2008-2009 (138). Herd protection from rotavirus 
vaccination was also suggested through a further study at the same hospital site with 
reductions in RVGE hospitalisations in older age groups, including those ineligible 
for vaccination (139). 
Belgium introduced vaccination in 2006 and achieved over 90% uptake of vaccine 
(predominately Rotarix®) rapidly (140). There were large reductions in RVGE 
hospitalisations in the vaccine eligible age group of between 60-80% (141) and 
smaller but significant reductions in older children (141,142).  
Since vaccine introduction in Austria, both RotaTeq® and Rotarix® vaccines have 
been used at different times, vaccine uptake was reported at over 87% by 2008, and 
in age eligible children up to 20 months of age RVGE hospitalised cases decreased 
by 74% in the first full surveillance year post-vaccine introduction (143,144). This 
impact has been sustained in children under two years of age up to 4 years after 
introduction, with reductions of over 80% (145). Older vaccine eligible cohorts have 
also seen sustained reductions of over 60% in children 2-3.5 years (145). Herd 
protection is also likely; there were small reductions of approximately 20-22% in 
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unvaccinated older children in 2008 and 2009 (143). However, caution is required, 
as in 2011, increases in RVGE hospitalisations were seen in children aged 5-14 years 
(145).  
In Finland where RotaTeq® is the sole vaccine in use, vaccine uptake reached over 
95% for the full schedule comparable to other childhood vaccines (146). In the first 
complete season post-vaccine introduction, RVGE hospitalisations fell by 80% in 
infants and all-cause AGE hospitalisations fell by over 54%. Herd protection was 
also indicated with RVGE hospitalisations falling by over 53% and AGE 
hospitalisations falling by over 27% in children aged 1-4 years who predominately 
would have been vaccine ineligible (146). The impact of vaccination in Finland has 
been shown to be sustained up to 3 years post-vaccine  introduction (147,148).   
In Germany routine rotavirus vaccination has been recommended by regional health 
authorities since 2008. Rotavirus vaccine was only available through health 
insurance in some states, and state-based coverage ranged from 11% to 77% 
(140,149). Since 2013 vaccination has been recommended nationally (both 
RotaTeq® and Rotarix® vaccines are available) and vaccine coverage has increased; 
although remains variable across states (149). Currently, there are no vaccine impact 
studies post-national recommendation. However, an early study compared vaccine 
impact on RVGE hospitalisations in Western States (vaccine uptake ~58%) and 
Eastern States (vaccine uptake ~ 22%) between 2008 and 2011 (150). In children <2 
years of age reductions were 35% in Western States compared to 25% in Eastern 
States. A further study analysing data from 2006-2012, showed that in areas reaching 
64% vaccine uptake there was a 60% reduction in RVGE hospitalisations in infants 
< 1 year of age compared to 19% in low uptake areas (149). Small reductions were 
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also seen for all-cause AGE hospitalisations. However, there was no reduction in 
RVGE hospitalisations in children 2 and 3 years of age detected.  
In Israel RotaTeq® was introduced into the national immunisation programme in 
2010, with vaccine uptake around 80% (151). In a prospective study in 3 acute 
hospitals, conducted 2008-2015, the incidence of RVGE hospitalised fell by 61%, 
and AGE hospitalisations by 34% in children under 5 years of age (151).  
In Spain vaccination has not been recommended for inclusion in the childhood 
immunisation schedule, however vaccination is available privately (only RotaTeq® 
since 2010) but vaccine coverage is low –moderate (140). National and regional 
studies have shown a reduction in RVGE hospitalisations and AGE hospitalisations, 
since vaccine introduction (152,153). However, the most significant finding occurred 
after a withdrawal of rotavirus vaccination for six months in 2010, due to the 
detection of DNA fragments of porcine circovirus in both Rotarix® and RotaTeq® 
(154). Subsequent analysis showed a drop in vaccine coverage and in parallel RVGE 
hospitalisations in infants increased by 260% in 2010/11 compared to the previous 
season (2009/10). However, reductions in RVGE hospitalisations resumed when 
vaccination was re-established (155).  
Impact on RVGE and AGE outpatient / primary care visits 
The impact of rotavirus vaccination on RVGE and AGE outpatient / primary care 
visits has been less well described. In Finland hospital outpatient reductions in 
RVGE were similar to that in inpatient cases for infants <12 months of age (79%) 
and 1 year olds (73%). There were lower but non-significant reductions in children 
2-4 years of age (146). A retrospective health record study in New Orleans, USA 
showed significant decreases in all-cause AGE primary care visits between 2007 and 
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2009; 29% for infants <12 months of age and 18% in predominately vaccine 
ineligible children aged 2-4 years (156). Again in the US, an insurance claims 
database study estimated similar reductions in all-cause diarrhoea-associated 
outpatient visits of 21% and 24% among infants <12 months of age for the 2008 and 
2009 rotavirus seasons (January to June), respectively (128). Reductions were lower 
among children 1 year of age. In 2-4 year olds a 8% reduction in 2008 was followed 
by a 10% increase in 2009 (128). 
Impact on hospital-acquired rotavirus 
Studies from the US, Australia, Austria, Belgium and Germany have all shown 
reductions in hospital-acquired RVGE comparable to community-acquired RVGE 
hospitalisations (131,139,142,150,157). This is indicative of a reduction in rotavirus 
transmission in the hospital setting. This is an important aspect of rotavirus 
vaccination as this should help protect hospitalised children with severe disease and 
comorbidities from exacerbation of underlying illness through hospital-acquired 
rotavirus infection.
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2 Thesis overview 
2.1 Project starting points 
The stimulus for this project was the introduction of routine rotavirus vaccination 
into the UK’s childhood immunisation schedule in July 2013 (158). Whilst the 
impact of rotavirus vaccine on severe disease has been well described, uncovering 
the impact of rotavirus on a “total health economy”, across primary and secondary 
care for rotavirus-specific and non-specific gastrointestinal outcome measures is yet 
to be documented. Furthermore, since it is known that in the UK the incidence of all-
cause acute gastroenteritis is highest in the most socioeconomically deprived 
populations and vaccine uptake is often lower in these populations (159–163), 
measuring vaccine impact in relation to socioeconomic deprivation is critical to 
assess whether vaccine uptake and impact is equitable. 
2.2 Aims and objectives 
Aim: To use routine healthcare data sources to estimate the direct and indirect 
impact of rotavirus vaccination on gastroenteritis indicators in the population of 
Merseyside, UK, in relation to vaccine coverage and sociodemographic indicators.  
Study objectives: 
The following questions will be addressed: 
 Is there a significant change in: 
 Laboratory detections of rotavirus in faecal samples? 
 Admissions to hospital for rotavirus or acute gastroenteritis? 
 Attendances to emergency departments for gastrointestinal 
conditions? 
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 Hospital-acquired cases of rotavirus infection?  
 GP and Walk-in-Centre consultations for gastroenteritis / diarrhoea? 
 What is the extent of indirect vaccine effectiveness or herd protection? 
 Is there a relationship between socioeconomic deprivation, vaccine uptake 
and vaccine impact? 
2.3 Outline of thesis 
The thesis contains a general introduction to rotavirus in chapter 1 and at the end a 
general discussion (Chapter 8). Chapter 3 includes a peer review published 
systematic review and meta-analysis of rotavirus vaccine effectiveness studies. The 
general methods chapter (chapter 4) includes the data sources and methods adapted 
from the published study protocol. The results chapters 5, 6 and 7 are in the form of 
studies written for publication and include, detailed methods and discussion: 
 The work encompassed in chapter 3 is published in BMC Infectious Diseases 
 The protocol presented in chapter 4 is published in BMJ Open 
 The study presented in chapter 5 is published in the Journal of Hospital 
Infection 
 The study presented in chapter 6 is published in BMC Medicine 
 The study presented in chapter 7 has been submitted for publication 
When the work for this thesis began the intention was to measure population vaccine 
impact in an ecological study design. However, in the process of sourcing data for 
the analysis of rotavirus vaccine impact on GP consultations, an important 
opportunity was identified. This prospect was to undertake a methodologically 
rigorous analysis of rotavirus vaccine effectiveness using a birth cohort design. This 
analysis would allow the different component of vaccine effectiveness to be 
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calculated and add important evidence of vaccine effectiveness on less severe / 
moderate disease burden, which is currently lacking from the literature. Therefore, a 
National Health Service (NHS) Research Ethics Committee study amendment for the 
addition of the GP birth cohort study was submitted and favourable opinion received 
in November 2014 (Appendix B). The GP birth cohort study began in parallel to the 
impact study and is described in its entirety in results chapter 7. 
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3 Population effectiveness of the pentavalent and 
monovalent rotavirus vaccines: a systematic review and 
meta-analysis of observational studies  
3.1 Abstract 
Background: Rotavirus was the leading cause of acute gastroenteritis (AGE) in 
infants and young children prior to the introduction of routine vaccination. Since 
2006 there have been two licensed vaccines available; with successful clinical trials 
leading the World Health Organization to recommend rotavirus vaccination for all 
children worldwide. In order to inform immunisation policy we have conducted a 
systematic review and meta-analysis of observational studies to assess population 
effectiveness against AGE. 
Methods: We systematically searched PubMed, Medline, Web of Science, Cinhal 
and Academic Search Premier, plus grey literature sources for studies published 
between January 2006 and April 2014. Studies were eligible for inclusion if they 
were observational measuring population effectiveness of rotavirus vaccination 
against healthcare attendances for rotavirus gastroenteritis (RVGE) or AGE. To 
evaluate study quality we use used the Newcastle-Ottawa Scale for non-randomised 
studies, categorising studies by risk of bias. Publication bias was assessed using 
funnel plots. If two or more studies reported a measure of vaccine effectiveness (VE), 
we conducted a random effects meta-analysis. We stratified analyses by World Bank 
country income level and used study quality in sensitivity analyses. 
Results: We identified 30 studies, 19 were from high income countries and 11 from 
middle-income countries. Vaccine effectiveness against hospitalisation for 
laboratory confirmed RVGE was highest in high income countries (89% VE; 95% 
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CI 84-92%) compared to middle-income countries (74% VE; 95% CI 67-80%). 
Vaccine effectiveness was higher for those receiving the complete vaccine schedule 
(81% VE; 95% CI 75-86%) compared to partial schedule (62% VE; 95% CI 55-
69%). Two studies from high-income countries measured VE against community 
consultations for AGE with a pooled estimate of 40% (95% CI 13-58%; 2 studies). 
Conclusions: We found strong evidence to further support the continued use of 
rotavirus vaccines. Vaccine effectiveness was similar to that reported in clinical 
trials for both high and middle-income countries. There is limited data from low-
income settings at present. There was lower effectiveness against milder disease. 
Further studies should continue to report effectiveness against AGE and less-severe 
rotavirus disease because as evidenced by pre-vaccine introduction studies this is 
likely to contribute the greatest burden on healthcare resources, particularly in high 
income countries. 
3.2 Background 
Prior to the introduction of rotavirus vaccine into childhood immunisation schedules, 
rotavirus was the most common cause of severe gastroenteritis in infants and young 
children. Thus, rotavirus gastroenteritis (RVGE) was estimated to be responsible for 
453,000 deaths worldwide in children under 5 years of age in 2008, with over 90% 
of deaths occurring in low income countries (12). The global morbidity from 
rotavirus infection was also substantial with pre-vaccine introduction studies 
indicating that approximately 40% of diarrhoeal hospitalisations in children were 
caused by rotavirus (164). In middle and high income countries without vaccination 
the burden of RVGE remains substantial in infants and young children with high 
rates of disease and rotavirus the major contributor to diarrhoea hospitalisation. In 
the UK prior to vaccine introduction RVGE was estimated to be responsible for 45% 
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of acute gastroenteritis (AGE) hospital admissions, 80,000 primary care 
consultations and 750,000 annual diarrhoeal episodes in children under 5 years of 
age (29,30). In middle-income countries such as, Mexico and Peru, prior to vaccine 
introduction the average incidence of RVGE was 0.3 episodes per child per year in 
children <2 years, resulting in significant healthcare use and mortality (165). 
Although the majority of severe RVGE occurs among young children, older children 
and adults can be affected, however rotavirus infection often causes milder 
symptoms or is asymptomatic in these ages, meaning the true burden and rate of 
disease incidence is poorly understood. 
Since improvements in sanitation and hygiene are not expected to substantially 
reduce the incidence of rotavirus infection, and treatment of RVGE is limited to 
rehydration therapy, immunisation of infants is considered the best option for control 
of the global burden of rotavirus disease (49,54,51). Since 2006 there have been two 
live-attenuated oral rotavirus vaccines that are licensed for use globally. A two dose 
monovalent vaccine (Rotarix®, GlaxoSmithKline Biologicals, Belgium), with the 
first dose typically administered at between 6-8 weeks of age and a second dose at 
least 4 weeks later and a three dose pentavalent vaccine (RotaTeq®, Merck), 
administered at 6-12 weeks of age with subsequent doses at 4-10 week intervals. 
Randomised controlled trials (RCTs) demonstrated both vaccines to be efficacious 
against severe RVGE; vaccine efficacy of over 80% has been shown in middle- and 
high-income countries, whilst trials in low-income settings have reported efficacy 
against severe RVGE of 40-60% (61). These trials led to a World Health 
Organisation (WHO) recommendation for universal vaccination of all children 
(12,166). More than 90 countries have since adopted rotavirus vaccination and the 
global mortality from RVGE is estimated to have fallen to 215 000 in 2013, with 
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almost 50% of deaths occurring in four lower-income countries (73,124). Currently 
within the European Union only nine countries include rotavirus vaccination in their 
childhood immunisation programme (140,167). 
It is now a decade since the licensing and first introduction of rotavirus vaccination 
into childhood vaccination schedule. In order to inform immunisation policy, we 
have conducted a systematic review and meta-analysis of the literature on 
observational studies in order to assess the population effectiveness of the Rotarix® 
and RotaTeq® against RVGE. Effectiveness was examined by severity and by 
region. 
3.3 Methods 
3.3.1 Inclusion / exclusion criteria 
We included prospective or retrospective observational studies (cohort and case-
control studies) reporting the population effectiveness of the monovalent Rotarix® 
(RV1) or pentavalent RotaTeq® (RV5) against healthcare attendance for RVGE or 
other AGE in countries where the vaccines are included in the national immunisation 
programme or privately offered through medical insurance. Studies published 
between January 2006 and 28th April 2014 were eligible for inclusion. Review 
articles, editorials and conference abstracts were included in citation checking but 
excluded from final analysis. Randomised controlled trials were also excluded. 
3.3.2 Search strategy 
We followed the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines. We systematically searched PubMed, Medline, Web 
of Science, Cinhal and Academic Search Premier, OpenGrey and the Cochrane 
Library databases using a well-defined search strategy following a protocol 
registered on the University of York database for Prospectively Registered 
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Systematic Reviews (PROSPERO: 2014:CRD42014012974). A number of relevant 
organisations websites were also systematically searched, and included the WHO, 
Public Health England, and Centers for Disease Control and Prevention. We 
systematically searched the literature by, pairing the terms [vacc*] and [rotavirus] 
with the following key words: [immuni*], [effect*], [evaluation], and [efficacy]. 
Authors (DH and CM) replicated the search strategy and independently screened 
titles and abstracts to identify full studies that were eligible for full publication 
review. Subsequently these two authors independently assessed the full text 
publications and their final inclusion was based on a consensus between the 
reviewers (DH, CM, KS, AT). 
3.3.3 Data extraction 
Data extraction was autonomously carried out by three authors (DH, AT, KS) and a 
collaborator (MSC) using a pre-designed internally piloted extraction tool. For each 
study the following information was extracted: Author, Year of publication, country 
and region of study, funding source, study period, country vaccine coverage, study 
type, sample size, age of subjects, type of vaccine (RV1 and / or RV5) in case and 
controls groups, case definition, control definition, number of vaccine doses, relative 
risks / risk ratios (RR) or odds ratio (OR) or vaccine effectiveness (VE) and 95% 
confidence intervals (95% CI) and, if applicable, a measure of intussusception. 
3.3.4 Grading of selected studies 
The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomised 
studies was identified as an appropriate tool to assess study quality (168). Case-
control and cohort-studies were assessed using the tool by the same three researchers 
that carried out data extraction. To quality assess case-control studies the scale used: 
1) adequate definition of a case and the representativeness of cases; 2) controls 
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selection and case definition; 3) matching of controls or adjustment for confounders 
in analysis; 4) ascertainment of method of cases and controls in terms of exposure 
(rotavirus vaccination) and non-response rate. To quality assess cohort-studies the 
factors assessed were: 1) representativeness of the vaccinated cohort and selection of 
unvaccinated cohort in relation to the vaccinated; 2) ascertainment of vaccination 
record, confirmation of rotavirus negative at start of study; 3) matching of exposed 
and non-exposed in design or adjustment for confounders in analysis; 4) 
ascertainment of outcome (rotavirus infection); 5) follow-up duration in relation to 
outcome appearance (e.g. 1 year from vaccination date) and was follow-up adequate 
(we defined adequate as ascertainment of outcomes for >80% of participants). The 
scale is categorised into three groups, selection, comparability and outcome / 
exposure; a maximum of nine stars can be awarded to each study. Studies scoring 0 
in any of the categories were classified as having a high risk of bias, studies scoring 
1 in any categories (moderate risk of bias) and 2 or above in all categories (low risk 
of bias). 
3.3.5 Statistical analysis 
We used Stata, version 14, statistical software (Stata Corp., College Station, TX, 
USA) to perform all statistical calculations for this meta-analysis. Meta-analyses 
were conducted separately for cohort and case-control studies. We used the study 
published RR for cohort studies and OR for case-control studies and calculated 
standard errors (SE) using study reported confidence intervals in the formula: 
𝑆𝐸 =
𝑙𝑛(𝑈𝑝𝑝𝑒𝑟 𝑐𝑜𝑛𝑓𝑖𝑑𝑒𝑛𝑐𝑒 𝑖𝑛𝑡𝑒𝑟𝑣𝑎𝑙) − 𝑙𝑛(𝐿𝑜𝑤𝑒𝑟 𝐶𝑜𝑛𝑓𝑖𝑑𝑒𝑛𝑐𝑒 𝑖𝑛𝑡𝑒𝑟𝑣𝑎𝑙)
3.92
 
Where studies did not report OR or RR, authors calculated crude OR or RR and SE 
using reported numbers of cases and controls. When a study reported both 
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unadjusted and adjusted RRs / ORs, adjusted RRs / ORs were included in meta-
analysis and unadjusted estimates excluded. Vaccine effectiveness was defined as 
100  ×  (1  −  𝑅𝑅) or 100  ×   (1  −  𝑂𝑅). A random effects model was used to 
provide pooled estimates of VE. Because of differences in reported vaccine efficacy 
a decision was taken during data extraction, for analyses to be stratified by country 
income category, as defined by the World Bank and measured using gross national 
income per capita (61,169). Where a study had reported VE for multiple years the 
estimate for mid or most recent year (if only two years) were included in the meta-
analysis. Heterogeneity was measured using chi-squared (χ2) heterogeneity p-values 
and I2 statistics. A p-value<0.1 was considered to identify statistically significant 
heterogeneity rather than 0.05 due to the small number of studies included. The 
percentage of variance across studies due to heterogeneity rather than chance was 
categorised as low, moderate and high using I2 values of 25-49%, 50-74% and 
>=75%, respectively (170). 
Sensitivity analysis was conducted based on the NOS score, excluding studies with a 
high or moderate risk of bias and assessing whether a study was conducted in a 
country with routine vaccination (part of recommended health policy) or in countries 
where vaccination provision is private or only available in some states. Subgroup 
analysis was conducted on: number of doses (1 dose, and full doses), age group, and 
vaccine type. Both number of doses and vaccine type were identified as important 
analyses post-hoc. Where studies reported more than one type of control group the 
following hierarchy was used to select estimates for use in meta-analyses: 1) 
community / neighbourhood; 2) hospital non-AGE controls; hospital rotavirus 
negative AGE controls. Publication bias was checked by funnel plot asymmetry and 
use of Begg’s test (171). 
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3.4 Results 
3.4.1 Study characteristics 
The initial search strategy identified 2,097 studies as potentially relevant; of these, 
30 were eligible for inclusion in the review (Figure 3-1) (85,172–200).  
 
Figure 3-1 Flow chart of publications included and excluded for this review 
Summary tables of study characteristics are available in Appendix C. Seven studies 
were cohort studies and 23 were case-control studies (Table 3-1 and Table 3-2). 
Nineteen were from high-income countries and eleven were from middle-income 
countries. Seven studies declared some funding from industry related to the rotavirus 
vaccines under study. Over a third of studies were conducted in the USA (n=12). 
The majority of studies (27/30) reported on RVGE hospitalisations and / or 
emergency department (ED) attendances for AGE with a positive laboratory test for 
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rotavirus. A study by Mast et al., (172) measuring VE against RVGE hospitalisation 
and ED attendances included only cases with severe disease defined by a Vesikari 
score of greater than 11 in their VE estimate (62,172,201). Two studies reported 
RVGE ED attendances and hospitalisations combined. Five studies included 
community consultations for either RVGE or AGE (173–177), which included a 
range of definitions including outpatient, physician and telephone consultation.  
Controls for case-control studies were primarily hospital controls that were admitted 
for AGE symptoms but with a rotavirus negative laboratory test result. A few studies 
also used community asymptomatic controls or non-AGE hospital controls, such as 
children admitted with acute respiratory infection (Appendix C: Table S2). VE was 
measured for a range of age groups across studies.  
The study by Fontes Vieira et al. 2011 conducted in Brazil on a community cohort 
examined VE against laboratory confirmed RVGE but did not report an estimate of 
VE; a crude estimate was therefore calculated by the authors (173). In the majority 
of studies, laboratory confirmation of RVGE followed hospitalisation, an ED 
attendance or GP consultation for gastroenteritis symptoms such as diarrhoea. Study 
selection identified five studies from countries (Spain and Israel) where routine 
childhood vaccination is not available but either the monovalent or pentavalent 
vaccine is available privately and / or only in some states (174,178,180,186,197).
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Table 3-1 Cohort studies estimating vaccine effectiveness against 
hospitalisations, emergency department attendances and community 
consultations for RVGE or AGE 
Study Country Vaccine Age 
(months) 
Cohort 
year 
Vaccinated (N) Unvaccinated 
(N) 
Vaccine effectiveness (95% 
CI) 
Dose Incidence Incidence Unadjusted Adjusted 
Hospitalisation for RVGE 
Eberly 
2011 
(179) 
USA RV1 and 
RV5 
<60 All 1 NR 581/237660 86 (78-91) NR 
1 or 
more 
42/140213 88 (83-91) NR 
2 RV1 
/ 3 
RV5 
11/NR 90 (82-95) NR 
Panozzo 
2014* 
(85)] 
USA RV1 and 
RV5 
8-20 1 1 or 
more 
3/68380 60/64929 NR 87 (58-96) 
2 23/175890 91/91051 NR 87 (80-92) 
3 22/250035 74/61218 NR 92 (87-95) 
4 8/254377 13/41946 NR 90 (75-96) 
Hospitalisation and ED attendance for RVGE 
Wang 
2010 
(176) 
USA RV5 <36 All 3 0/7700 23/5831 100 (87-
100) 
NR 
Wang, 
2013 
(177) 
USA RV5 <36 All 1 2/5019 11/3343 88 (45-99) NR 
All 2 1/5886 13/4432 94 (61-100) NR 
Hospitalisation and ED attendance for AGE 
Wang  
2010 
(176)] 
USA RV5 <36 All 3 87/7700 160/5831 59 (46-69) 59 (47-68) 
Wang, 
2013 
(177)] 
USA RV5 <36 All 1 53/5019- 63/3343 44 (18-62) 46 (22-63) 
All 2 78/5886 98/4432 40 (18-56) 39 (16-55) 
Hospitalisation for AGE 
Panozzo 
2014* 
(85)] 
USA RV1 and 
RV5 
8-20 1 1 or 
more 
142/68378 271/64928 NR 22 (3-37) 
2 413/175765 317/90882 NR 40 (30-48) 
3 512/249838 300/61136 NR 56 (49-62) 
4 398/254232 109/41888 NR 41 (27-53) 
Community consultations for RVGE 
Wang  
2010 
(176)] 
USA RV5 <36 All 3 1/7700 20/5831 96 (76-100) NR 
Wang  
2013 
(177)] 
USA RV5 <36 All 1 0/5019 - 7/3343 100 (54-
100) 
NR 
All 2 4/5886 5/4432 40 (<0-88) NR 
Community consultations for AGE 
Fontes-
Vieira  
2011 
(173)** 
Brazil RV1 <12 1 2 87/100 84/100 -4 (-16 to 8) NR 
2 52/100 42/100 -24 (-
67 to 8) 
NR 
Muhsen 
2011 
(174)] 
Israel RV1 <12 All 1 153/716 8801/18591 54 (47-60) NR 
All 2 1605/6870 50 (47-52) NR 
Nolan  
2012 
(175)† 
USA RV5 <24 1 1 or 
more 
NR NR NR 28 (-21 
to58) 
1 NR NR NR 22 (-
13 to 46) 
2 NR NR NR 37 (-
37 to 71) 
Wang  
2010 
(176)] 
USA RV5 <36 All 3 1321/7700 1377/5831 27 (22-33) 28 (22-33) 
Wang  
2013 
(177)] 
USA RV5 <36 All 1 651/5019 521/3343 17 (6-26) 17 (7-26) 
All 2 774/5886 847/4432 31 (24-38) 28 (21-35) 
* Direct effect estimates, ** Crude VE calculated by authors, NR not reported, ED emergency department, d 
days, AGE acute gastroenteritis, RVGE rotavirus gastroenteritis, †GP consultations reported, paper also reported 
telephone triage and episodes (calls and visits within ten days), two cohorts were followed, the 1st for two 
seasons and 2nd for one season 
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Table 3-2 Case-control studies estimating vaccine effectiveness against 
hospitalisations, ED attendances for RVGE or AGE [partial: 1 dose of RV1 or RV5] 
Study Country Vaccine Age 
months 
(m) or 
days (d) 
Control 
group 
Cases vaccinated 
(n/N) 
Controls vaccinated 
(n/N) 
Vaccine 
effectiveness (95% 
CI) 
Partial Full Partial Full Partial Full 
Hospitalisations for RVGE 
Braeckman 
2012 (187) 
Belgium RV1 <36 Hospital - 
RV (-) AGE 
81/179* 70/160 208/228 179/198 91 (82-
95) 
90 (81-
95) 
3-11 36/77* 30/66 99/104 79/84 93 (80-
97) 
91 (75-
97) 
12-31 45/102* 40/94 109/124 100/114 89 (75-
95) 
90 (76-
96) 
Carvalho-
Costa 2009 
(181)] 
Brazil RV1 <60 Hospital - 
RV (-) AGE 
NR 4/14 NR 35/60 NR 71 (-15-
93) 
Castilla 
2012 (186)] 
Spain RV1 & 
RV5 
3-59 Hospital - 
RV (-) AGE 
NR 9/262 NR 80/518 NR 83 (65-
93) 
<24 NR 8/215 NR 69/371 NR 82 (60-
93) 
24-59 NR 1/43 NR 11/99 NR 89 (17-
99.8) 
Correia 
2010 (190) 
Brazil RV1 6-11 Hospital - 
RV (-) AGE 
NR NR NR NR NR 77 (42-
91) 
Cortese 
2011 (191) 
USA RV5 >7 Hospital - 
RV (-) AGE 
NR 20/140 NR 163/280 NR 92 (86-
96) 
>7 Communitya  NR 17/221 NR 672/195
3 
NR 90 (84-
94) 
Cortese 
2013 (192)] 
USA RV1 >7 Hospital - 
RV (-) AGE 
NR 2/30 NR 101/140 NR 98 (90-
100) 
>7 Communitya  NR 2/28 NR 206/440 NR 94 (71-
99) 
Cotes-
Cantillo 
2014 (185)] 
Colombia RV1 <60 Hospital - 
RV (-) AGE 
NR 6/84 NR 670/711 NR -2 (-182 
to 63) 
6-11 NR 12/15 NR 628/655 NR 84 (23-
97) 
≥12 NR 64/67 NR 628/655
R 
NR -80 (-
559 to 
51) 
de Palma 
2010 (193) 
El 
Salvador 
RV1 <25 Community 72/171 152/251 199/352 617/770 51 (26-
67) 
76 (64-
84) 
6-11 NR 49/63 NR 205/222 NR 83 (68-
91) 
12-24 NR 79/108 NR 284/335 NR 59 (27-
77) 
Desai 2010 
(194) 
USA RV1 & 
RV5 
2-35 Hospital - 
RV (-) AGE 
5/42* NR 24/80 NR 94 (55-
99) 
NR 
Community 5/42* NR 21/73 NR 96 (59-
99.8) 
NR 
Guh 2011 
(195)] 
USA RV5 <36 Community 2/54 0/54 34/270 25/270 84 (25-
96) 
92 (48-
100) 
Ichihara 
2014 (196)] 
Brazil RV1 4-24 Hospital – 
RV (-) and 
non-vaccine 
preventable 
33/215 115/215 279/1961 1481/19
61 
60(37-
75) 
72(44-
85) 
Justino 
2011 (188)* 
Brazil RV1 3-11 Hospital - 
non AGE or 
vaccine 
preventable 
NR/120 NR/77 NR/120 NR/77 61 (28-
78) 
56 (12-
78) 
12-35 NR/324 NR/235 NR/324 NR/235 35 (4-
56) 
32 (-4 
to 46) 
3-35 NR/444 NR/312 NR/444 NR/312 44 (23-
60) 
40 (14-
58) 
3-11 Community 
no AGE 
symptoms 
NR/91 NR/64 NR/91 NR/64 89 (63-
97) 
96 (68-
99) 
12-35 NR/240 NR/185 NR/240 NR/185 48 (17-
68) 
65 (37-
81) 
3-35 NR/331 NR/249 NR/331 NR/249 62 (42-
75) 
76 (58-
86) 
Muhsen 
2010 (197)* 
Israel RV1 & 
RV5 
<28 
(approx.) 
Hospital - 
RV (-) AGE 
2/111 NR 36/216 NR 89 (52-
98) 
NR 
Martinon-
Torres 
2011 (180) 
Spain RV1 & 
RV5 
<24 Hospital - 
RV (-) AGE 
2/75 1/74 22/186 130/294 80 (11-
95) 
98 (87-
99.8) 
Patel 2009 Nicaragua RV5 <24 Community 31/80 143/192 116/213 442/539 52 (14- 43 (9-
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Study Country Vaccine Age 
months 
(m) or 
days (d) 
Control 
group 
Cases vaccinated 
(n/N) 
Controls vaccinated 
(n/N) 
Vaccine 
effectiveness (95% 
CI) 
Partial Full Partial Full Partial Full 
(182) 73) 64) 
Hospital - 
RV (-) AGE 
31/80 143/192 106/181 350/425 60 (24-
78) 
49 (17-
68) 
Community 
and 
Hospital - 
RV (-) AGE 
31/80 143/192 222/394 792/964 55 (22-
74) 
44 (15-
63) 
Patel 2013 
(198) 
Bolivia RV1 6-11 Hospital - 
RV (-) non 
AGE 
NR NR NR NR NR 77 (51-
89) 
12-35 NR NR NR NR NR 76 (59-
86) 
<36 100/192 208/300 226/343 857/974 56 (32-
72) 
77 (65-
84) 
6-11 Hospital - 
RV (-) AGE 
NR NR NR NR NR 64 (34-
80) 
12-35 NR NR NR NR NR 72 (52-
86) 
<36 100/192 208/300 131/208 510/587 36 (0-
59) 
69 (54-
79) 
Patel 2012 
(183) 
Nicaragua RV5 6-44 Hospital - 
RV (-) Non 
AGE or 
vaccine 
preventable 
and 
Community 
NR 773/849 NR 3914/40
62 
NR 70 (59-
78) 
6-11 NR NR NR NR NR 73 (54-
84) 
12-44 NR NR NR NR NR 68 (51-
79) 
6-44 Hospital - 
RV (-) AGE 
NR 773/849 NR 3097/32
47 
NR 45 (25-
59) 
6-11 NR NR NR NR NR 64 (43-
78) 
12-44 NR NR NR NR NR 30 (-5 – 
53) 
Payne 2013 
(184)] 
USA RV1 <60 Hospital - 
RV (-) AGE 
NR/22 NR NR/34 NR 32 (-
156-82) 
NR 
RV5 NR/130 NR NR/372 NR 86 (74-
91) 
NR 
Snelling 
2009 (199)] 
Australia RV1 <60 Community 10/21 3/21 58/83 32/83 57 (<0-
83) 
85 (23-
97) 
Staat 2011 
(189)] 
USA RV5 1-37 Hospital - 
RV (-) AGE 
1/38 3/40 12/44 17/49 89 (16-
99) 
95 (48-
99) 
1-37 Hospital - 
RV (-) ARI 
1/60 29/102 5/64 40/113 94 (55-
99) 
82 (50-
93) 
Hospital admissions for AGE 
Snelling 
2009 (199) 
Australia RV1 <60 Community 21/42 11/42 120/166 72/166 67 (29-
84) 
78 (40-
92) 
ED attendances for RVGE 
Cotes-
Cantillo 
2014 (185)] 
Colombia RV1 <60 ED - RV (-) 
AGE 
NR 143/156 NR 670/711 NR 16 (79-
61) 
6-11 NR 27/31 NR 27/655 NR 79 (24-
94) 
≥12 NR 112/119 NR 628/655 NR -40 (-
271 to 
47) 
Cortese 
2011 (191)] 
USA RV5 >7 Hospital- 
RV (-) AGE 
NR 8/41 NR 163/280 NR 81 (53-
92) 
>7 Community NR 6/62 NR 138/567 NR 84 (58-
94) 
Cortese 
2013 (192) 
USA RV1 >7 Hospital- 
RV (-) AGE 
NR 20/65 NR 101/140 NR 86 (67-
94) 
>7 Community NR 17/61 NR 438/862 NR 65 (35-
81) 
Payne 2013 
(184)] 
USA RV1 <60 ED- RV (-) 
AGE 
38 NR 121 NR 78 (46-
91) 
NR 
RV5 <60 ED- RV (-) 
AGE 
229 NR 1439 NR 81 (70-
84) 
NR 
Staat 2011 
(189) 
USA RV5 15 d-
47m 
ED- RV (-) 
AGE 
5/56 8/59 12/66 22/76 75 (-64 
-96) 
74 (16-
92) 
15 d-
47m 
ED - ARI 7/76 8/77 16/101 54/139 45 (-80 
-83) 
88 (64-
96) 
Hospitalisations and ED attendances for RVGE 
Cortese 
2011 (191)] 
USA RV5 >7 Hospital RV 
(-) AGE 
10/163 23/283 20/137 141/341 69 (27-
87) 
89 (81-
94) 
8-11 NR 4/24 NR 63/92 NR 93 (75-
99) 
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Study Country Vaccine Age 
months 
(m) or 
days (d) 
Control 
group 
Cases vaccinated 
(n/N) 
Controls vaccinated 
(n/N) 
Vaccine 
effectiveness (95% 
CI) 
Partial Full Partial Full Partial Full 
12-23 NR 21/102 NR 86/147 NR 89 (77-
94) 
>23 NR 3/55 NR 14/41 NR 91 (62-
99) 
56d-5m 11/69 NA 97/248 NA 71 (40-
87) 
NA 
56d-5m Communitya  11/69 NA 184/633 NA 62 (20-
82) 
NA 
>7 NR 23/283 NR 850/252
0 
NR 89 (83-
93) 
8-11 NR 3/109 NR 194/100
9 
NR 94 (78-
99) 
12-23 NR 17/116 NR 517/988 NR 88 (80-
93) 
>23 NR 3/58 NR 139/523 NR 87 (56-
96) 
Cortese 
2013 (192)] 
USA RV1 >7 Hospital RV 
(-) AGE 
NR 22/95 NR 101/140 NR 91 (80-
95) 
8-11 NR 5/14 NR 45/61 NR 85 (35-
97) 
12-23 NR 14/66 NR 46/68 NR 91 (75-
96) 
>7 Communitya  NR 19/89 NR 644/130
2 
NR 76 (58-
86) 
8-11 NR 4/14 NR 114/196 NR 70 (24-
91) 
12-23 NR 13/65 NR 462/967 NR 76 (53-
87) 
Donauer 
2013 (200)] 
USA RV5 <36 Community 8/76 2/76 165/743 329/743 77 (14-
94) 
92(60-
99) 
Hospital - 
RV (-) AGE 
8/76 2/76 47/179 15/179 68 (-18 
to 91) 
92(21-
99) 
Hospital - 
RV (-) ARI 
8/76 2/76 71/288 27/288 58 (-38 
to 87) 
92(33-
99) 
Mast 2011 
(172)] 
Nicaragua RV5 Overall Community NR 241/300 NR 812/851 NR 87(74-
93) 
<12 NR 62/84 NR 219/225 NR 93(62-
99) 
≥ 12 NR 179/216 NR 593/626 NR 85(69-
93) 
Overall Hospital – 
RV(-) AGE 
NR 241/300 NR 711/792 NR 64(44-
78) 
<12 NR 62/84 NR 215/233 NR 78(49-
91) 
≥ 12 NR 179/216 NR 496/559 NR 55(22-
74) 
Overall Combined NR 241/300 NR 1523/16
43 
NR 76(63-
84) 
<12 NR 62/84 NR 434/458 NR 85(66-
93) 
≥ 12 NR 179/216 NR 1089/11
85 
NR 71(51-
82) 
Payne 2013 
(184)] 
USA RV1 <60 Hospital - 
RV (-) AGE 
46 56 83 140 57 (-45-
87) 
70 (39-
86) 
12-23 7 NR 54 - 56 (-59-
100) 
NR 
24-35 46 NR 79 NR 86 (60-
95) 
NR 
RV5 <60 Hospital - 
RV (-) AGE 
233 537 307 1445 70 (50-
82) 
84 (78-
88) 
12-23 34 NR 402 NR 85 (63-
94) 
NR 
24-35 121 NR 681 NR 89 (82-
93) 
NR 
36-47 91 NR 414 NR 83 (69-
90) 
NR 
Staat 2011 
(189)] 
USA RV5 15d -
37m 
Hospital - 
RV (-) AGE 
9/136 16/143 40/191 87/238 74 (37-
90) 
87 (71-
94) 
1-11 6/65 3/62 30/109 19/98 63 (7-
87) 
86 (31-
97) 
12-23 3/38 8/43 6/45 48/87 81 (22-
97) 
90 (65-
97) 
15d -
37m 
Hospital - 
RV (-) ARI 
10/159 17/166 79/391 195/507 73% 
(43-88) 
85 (72-
91) 
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Study Country Vaccine Age 
months 
(m) or 
days (d) 
Control 
group 
Cases vaccinated 
(n/N) 
Controls vaccinated 
(n/N) 
Vaccine 
effectiveness (95% 
CI) 
Partial Full Partial Full Partial Full 
1-11 6/76 3/73 60/230 43/213 74 (31-
90) 
84 (41-
96) 
12-23 4/41 9/46 15/87 104/176 70 (16-
92) 
87 (68-
95) 
Any episode of RVGE 
Bellido-
Blasco 
2012 (178)] 
Spain RV1 & 
RV5 
<36 RV (-) AGE 2/71 NR 57/261 NR 88 (46–
99.7) 
NR 
Castilla 
2012 (186)] 
Spain RV1 & 
RV5 
3-59 RV (-) AGE 45/756* 34/756 1094/603
6* 
849/603
6 
78 (70-
84) 
78 (68-
85) 
3-11 NR 12/309 NR 248/136
5 
NR 78 (58-
88) 
12-23 NR 16/318 NR 481/267
8 
NR 82 (69-
89) 
24-59 NR 6/118 NR 120/174
8 
NR 61 (0-
84) 
Martinon-
Torres 
2011 (180)] 
Spain RV1 & 
RV5 
<24 RV (-) AGE 3/143 8/148 22/186 130/294 84(46-
95) 
93  
AGE, all cause gastroenteritis symptoms; ARI, acute respiratory infection; RV (-), rotavirus test negative; ED, 
emergency department; d, days. *One or more doses reported for partial 
3.4.2 Quality of included observational studies 
The quality of studies varied considerably (Table 3-3). It was difficult to ascertain 
for most studies whether history of disease in control subjects was considered. The 
majority of studies used a combination of vaccination cards and medical records to 
ascertain vaccination status. The majority of studies either matched controls or 
adjusted for age in the analysis as a minimum and those with community controls 
often used an indicator of residence such as GP location as a covariate. A high risk 
of bias was identified in two out of seven cohort studies (173,179) and two out of 23 
case-control studies had a high risk of bias (180,181).
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Table 3-3 Quality of observational studies included in the review of rotavirus 
vaccine effectiveness 
Study Country 
Study 
design 
Selection Comparability 
Outcome / 
exposure 
Overall Bias 
Bellido-Blasco 2012 
(178) 
Spain 
Case-
control 
3 2 3 8 Low 
Braeckman 2012 (187) Belgium 
Case-
control 
3 2 3 8 Low 
Carvalho-Costa 2009 
(181) 
Brazil 
Case-
control 
2 0 1 3 High 
Castilla 2012 (186) Spain 
Case-
control 
3 2 3 8 Low 
Correia 2010 (190) Brazil 
Case-
control 
3 1 3 8 Moderate 
Cortese 2011 (191) USA 
Case-
control 
3 2 3 8 Low 
Cortese 2013 (192) USA 
Case-
control 
3 2 3 8 Low 
Cotes-Cantillo 2014 
(185) 
Colombia 
Case-
control 
3 2 3 8 Low 
de Palma 2010 (193) 
El 
Salvador 
Case-
control 
3 2 3 8 Low 
Desai 2010 (194) USA 
Case-
control 
3 2 2 7 Low 
Donauer 2013 (200) USA 
Case-
control 
2 2 2 6 Low 
Guh 2011 (195) USA 
Case-
control 
4 1 3 9 Moderate 
Ichihara 2014 (196) Brazil 
Case-
control 
3 2 2 7 Moderate 
Justino 2011 (188) Brazil 
Case-
control 
4 2 3 9 Low 
Martinon-Torres 2011 
(180)] 
Spain 
Case-
control 
4 0 2 6 High 
Mast 2011 (172) Nicaragua 
Case-
control 
3 2 1 7 Moderate 
Muhsen 2010 (197)] Israel 
Case-
control 
3 2 1 6 Moderate 
Patel 2009 (182) Nicaragua 
Case-
control 
4 2 3 9 Low 
Patel 2012 (183)] Nicaragua 
Case-
control 
4 2 2 8 Low 
Patel 2013 (198) Bolivia 
Case-
control 
3 2 3 8 Low 
Payne 2013 (184) USA 
Case-
control 
3 2 2 7 Low 
Snelling 2009 (199) Australia 
Case-
control 
3 2 3 8 Low 
Staat 2011 (189) USA 
Case-
control 
3 2 2 7 Low 
Eberly 2011 (179) USA Cohort 3 0 3 6 High 
Fontes-Vieira 2011 
(173) 
Brazil Cohort 3 0 2 5 High 
Muhsen 2011 (174) Israel Cohort 3 1 3 7 Moderate 
Nolan 2012 (175) USA Cohort 4 2 3 9 Low 
Panozzo 2014 (85) USA Cohort 4 2 3 9 Low 
Wang 2010 (176) USA Cohort 4 1 3 8 Moderate 
Wang 2013 (177) USA Cohort 4 1 3 8 Moderate 
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3.4.3 Meta-analysis of vaccine effectiveness against hospitalisation or 
combined hospitalisation and emergency department attendance for 
RVGE 
For this outcome measure cohort studies were too few to conduct a meta-analysis 
(Table 3-1). We therefore, included 21 out of the 22 case control studies that 
measured VE against hospitalisation or hospitalisation and ED attendance for 
laboratory confirmed RVGE in the meta-analysis. Patel et al. 2009 was excluded 
because a more recent publication Patel et al., 2012 provided more recent estimates 
of effectiveness for the same cohort (182,183). If studies reported more than one age 
group the overall estimate for the broadest age group was included in the meta-
analysis. Studies which reported on 0 doses vs full dose or 0 dose vs 1+ dose were 
included. Some 22 estimates from 21 studies were included, as Payne et al, 2013 had 
separate results for RV1 and RV5 (184). The funnel plot shows some asymmetry, 
however this is not significant for Begg’s (p=0.06) tests (Figure 3-2). Therefore, we 
included all 21 studies in the meta-analysis. 
 
Figure 3-2 Funnel plot of vaccine effectiveness against hospitalisation or 
hospitalisation and emergency department attendance for RVGE [only adjusted 
effect estimates included]  
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There was statistically significant heterogeneity (I2 = 60.6, p < 0.001) across all 
studies (Figure 3-3). Therefore pooled estimates of OR (0.18, 95% CI 0.14–0.23, 21 
studies [22 estimates], p<0.001) were calculated using a random effects model. The 
pooled VE was therefore 82% (95% CI 77–86%; 21 studies [22 estimates], p<0.001). 
A stratified analysis by World Bank Country Classifications calculated pooled 
estimated ORs. Pooled VE was lower in middle-income countries (74% VE; 95% CI 
67-80%; 9 studies, p<0.001) compared with high income countries (89% VE; 95% 
CI 84-92%; 12 studies [13 estimates], p<0.001). There was low to moderate 
heterogeneity for middle (I2 = 37.4%, p=0.120) and high income countries (I2 = 
40.8%, p=0.06). The study by Cotes-Cantillo et al., 2014 was the only study to report 
a negative vaccine effectiveness (-2 VE; 95% CI -182 to 63%) (185). 
Pooled estimates for case-control studies in high income settings (89% VE; 95% CI 
84-92%; 12 studies [13 estimates]) were comparable to the three unpooled cohort 
study estimates. All cohort studies were conducted in high-income settings. One 
study reported an adjusted VE estimate of 87% (95% CI 80-92%) and other two 
studies stated unadjusted estimates of 100% (95% CI 87-100%), and 90% (95% CI 
82-95%) (176,179,85). 
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Figure 3-3 Vaccine effectiveness against hospitalisation or hospitalisation and 
emergency department attendance for RVGE [only adjusted effect estimates included]  
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Sensitivity analysis  
We identified the possibility of study bias using the NOS. The pooled OR for studies 
with a low risk of bias was 0.18 (95% CI 0.13-0.25; 13 studies [14 estimates], 
p<0.001), suggesting that any bias in these studies may have been minimal. The 
corresponding pooled estimates by World Bank Country classification did not 
change substantially. When studies from countries with state-based or private 
rotavirus vaccine provision (Castilla et al 2012, Martinon-Torres, 2011 and Muhsen 
et al., 2010) were dropped from the meta-analysis the pooled OR remained similar 
(0.19 OR; 95% CI 0.14-0.25; 18 studies [19 estimates], p<0.001) (180,186,197). 
To further investigate the potential for publication bias, specifically that the effect of 
industry funding, we excluded 4 studies which had measured RVGE hospitalisations 
but were funded by industry (172,187–189). Overall pooled ORs remained 
comparable (0.19 OR; 95% CI 0.14-0.26; 17 studies [18 estimates], p<0.001). We 
also established that including an estimate from a study which measured vaccine 
effectiveness against severe disease (Vesikari score ≥11), did not cause an 
overestimation of the pooled estimate (172). 
Subgroup analyses 
Age: Because the age groups included in studies were varied we grouped ages in to 
the following groups to assess VE by crude age groups: <1 year, <2 years, >1 year 
and 1-2 years of age. In middle-income countries there was some variation in pooled 
estimates by age group but confidence intervals overlapped between estimates 
(Figure 3-4a). Here estimates should be interpreted with caution as there was only 1 
study in each of the 1-2 year and <2 year groups. Additionally, the VE estimate for 
children aged >12 months from the 2014 study by Cotes-Cantillo stood out as being 
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heterogeneous. As the authors note this is likely to be due to the low sample size in 
this group and potentially due to a variation in strain dominance by age (185). 
Estimates were very similar across age ranges in high income countries (Figure 
3-4b). 
Full v partial vaccine dose: To determine the impact of the number of vaccine 
doses on VE we compared studies which reported full dose vaccination with first 
dose vaccination for RV1 and RV5 VE estimates. There were 21 studies which 
either reported full or partial vaccination giving 32 estimates (13 partial schedule; 19 
full vaccine schedule). Pooled VE for full dose (81% VE; 95% CI 75-86%, p<0.001) 
was higher than for partial dose (62% VE; 95% CI 55-69%, p<0.001). However, 
there was moderate to high heterogeneity for studies reporting estimates for full dose 
(I2= 60.2%, p<0.001). When stratified by World Bank Country classification, this 
difference was most pronounced in middle-income countries, where pooled vaccine 
effectiveness for full dose was 74% (95% CI 67-80%, p<0.001) and 57% (95% CI 
47-66%, p<0.001) for partial dose (Figure 3-5a). Wider CIs were reported in studies 
reporting full vaccination, likely due to smaller available sample sizes. In high-
income countries VE for partial vaccine dose was 72% (95% CI 60-80%, p<0.001) 
compared to 87% (95% CI 81-91%, p<0.001) for full dose (Figure 3-5b). 
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Figure 3-4 Vaccine effectiveness against hospitalisation or hospitalisation and 
emergency department attendance for RVGE comparing partial age groups a 
middle income countries, b high income countries [only adjusted effect estimates included] 
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Figure 3-5 Vaccine effectiveness against hospitalisation or hospitalisation and 
emergency department attendance for RVGE comparing partial dose to full 
dose a) middle income countries, b) high income countries [only adjusted effect estimates 
included]  
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RV1 and RV5 vaccine effectiveness: Pooled VE for RV1 and RV5 stratified by 
World Bank Country classification showed that RV5 has slightly higher VE point 
estimates in both high and middle income countries but this difference was not 
significant. RV1 is the predominant vaccine used in studies from middle income 
countries included in the meta-analysis (7/10). In high income countries three studies 
reported VE for RV1, six for RV5 and four RV1 and RV5 combined. 
3.4.4 Meta-analysis of vaccine effectiveness against emergency department 
attendances for RVGE 
There were 4 estimates from three studies that included VE for ED attendances for 
RVGE (184,185,189). Three estimates were from high-income countries and one 
from middle-income. Publication bias was not assessed as there were inadequate 
numbers of studies to properly assess via a Begg’s test. Heterogeneity was high for 
these studies (I2 = 78.7%, p<0.001). Random effects meta-analysis gave a pooled OR 
of 0.26 (95% CI 0.12-0.57, p=0.001), indicating a significant effect of vaccination 
against ED attendances for RVGE (Figure 3-6). Analysis stratified by World Bank 
country classifications showed significant VE of 81% (95% CI 75-86%, p<0.001) 
for studies from high income countries. There was only one study from middle 
income countries with a VE of 16% (95% CI -79% to 61%, p=0.651). 
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Figure 3-6 Vaccine effectiveness against emergency department attendances for 
RVGE [only adjusted effect estimates included] 
3.4.5 Meta-analysis of vaccine effectiveness against community consultations 
for AGE 
A single study reported full dose VE against community consultations for laboratory 
confirmed RVGE, reporting a high unadjusted VE estimate of 96% (95% CI 76-
100%) (176,177). Four cohort studies included estimates of VE for community 
consultations for AGE (173–177). Three studies were from high-income countries 
and one from middle-income. Only two out of the four studies reported adjusted 
estimates. The study by Nolan et al., 2012 only reported an adjusted VE for 1 or 
more doses (175). We therefore could only include three cohort studies which report 
unadjusted VE in the meta-analysis. Publication bias was not assessed as there were 
inadequate numbers of studies to properly assess via a Begg’s test. Heterogeneity 
was very high for these studies (I2 = 97.9%, p<0.001). Random effects meta-analysis 
gave a pooled RR of 0.74 (95% CI 0.52-1.06, p=0.10), indicating a non-significant 
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effect of vaccination against community consultations for AGE (Figure 3-7). 
However, analysis stratified by World Bank Country classifications showed 
significant VE of 40% (95% CI 13-58%, p=0.008) for studies from high-income 
countries.  
There was only one study from middle income countries with a VE of -24% (95% -
67% to 8%, p=0.157), this study was assessed as having a high risk of bias as crude 
VE was calculated by the authors and children in the vaccinated cohort were 
significantly younger than the unvaccinated cohort. 
 
Figure 3-7 Vaccine effectiveness against community consultations for AGE [only 
unadjusted effect estimates included]  
3.5 Discussion 
The pooled data from case-control studies indicates that rotavirus vaccination is 
highly effective for preventing hospitalisations and / or ED attendances for 
laboratory confirmed rotavirus, as VE was 89% (95% CI 84-92) for high-income 
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countries and 74% (95% CI 67-80) for middle-income countries. This finding is 
further supported by comparable estimates from the unpooled cohort studies. Most 
studies reporting VE for community consultations could not identify the causative 
organism and therefore reported a much lower effectiveness against community 
consultations for AGE (26% VE; 95% CI -6 to 48%). However, like VE against 
RVGE hospitalisations and ED attendances, the pooled VE for community 
consultations for AGE was significant in high-income countries (40% VE; 95% CI 
13-58%). This study was also able to show that studies from countries with similar 
economic classification demonstrate similar VE and that VE was lower in middle-
income countries compared with high-income countries. Vaccine effectiveness 
against RVGE hospitalisations in high-income countries (89% VE; 95% CI 84-92%) 
was consistent with but at the upper limit of that reported in a Cochrane Review of 
RCTs; 85% (95% CI 80-88%) for RV1 and 82% (95% CI 50-93%) for RV5 for 
preventing severe rotavirus diarrhoea in children up to two years of age (61). 
Differing study definitions of severity and age may be responsible for the slight 
difference between pooled estimates. Additionally, pooled VE estimates from meta-
analysis for RVGE hospitalisations in middle income countries (Brazil, Colombia, 
Nicaragua and Bolivia) were significantly lower than high income countries, again 
consistent with estimates from efficacy studies (61,67). 
Our systematic review found substantial differences in the quality and design of 
studies and considerable heterogeneity. However, there was no evidence of 
publication bias. Heterogeneity was dealt with by stratifying the analysis by World 
Bank Country classification when heterogeneity was low to moderate and by using 
sensitivity analysis to identify factors which may have caused bias in the overall 
estimate. We conclude that the best pooled estimates are provided by stratifying by 
Population effectiveness of the pentavalent and monovalent rotavirus vaccines 
Measuring the effect of rotavirus vaccination on primary and secondary care 76 
World Bank country classification. Sensitivity analyses for RVGE hospitalisations 
and or ED attendances did not identify any substantial effects resulting from 
differences in study quality. Exclusion of studies from countries with only state 
based or private provision of rotavirus vaccination made little difference to the 
overall effect estimates. 
Sub-analyses by vaccine dose identified that 1 dose of rotavirus vaccine conferred a 
lower overall VE estimate than full course dose, particularly in middle-income 
countries, indicating that there is a clear benefit for children completing the full 
schedule. Wider confidence intervals were seen for partial dose estimates due to 
smaller available sample sizes which are likely a result of the majority of children 
completing recommended schedules. 
It was difficult to assess VE by age as the different studies reported VE for different 
age groups and therefore finding standard categorisations for age was problematic. 
Pooled VE estimates in children >1 year of age in middle-income countries were 
lower than for that for infants <1 year of age. This could be due to the higher relative 
disease burden in infants, a consequence of acquiring natural immunity with age, 
independent of vaccination (114). Nonetheless, classifications used here showed no 
significant differences between age groups in both high- and middle-income 
countries, suggesting that the RV vaccination is highly effective against RVGE 
hospitalisation regardless of age. Interestingly, one study from Colombia reported 
high VE in the <1 year olds (84.4% VE; 95% CI 23-97%) but negative VE in >1 
year olds (-79% VE; 95% CI -556 to 51%), the authors indicated that this could be 
because of a low sample size in the older group and a change in the predominant 
rotavirus strains circulating in Colombia during the study to heterotypic non-vaccine 
strains (185). 
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Additionally, whilst prior to vaccination the predominant strain type in many high-
income countries was G1P (36,124) in lower and middle-income countries there is 
often greater strain diversity and concurrent circulation of several strains (12,36). It 
is possible that the frequency of more strains that are heterotypic to vaccine types 
may contribute to the lower VE in middle-income countries. However, there are 
likely to be inherent immunological and epidemiological factors at play (202). 
Using meta-analysis to review VE against community consultations for AGE is 
particularly important in high income countries where the majority of the healthcare 
burden from rotavirus infection is in community healthcare settings. For instance in 
the UK rotavirus was deemed to be responsible for approximately 800 000 general 
practice consultations per year prior to vaccine introduction (30). Pooled estimates 
presented here show considerably lower VE against AGE community consultations 
compared with RVGE hospitalisations in high income countries. Since only one 
study is available for middle income countries, evaluation of the effectiveness of 
vaccination against AGE community consultations in this setting is difficult, 
particularly because this study had high risk of bias predominantly due to significant 
differences in age of the vaccinated and unvaccinated cohorts. 
Whereas clinical trials have suggested lower efficacy against milder disease (67,203), 
a single study here reported VE against laboratory confirmed RVGE community 
consultations on par with VE against RVGE hospitalisations (176,177). Whilst there 
was no indicator of disease severity in the study, the healthcare setting suggests 
milder disease. Therefore there is a need for more robustly designed studies in 
middle-income settings and high-income countries in order to properly assess 
rotavirus VE against milder disease resulting in community consultations for RVGE. 
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Studies reviewed here represent countries with a World Bank Country classification 
of high- or middle-income, and clearly show lower VE in middle-income countries. 
However, the burden of disease is likely to be greater in middle-income countries 
representing a greater potential population benefit of vaccination in these settings. At 
the time of review no studies could be included from low-income settings However, 
findings from a recent study in Malawi suggest a VE of 64% (95% CI 24–83), 
similar to that reported in middle-income countries (204). Future reviews will be 
required to capture studies from these settings. 
As these studies were conducted in the “real world” with population level vaccine 
introduction the VE estimates are likely to include both the direct effect and any herd 
protective effect of population vaccination. This could be particularly significant in 
cohort studies with high population vaccine uptake. Indeed only one study attempted 
to separate the herd protection and direct effect from the overall effect of vaccination, 
estimating a substantial increase in indirect effect of vaccination as cohort vaccine 
uptake increased over time (85). More evidence of the indirect effect of vaccination 
is therefore required through subsequent cohort studies. 
We searched three widely used databases—PubMed, Web of Science, and Academic 
Search Premier —as well as grey literature using a pre-specified, systematic search 
protocol. We were able to quality assess the studies included using an established 
critically appraised tool specifically for use with non-randomised studies in meta-
analysis, allowing a good understanding of a studies validity importantly with 
reference to RCT as a gold standard. The majority of studies were assessed as being 
at low or moderate risk of bias strengthening the meta-analysis for RVGE 
hospitalisation. However, our assessment of study bias used one specific tool, the 
NOS, with some author defined criteria. Therefore, it is possible that another bias 
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assessment tool and criteria would identify a different risk of bias. Furthermore, 
variations in study outcome definitions and statistical methods could have introduced 
error into some of our meta-analyses. For instance, heterogeneity was moderate to 
high in some of the meta-analyses, particularly those that examined community 
consultations; this could be related to varying definitions of a community 
consultation. 
3.6 Conclusions 
This review and meta-analysis has enabled the systematic production of pooled VE 
estimates for rotavirus vaccination globally from the literature. We conclude that 
rotavirus vaccines represent a highly effective preventive measure against severe 
rotavirus disease, with “real world” VE estimates as high as efficacy measures from 
RCTs. There is sufficient evidence to promote the continued roll out of both 
rotavirus vaccines in both high- and middle-income settings. The modest benefits 
from vaccination against community consultations for RVGE represent information 
which can be used in appropriate cost-effectiveness studies, which may provide 
better understanding of the value of reducing mild to moderate disease through 
vaccination. 
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4 Study protocol and general methods 
4.1 Abstract 
Introduction: Rotavirus was the most common cause of severe gastroenteritis in 
infants and young children worldwide. Currently 90 countries include rotavirus 
vaccine in childhood immunisation programmes, but uptake in Western Europe has 
been slow. In July 2013, rotavirus vaccine was introduced into the UK's routine 
childhood immunisation programme. Prior to vaccine introduction in the UK, 
rotavirus was estimated to result in 750,000 diarrhoea episodes and 80,000 general 
practice (GP) consultations each year, together with 45% and 20% of hospital 
admissions and emergency department attendances for acute gastroenteritis, in 
children under 5 years of age. This chapter describes the protocol for an ecological 
study that assessed rotavirus vaccine impact in the UK, to inform rotavirus 
immunisation policy in the UK and in other Western European countries. 
Methods and analysis: In Merseyside, UK, we conducted an ecological study using 
a ‘before and after’ approach to examine changes in gastroenteritis and rotavirus 
incidence following the introduction of rotavirus vaccination. Data were collected on 
mortality, hospital admissions, nosocomial infection, emergency department 
attendances, GP consultations and community health consultations to capture all 
healthcare providers in the region. We assessed both the direct and indirect effects of 
the vaccine on the study population. Comparisons of outcome indicator rates were 
made in relation to vaccine uptake and socioeconomic status. 
Ethics and dissemination: The study was approved by NHS Research Ethics 
Committee, South Central-Berkshire REC Reference: 14/SC/1140. Study outputs 
will be disseminated through scientific conferences and peer-reviewed publications. 
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The study will demonstrate the impact of rotavirus vaccination on the burden of 
disease from a complete health system perspective. 
4.2 Background 
In the UK, rotavirus gastroenteritis (RVGE) is seasonal, with most cases occuring 
between February and April each year. Prior to vaccine introduction rotavirus was 
estimated to result in 750,000 diarrhoea episodes and 80,000 general practice (GP) 
consultations each year in the UK (30), together with 45% and 20% of hospital 
admissions and emergency department (ED) attendances for acute gastroenteritis 
(AGE), respectively, in children under 5 years of age (29). The economic cost of 
RVGE to the health service was estimated to be approximately £14 million per year 
in England and Wales (29). At Alder Hey Children's NHS Foundation Trust, 
Liverpool, UK, rotavirus was a major cause of community-acquired and healthcare-
associated diarrhoea; in a 2-year prospective study among hospitalised children, 
rotavirus was detected by RT-PCR in 43% of community-acquired and in 31% of 
healthcare-associated gastroenteritis cases (205). AGE hospital admissions are 
known to have a positive correlation with socioeconomic deprivation and globally 
the burden of severe RVGE is much higher in low income countries (159). However, 
RVGE has not yet been correlated with socioeconomic deprivation in the UK. 
In July 2013, the Department of Health introduced a rotavirus vaccine into the UK's 
routine childhood immunisation programme (158,206). The live-attenuated, two 
dose oral monovalent vaccine (RV1, Rotarix®, GlaxoSmithKline Biologicals, 
Belgium) is administered at 2 and 3 months of age. At present more than 90 
countries include a rotavirus vaccine in their childhood immunisation programmes 
(73). Based on the uptake of other routine childhood vaccinations in the UK, 
coverage of over 90% would be expected for rotavirus vaccine (207); initial figures 
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for England indicate 93% uptake for first dose and 88% for the second dose of 
rotavirus vaccine (208). 
Clinical trials in middle-income and high-income countries demonstrated high 
(>85%) efficacy against severe RVGE (61). The introduction of rotavirus vaccines in 
the immunisation programmes of these countries has demonstrated direct benefits on 
a par with those observed in clinical trials, with significant reductions in diarrhoea 
hospitalisations (209). An unanticipated but beneficial consequence of rotavirus 
vaccination has been the reduction of rotavirus disease in unvaccinated individuals 
(‘herd’ protection), likely due to reduced virus transmission. Such ‘indirect benefits’ 
include reduced disease in non-vaccinated older children and adults who were not 
thought to sustain a significant burden of rotavirus disease (134). In the UK, the 
burden of RVGE in older children and adults is difficult to estimate but admissions 
for AGE are 2 per 1,000 population in 5–14-year-olds and 7 per 1,000 in those 15+ 
years of age (210). Hence monitoring changes in AGE incidence in non-vaccinated 
older children and adults is critical to assess indirect impact. 
Ecological rotavirus vaccine effectiveness studies have primarily focused on 
mortality, hospitalisations and laboratory detections as a measure of burden 
(103,136,145,187,192,211–213). Severe cases of rotavirus infection will often end 
up in hospital and receive full diagnostic evaluation. However, many cases of 
rotavirus infection, particularly in older children and adults, will not attend hospital 
but will be seen by primary and community healthcare providers. Therefore, in order 
to better understand the burden of RVGE and AGE on all ages and the impact of 
routine immunisation on the health system, it is crucial to examine routine data 
sources for all health service providers in a defined study area. Taking advantage of 
a range of regional healthcare facilities in Merseyside, UK, we conducted an 
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ecological study which uses a ‘before and after’ approach allowing comprehensive 
evaluation of the direct and indirect vaccine impact following the introduction of the 
monovalent rotavirus vaccine into the UK's routine childhood immunisation 
programme. We investigated the relationship between socioeconomic deprivation, 
and vaccine uptake and disease burden. These data will provide evidence to support 
future rotavirus vaccination in the UK and will inform rotavirus immunisation policy 
in other Western European countries (158). 
4.3 Methods 
Each results chapter in this thesis includes a detailed methods section. Presented 
below is a generalised summary of the methods used, adapted from the published 
study protocol (214). 
4.3.1 Study aim 
Routine data sources were used to estimate the direct and indirect effects of 
monovalent rotavirus vaccination on gastroenteritis indicators in the population of 
Merseyside, UK, and their relationship to vaccine coverage and sociodemographic 
indicators. We also hoped to identify the key areas that require extended and 
improved data collection tools to maximise the usefulness of this surveillance 
approach. The main outcome measures are: 
 Laboratory detections of rotavirus in faecal samples; 
 Admissions to hospital for RVGE or AGE; 
 Attendances to EDs for AGE; 
 Number of nosocomially acquired cases of RVGE; 
 GP and community consultations for diarrhoea and AGE; 
 Routine rotavirus vaccine coverage mapping by small area geography; 
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 Relative contribution of direct (those vaccinated) and indirect (not 
vaccinated) effects to overall vaccine benefit in health system usage for both 
RVGE and AGE; 
 Relationship between socioeconomic deprivation, vaccine uptake and RVGE 
/ AGE incidence. 
4.3.2 Study setting and location 
The study was conducted in the large metropolitan area of Merseyside in North West 
England which contains five local authorities (Knowsley, Liverpool, Sefton, St 
Helens and Wirral). Merseyside has a population of ~1.4 million people, with 
approximately 80,000 of its population under 5 years of age. Socioeconomic 
deprivation within Merseyside is variable but over 60% of its population live in a 
more socioeconomically deprived area than the England average (Figure 4-1) (215). 
Vaccination uptake for most routine childhood vaccinations is also variable in small 
areas, but overall Merseyside has uptake above the national average for England 
(207). Healthcare for the population is self-contained with the region and including a 
specialist paediatric hospital. 
4.3.3 Study overview and choice of study designs 
The study employed an ecological design, utilising routine health surveillance data 
before and after rotavirus vaccine introduction. The evaluation incorporates 
interrupted time-series analyses of outcome indicators across the study population. 
Comparisons of outcome indicator rates were made between communities with high 
vaccine uptake and those with lower vaccine uptake and the relationship with 
socioeconomic deprivation. The ecological study approach allows population-based 
rates of outcomes to be compared in space and time using vaccine uptake and 
community-level socioeconomic deprivation as covariates. 
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Figure 4-1 Socioeconomic deprivation in Merseyside  
[Produced using the English Indices of Deprivation 2010, national quintiles for the Index of Multiple Deprivation 
(210).] 
4.3.4 Study data 
The National Health Service (NHS) in England and other government service 
agencies collect a range of administrative and healthcare data which is held at both 
local service level and centrally. Figure 4-2 outlines the data sources that were used 
for the evaluation and Table 4-1 shows the case definitions. 
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Figure 4-2 Schematic of study data sources and outcome measures [LSOA, Lower 
Super Output Area] 
Hospital admission and ED attendance data were obtained from hospital episode 
statistics (HES) (210), which record all inpatient admissions in NHS hospitals in 
England. The study measured hospitalisations and ED attendances for residents of 
Merseyside receiving care in hospitals throughout England. 
GP consultation data for diarrhoea or gastroenteritis was obtained from Clinical 
Commissioning Groups covering Merseyside. Community consultations for 
diarrhoea and gastroenteritis at ‘Walk-in Centres’ were sourced from NHS 
Community Health Trusts. Walk-in Centres are primarily nurse-led primary care 
facilities for illness and injuries without need for prior appointment. 
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RVGE at Alder Hey Children's NHS Foundation Trust (Alder Hey) in Liverpool is 
classified as community acquired or nosocomial. Alder Hey's footprint covers the 
majority of Merseyside's children, so these data enabled the evaluation of the effect 
of rotavirus vaccination on nosocomial rotavirus infection in children across 
Merseyside. 
Each dataset covered at least 3 years either side of vaccine introduction. All data 
were pseudoanonymised to allow distinction of records but no linking of datasets or 
identification of individuals was undertaken. Data were either geocoded from 
postcode to small statistical geographical community units termed Lower Super 
Output Areas (LSOAs) or sourced with this geography. In each LSOAs there is 
approximately 1,500 persons, with denominator populations derived from the Office 
for National Statistics (ONS) mid-year population estimates by LSOA (216). 
Indicators of socioeconomic deprivation at LSOA level were measured using the 
English Indices of Deprivation. The UK Department for Communities and Local 
Government produce the English Indices of Deprivation using census and other local 
administrative data (215). Rotavirus vaccination uptake data were sourced from the 
Child Health Information System (CHIS) which is held by community NHS health 
Trusts in Merseyside. Records of doses of vaccinations given as part of the UK 
childhood vaccine schedule are recorded in CHIS for each child.
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Table 4-1 Case definitions by health dataset 
Dataset Case definition 
Nosocomial and 
community acquired 
Nosocomial – Laboratory confirmed rotavirus case. Gastroenteritis 
symptoms beginning more than 48 hours after admission 
Community acquired – Laboratory confirmed rotavirus case. 
Gastroenteritis symptoms starting within 48 hours of admission  
Hospital admissions Rotavirus case definition - Inpatient finished consultant episodes (FCE) 
with a primary or subsidiary diagnosis International Classification of 
Disease version-10 (ICD-10) diagnosis code of A08.0 
AGE case definition – inpatient FCE with a primary or subsidiary 
diagnosis ICD10 code of intestinal infectious disease (A00 - A09) and 
non-infectious gastroenteritis (K52.9).  
Emergency attendances Attendance with a primary or secondary diagnosis HES Accident and 
Emergency diagnosis code of 26 Gastrointestinal conditions (those 
subsequently admitted excluded to prevent duplication in hospital 
admissions) 
GP Consultations GP consultations with a Read Code of (Read Codes in parenthesis): 
gastroenteritis—presumed infectious origin (A0812), diarrhoea of 
presumed infectious origin (A083); infantile viral gastroenteritis 
(A07y1); infectious gastroenteritis (A0803); enteritis due to rotavirus 
(A0762); infectious diarrhoea (A082); diarrhoea and vomiting (19G); 
diarrhoea symptom NOS (19F6); and diarrhoea (19F2). Infectious 
gastroenteritis will be used as the primary case definition but diarrhoea / 
vomiting will also be included for a secondary indicator of burden. 
Community 
consultations (Walk-in-
Centres) 
There is no consistent approach to diagnosis coding across providers. 
Read Codes (see above codes), Accident and Emergency diagnosis 
codes (see above codes), and free-text are used across Merseyside. 
Laboratory detections Detection of rotavirus in a faecal specimen by a standard enzyme 
immunoassay. 
 
4.3.5 Quality control 
Data sources such as HES and laboratory detections will be influenced by testing 
practices; for instance, testing of some organisms is more likely to occur at certain 
times of the year. In the hospital admission dataset, it is possible that some cases of 
RVGE will not be coded as rotaviral enteritis (ICD10: A08.0) and may be classified 
as other unspecified either due to an absence of laboratory confirmation or 
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misclassification / miscoding. In order to attempt to quantify this information bias, 
the investigator team performed quality control on hospital admissions and 
laboratory detections at the lead NHS Trust hospital site (Alder Hey). Using a 
sample of cases from at least 3 years, those cases with a laboratory confirmation 
were checked against clinical records and clinic coding and those coded as ICD10 
A08.0 rotaviral enteritis were cross-matched against laboratory detections. 
4.3.6 Ethical considerations 
The study has been approved by NHS Research Ethics Committee, South Central-
Berkshire REC Reference: 14/SC/1140. Data sharing agreement were obtained 
between PHE, participating NHS Trusts and the University of Liverpool. Research 
governance approval and data sharing agreements were sought from all participating 
NHS Trusts, Clinical Commissioning Groups and GP practices. 
4.3.7 Data analysis 
Changes in trends of primary care consultations, community consultations, ED 
attendances, hospitalisations and rotavirus detections were explored using 
interrupted time-series analysis. Population-based rates for a minimum of a 3-year 
period prior to vaccination and year on year after vaccination (for 3 years) were 
compared. For the regression analyses, Poisson or negative binomial regression were 
used. We first computed monthly population-based rates that were expected to occur 
in the absence of a rotavirus vaccination programme by fitting the model to pre-
vaccine data. We then adjust for secular and seasonal trends. The models were used 
to estimate ‘expected’ population-based rates after vaccination and compared with 
‘observed’ population-based rates. Rate ratios were calculated to assess the 
magnitude of decline in rates. Potential data biases were controlled for by the access 
and analysis of multiple health data sources. 
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4.3.8 Power calculation 
Based on hospital admissions for RVGE in 2012 obtained from HES data, the 
estimated rate of RVGE hospitalisation is approximately 1 per 1,000 children under 
age 5 years in England (210). Assuming high vaccine uptake rates (i.e. 95%), similar 
to uptake of other routine childhood vaccines in Merseyside, we used a one sample 
comparison of proportions for a two-sided test to calculate the power estimates 
(Table 4-2). Studies from other high income countries on the population effects of 
rotavirus vaccination have shown reductions in hospital admissions of over 50% in 
children under 5 years of age (140). Assuming a similar reduction in Merseyside, 
this study has over 90% power to detect a significant change in RVGE hospital 
admissions. 
Table 4-2 Predicted power of study for main outcome (hospitalisation rate) in 
Merseyside and selected sub-districts 
Area Estimated population 
(children <5 years of age) 
Assumed reduction in rotavirus 
hospitalisation rate 
25% 30% 40% 50% 75% 
Liverpool 27000 0.22 0.31 0.56 0.82 1 
Liverpool and Sefton 41000 0.34 0.48 0.78 0.96 1 
Liverpool, Sefton and 
Knowsley 
50000 0.41 0.58 0.87 0.99 1 
Merseyside 80000 0.63 0.8 0.98 1 1 
 
The study is also powered for detecting an indirect effect in adults. Using an AGE 
hospital admission rate of 7 per 1,000 population aged 15+ years (210), we would 
expect power to be at least 0.97 for Merseyside at assumed hospitalisation rate 
reductions post vaccination of 5%, 8% and 10%. Additionally, for GP consultations 
for AGE in children under 5, a power of 0.89 and 1 can be achieved, for assumed 
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consultation rate reductions post vaccination of 5% and 10% respectively. No formal 
power calculations have been undertaken for other end points under study. 
4.3.9 Project governance 
A stakeholder group within Merseyside was established to enable effective 
achievement of the project objectives and ownership by the professional community. 
The stakeholder group includes representatives from: Liverpool Health Partners 
(217); Liverpool Community Health NHS Trust (218); NHS England Merseyside 
Area Team Screening and Immunisation Team (207); Alder Hey Children's NHS 
Foundation Trust (219); NHS CCGs in Merseyside and Public Health England-
Liverpool (220).  
4.4 Discussion 
This study will enable demonstration of a complete health system perspective of the 
impact of rotavirus vaccination on the burden of disease in Merseyside, UK. It aims 
to study both direct and indirect effects of routine rotavirus vaccination. The study 
will also enable data on vaccine efficacy to infer the relative contribution of RVGE 
to AGE primary care, and emergency care consultations. Furthermore, as data will 
be linked to specific geographical units, for which information on socioeconomic 
deprivation and vaccine uptake is available, the association of these with disease 
burden can be explored. Quality control procedures contained within the study will 
provide a means of adjusting analysis for information bias and also enable 
identification of the key data collection issues that require improvement to maximise 
the usefulness of this surveillance approach. It is also hoped that this study will 
provide a learning resource and template for similar ecological approaches to 
examine effectiveness of other vaccines in the UK in the future. 
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4.4.1 Strengths 
A whole health system approach in a geographically defined area provides a number 
of strengths. Using datasets from a range of healthcare providers within a health 
economy will allow us to examine the relative impact of vaccination on the various 
health providers rather than the individual. The use of multiple data sources to 
measure independent indicators of vaccination effect also provides robustness, 
enabling easier identification of outliers from overall trends. 
Since there is annual variability in the number of rotavirus cases, it is imperative to 
conduct surveillance of rotavirus incidence over a number of years pre-vaccine and 
post-vaccine introduction. This study will provide a mechanism to do this as it will 
cover three rotavirus seasons post-vaccine introduction. Thus, cofounding caused by 
yearly variance in rotavirus numbers will be minimised. 
There are limited published data describing the indirect effect of routine vaccination 
on unvaccinated older children and adults and the majority of studies have focused 
on hospital admissions. As this study will collect data for all ages and cover RVGE 
and AGE incidence 3 years post-vaccination, it will provide sufficient data for 
measurement of the indirect effect on hospital admissions. As well as examining 
indirect effects in EDs and community settings. This is particularly important as it is 
perhaps more likely that moderate / severe RVGE in unvaccinated older children and 
adults will be treated at EDs and through community consultations. 
Another potential strength of the study is the ability to conduct analysis at small 
community (LSOA) level. This will enable small area sociodemographic information 
such as socioeconomic deprivation to be included in the analyses as a covariate at 
the lowest possible unit of analysis other than the individual. Thus, allowing the 
Study protocol and general methods 
Measuring the effect of rotavirus vaccination on primary and secondary care 93 
exploration of the association between socioeconomic deprivation, burden of RVGE 
/ AGE and vaccine uptake while limiting the ecological fallacy of analysis. 
As many of the data sources included in this study do not include specific RVGE 
classification, AGE is used as an outcome measure for most datasets. Laboratory 
detection data which are organism specific has allowed the adjustment of these 
measures based on the seasonal contribution of organisms other than rotavirus such 
as norovirus. For example, RVGE seasonality is fairly constant but that of norovirus 
tends to vary over the winter and spring months in the UK. These AGE indicators 
were adjusted for seasonality (Figure 4-3) to give a better proxy of the contribution 
of rotavirus to overall AGE causes and the relative impact of rotavirus vaccination 
(221). 
 
Figure 4-3 Laboratory detections of norovirus (top) and rotavirus (bottom) in 
the North West, England, 2009/10–2013–14 [Laboratory reports are from LabBase2 system at 
Public Health England, (221)] 
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4.4.2 Limitations 
The gold standard for measurement of vaccine efficacy is the randomised controlled 
trial. However, this ecological study will investigate the impact of vaccination on 
population disease burden within a health system; therefore, an ecological study is 
appropriate. Conversely it is recognised that an ecological approach cannot show 
individual-level effects of vaccine and can only infer the impact of the vaccine at the 
population level without causation. Additionally, a key focus of this study is to 
quantify variation in the outcomes measured according to vaccine uptake levels and 
socioeconomic deprivation. Confounding may be an issue since cases living in areas 
with low vaccine uptake or high socioeconomic deprivation may also have other 
characteristics that will affect the risk of RVGE or AGE. 
For measures of AGE activity in community settings (e.g., GP and Walk-in Centre), 
syndromic indicators that are non-specific to rotavirus, for example, diarrhoea, 
vomiting, were used. An inherent issue is that the ability to detect effect on these is 
likely to be limited to large effects rather than small variations. 
A further limitation of the study is that investigators will not collect data directly as 
all data are secondary, with consequent risk of bias. There is potential for clinical 
coding to lead to misclassification of disease, and this misclassification may vary by 
different data sources. We will describe these biases through quality control and 
subsequently adjust for them at the analysis stage. The use of multiple datasets for 
outcome indicators limits these issues by improving robustness. 
It is likely that there have been changes in data collection methods over the study 
period, for example, changes to the assay used for rotavirus laboratory testing, 
leading to testing bias. One way to adjust for this in the analysis is to smooth 
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fluctuations caused by changes in testing methods. Contact with rotavirus testing 
laboratories and NHS Trusts, has allowed changes to be described and where 
possible assist appropriate analytical adjustments. It is also feasible that the 
introduction of vaccination may also trigger changes in clinician requests for 
rotavirus and other AGE diagnostic testing, particularly in the vaccination age group. 
Any possible testing bias was assessed at the lead NHS Trust via comparisons with 
pre-vaccine testing probabilities. 
The study does not include any economic component. However, previous studies 
have reported the likely cost-effectiveness of rotavirus vaccination for the population 
under 5 years of age (222). This study will provide the results and data necessary for 
economic evaluation based on the direct and indirect impact of rotavirus vaccination.
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5 Early impact of rotavirus vaccination in a large 
paediatric hospital in the UK 
5.1 Abstract 
The impact of routine rotavirus vaccination on community-acquired (CA)- and 
healthcare-associated (HA)-rotavirus gastroenteritis (RVGE) at a large paediatric 
hospital, UK, was investigated over a 13 year period. A total of 1644 hospitalised 
children aged 0-15 years tested positive for rotavirus between July 2002 and June 
2015. Interrupted time-series analysis demonstrated that post-vaccine introduction 
(July 2013-June 2015), CA- and HA-RVGE hospitalisations were 83% (95% CI 72-
90%) and 83% (95% CI 66-92%) lower than expected, respectively. Rotavirus 
vaccination has rapidly reduced the hospital rotavirus disease burden among both 
CA- and HA-RVGE cases.  
5.2 Background 
Prior to rotavirus vaccine introduction rotavirus was an important cause of 
healthcare-associated (HA) gastroenteritis; among children at a large paediatric 
hospital, UK, rotavirus was detected by reverse transcription-polymerase chain 
reaction (RT-PCR) in 43% of community-acquired (CA) and in 31% of HA-
gastroenteritis cases (205). Since the UK introduced the live-attenuated, two dose 
oral monovalent rotavirus vaccine (RV1, Rotarix®, GlaxoSmithKline Biologicals 
SA, Belgium) with doses given at two and three months of age (158). Early impact 
studies in the UK suggested a large reduction (77%) in laboratory-confirmed 
rotavirus infections in vaccine age-eligible infants (223). However, no impact on 
HA-infection has yet been described. Understanding the impact of rotavirus 
vaccination on both CA- and HA-RVGE cases may have implications for both 
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hospital infection control and bed management policies, and will help inform the 
evidence base for continued immunisation in the UK. 
This retrospective investigation aimed to quantify the impact of rotavirus vaccination 
on HA- and CA-RVGE cases at the same children’s hospital as our prospectively 
conducted study from the pre-vaccine period (205). 
5.3 Methods 
5.3.1 Study setting 
The study was conducted at Alder Hey Children's NHS Foundation Trust, Liverpool, 
UK (Alder Hey). Alder Hey provides primary, secondary, and tertiary care facilities 
for >200,000 children each year and has approximately 240 inpatient beds. General 
medicine, general surgery, and a range of specialist services including critical care, 
oncology, cardiac, and neurosurgery are provided; there is also a large emergency 
department. 
5.3.2 Case definition 
Children aged between 0 and 15 years who were admitted with RVGE between July 
2002 and June 2015, or those in whom RVGE developed after hospitalisation, were 
eligible for inclusion. Testing for rotavirus was conducted on clinician request 
throughout the study period with no age restriction. RVGE was defined as rotavirus 
antigen detected by immunochromatographic test or by enzyme immunoassay in a 
faecal specimen of a child with acute gastroenteritis. RVGE was considered HA if 
gastroenteritis developed ≥48 hours after admission and there was no record of 
diarrhoea or vomiting on admission. Clinical and anonymised demographic data 
were collected for each participant, and included information on specimen date, 
admission date, age and symptoms on admission. The pre-vaccine period was 
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defined as July 2002 to June 2013 and the vaccine period was defined as July 2013 
to June 2015. 
5.3.3 Statistical analysis 
To assess the impact of rotavirus vaccination on hospitalisations for CA- and HA-
RVGE, an interrupted time-series methodology was used. Firstly, monthly expected 
incidence of rotavirus hospitalisations was estimated by fitting a negative binomial 
regression model to pre-vaccine monthly incidence data, offset for total monthly 
admissions and adjusting for seasonality and secular trends using calendar month 
and rotavirus year (July to June), respectively (214). This model was used to predict 
the counter-factual numbers of RVGE hospitalisations (in the absence of 
vaccination) for the vaccine period, where the impact of vaccination is expressed by 
the difference between the counter-factual expectation and observed number of 
hospitalisations. To quantify change in the number of RVGE hospitalisations by the 
introduction of the vaccine, a second model included a derived binary indicator 
variable for the post-vaccine period, enabling the computation of risk ratios (RR) and 
associated 95% confidence interval (CI). This second model offset for total monthly 
admissions and adjusted for month and rotavirus year. Percentage change in 
incidence was calculated as 100 × (1 –  𝑅𝑅). The analysis was undertaken 
separately for CA- and HA-RVGE hospitalisations.  To investigate the impact of 
routine vaccination on different age groups the analysis stratified overall RVGE 
hospitalisations by age group (<2 years old and 2-4 years). 
Demographic and clinical characteristics were compared between RVGE cases from 
the pre and post-vaccine periods and between CA- and HA-RVGE cases. For 
continuous variables we used a t-test or Wilcoxon rank-sum test if not normally 
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distributed and χ² or Fisher's exact test for categorical variables. All data handling 
and statistical analyses were performed using R Version 3.1.2 (224).  
5.3.4 Ethical approval 
Ethical approval was provided by NHS Research Ethics Committee, South Central-
Berkshire (Reference: 14/SC/1140). 
5.4 Results 
A total of 1644 hospitalised cases of RVGE were documented between July 2002 
and June 2015. CA-cases accounted for 74.2% (n=1220) of all RVGE cases, 25.4% 
(n=418) cases were HA-RVGE and 0.4% (n=6) did not meet the case definition for 
either HA or CA. In the pre-vaccine period there was a mean of 145 RVGE 
hospitalisations per year (range: 109-191), comprising 108 (83-150) CA- and 37 (18-
58) HA cases (Table 5-1). In the first post-vaccine year (July 2013-June 2014) there 
were a total of 22 RVGE cases and in the subsequent year (July 2014 – June 2015) 
there were 30 RVGE cases. In the pre-vaccine period 25% (range: 15-35%) of 
RVGE cases were classified as HA compared with 29% (18% in 2013/14; 37% in 
2014/15) in the vaccine period (p=0.6). 
There was an estimated 82% reduction in RVGE hospitalisations (95% CI 70-89%) 
in the vaccine period, compared with what would have been expected in the absence 
of vaccination (Table 5-1; Figure 5-1). Most of the decline occurred in vaccine age-
eligible children <2 years old (84%: 95% CI 74-90%). A reduction of 69% (95% CI 
38-86%) was observed in children age 2-4 years who were too old to have been 
vaccinated. There was an insufficient number of RVGE hospitalisations in children 
aged over 5 years in the pre-vaccine era (mean per year=12; range 6-20) to enable 
fitting of the regression model (Table 5-1). The magnitude of reduction in 
Early impact of rotavirus vaccination in a large paediatric hospital 
Measuring the effect of rotavirus vaccination on primary and secondary care 100 
hospitalisations in the vaccine period was similar in both CA-RVGE (83%: 95% CI 
72-90%) and HA-RVGE (83%: 95% CI 66-92%) cases (Table 5-1; Figure 5-1).  
The median age of pre-vaccine CA-RVGE cases (12 months, Interquartile Range 
[IQR] 7-23), was lower than the age of CA-RVGE cases from the vaccine period (23 
months, IQR 14-26; p<0.001). The median age of -HA-RVGE cases that occurred in 
the pre-vaccine period (9 months, IQR 4-22), was non-significantly higher than that 
of HA-RVGE cases in the vaccine period (5 months, IQR 4-14; p=0.131). The 
median age of CA-RVGE cases in the pre-vaccine period was significantly higher 
than that of HA-RVGE cases (p<0.001), with this age difference even greater in the 
vaccine period (p<0.001). 
Table 5-1 RVGE hospitalisations at Alder Hey among children 0-15 years of 
age, pre- and post-rotavirus vaccine introduction 
 Yearly mean No. of 
hospitalisations (range) 
pre-vaccine 
introduction, July 
2002-June 2013* 
No. of 
hospitalisations 
post-vaccine 
introduction, July 
2013-June 2015 
Risk Ratio 
(95% CI) 
Percent decline 
in 
hospitalisations 
(95% CI)† 
p-value 
Age  Year 1 Year 2    
0-15 years 145 (109-191) 22 30 0.18 (0.11-0.30) 82 (70-89) <0.001 
<2 years 111 (88-145) 17 16 0.16 (0.10-0.26) 84 (74-90) <0.001 
2-4 years 22 (15-32) 2 13 0.31 (0.14-0.62) 69 (38-86) 0.017 
5-15 years 12 (6-20) 2 1 - - - 
CA-RVGE 108 (83-150) 18 19 0.17 (0.10-0.28) 83 (72-90) <0.001 
HA-RVGE 37 (18-58) 4 11 0.17 (0.08-0.34) 83 (66-92) <0.001 
*yearly means are based on a rotavirus year running July to June 
†Calculated as 1-risk ratio. Risk ratio was calculated using a negative binomial model adjusting for 
calendar month and rotavirus year. 
 
Early impact of rotavirus vaccination in a large paediatric hospital 
Measuring the effect of rotavirus vaccination on primary and secondary care 101 
  
Figure 5-1 CA- and HA-RVGE hospitalisations at Alder Hey, July 2002 to June 
2015 [The blue line is the number of observed RVGE hospitalisations; the red line is the RVGE hospitalisations 
expected and the grey shading the 95% confidence intervals for the expected. The black hashed line represents 
the introduction of rotavirus vaccine in the UK in July 2013.] 
5.5 Discussion 
Since the introduction in 2013 of routine rotavirus vaccination in the UK there has 
been a significant decline in hospitalisations for RVGE in this large paediatric 
hospital. The magnitude of reduction was similar for both CA- and HA-RVGE cases. 
Age stratified analysis provided further evidence that the reduction in 
hospitalisations is highly likely to be due to the impact of vaccination as the largest 
reduction was observed in vaccine eligible infants <2 years of age. Furthermore, as 
shown in other settings, there was an increase in age of RVGE cases  post-vaccine 
introduction (204,223). The observed reduction in vaccine ineligible older age 
groups (2-4 years) is similar to that observed through national laboratory 
surveillance and may be indicative of an indirect effect of vaccination (223). 
We established that HA-RVGE cases were significantly younger than CA-RVGE 
cases. Furthermore, an increase in age in the vaccine period was observed among 
CA-RVGE cases but this was not observed among HA-RVGE cases. Similar age 
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profiles were also observed at a paediatric hospital in Greece following vaccine 
introduction (225). These data suggest that hospitalised infants remain at risk of 
developing HA-RVGE even among highly vaccinated populations, possibly through 
direct or indirect exposure to rotavirus from older children and adults. 
Our study relied upon rotavirus antigen testing in stools, which is known to be a 
better predictor of symptomatic rotavirus disease than PCR-based methods; 
interpretation of a positive PCR result is rendered difficult because of the high 
frequency of asymptomatic rotavirus shedding in young children, necessitating the 
development of a real-time PCR cut-off to define symptomatic infection (21). 
Therefore, it is likely that the cases in this study represent clinical disease. Although 
rotavirus vaccination cannot be definitively established as the cause of the observed 
reduction in RVGE hospitalisations due to the ecological nature of this study, there 
are additional factors which suggest vaccine impact. The reduction in CA- and HA-
RVGE cases in the vaccine period has not been mirrored by a similar decline in 
respiratory syncytial virus (RSV) infection, another viral pathogen that 
predominately affects young children in winter; indeed, the incidence of HA-RSV 
infection has remained stable whilst RSV infection has increased in the community 
(data not shown). There were also no major changes in hospital infection prevention 
and control policies during the period of study. Finally, our study examined two 
post-vaccine seasons and took into account long-term seasonal and annual trends.  
This study has demonstrated that since the introduction of routine rotavirus 
vaccination in the UK, in addition to a marked decline of CA-RVGE cases, there has 
been a similar fall in HA-RVGE hospitalisations. The reduction in RVGE cases is 
expected to save bed days and reduce the burden on infection control teams with 
potential for both clinical and economic benefit.
Rotavirus vaccine impact and socioeconomic deprivation 
Measuring the effect of rotavirus vaccination on primary and secondary care 103 
6 Rotavirus vaccine impact and socioeconomic 
deprivation: an interrupted time-series analysis of 
gastrointestinal disease outcomes across primary and 
secondary care in the UK 
6.1 Abstract 
Background: Rotavirus causes severe gastroenteritis in infants and young children 
worldwide. The UK introduced childhood rotavirus vaccination in July 2013. We 
evaluated vaccine impact across a health system in relation to socioeconomic 
deprivation. 
Methods: We used interrupted time-series analyses to assess changes in monthly 
healthcare attendances in Merseyside, UK for all ages, from July 2013 to June 2016, 
compared to predicted counterfactual attendances without vaccination spanning 3-11 
years pre-vaccine. Outcome measures included laboratory confirmed rotavirus 
gastroenteritis (RVGE) hospitalisations; acute gastroenteritis (AGE) hospitalisations; 
emergency department (ED) attendances for gastrointestinal conditions; and 
consultations for infectious gastroenteritis at community walk-in-centres (WIC) and 
general practices (GP). All analyses were stratified by age, hospitalisations were 
additionally stratified by vaccine uptake and small area-level socioeconomic 
deprivation. 
Results: Uptake of first and second dose of rotavirus vaccine was 91.4% 
(29,108/31,836) and 86.7% (27,594/31,836), respectively. Among children aged <5 
years, the incidence of gastrointestinal disease decreased across all outcomes post-
vaccine introduction: 80% (95% confidence interval [95% CI] 70-87%; p<0.001) for 
RVGE hospitalisation; 44% (95% CI 35-53%; p<0.001) for AGE hospitalisations; 
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23% (95% CI 11-33%; p<0.001) for ED; 32% (95% CI 7-50%; p=0.02) for WIC; 
and 13% (95% CI -3-26%; p=0.10) for GP. Impact was greatest during the rotavirus-
season and for vaccine eligible age groups. In adults aged 65+ years, AGE 
hospitalisations fell by 25% (95% CI 19-30%; p<0.001).  
The pre-vaccine risk of AGE hospitalisation was highest in the most 
socioeconomically deprived communities (adjusted incident rate ratio 1.57; 95% CI 
1.51-1.64; p<0.001), as was the risk of non-vaccination (adjusted risk ratio 1.54; 
95% CI 1.34-1.75; p<0.001). The rate of AGE hospitalisations averted per 1,000 first 
doses of vaccine was higher among infants in the most deprived communities 
compared to the least deprived in 2014/15 (28; 95% CI 25-31 vs 15; 95% CI 12-17) 
and in 2015/16 (26; 95% CI 23-30 vs 13; 95% CI 11-16). 
Discussion: Following rotavirus vaccine introduction gastrointestinal disease 
reduced across the healthcare system. Vaccine impact was greatest among the most 
deprived populations, despite lower vaccine uptake. Prioritising vaccine uptake in 
socioeconomically deprived communities should give the greatest health benefit in 
terms of population disease burden. 
6.2 Background 
The monovalent rotavirus vaccine (Rotarix®) was introduced into the UK childhood 
immunisation schedule in July 2013, with two doses delivered at 8 and 12 weeks of 
age (158). Vaccine uptake in England increased rapidly, reaching over 91% for 1 
dose by February 2014 and over 94% by mid-2016 (226). To date, studies in the UK 
have separately, and for varied populations and time periods, analysed vaccine 
impact on rotavirus laboratory detections (77% reduction in infants) (223), RVGE 
hospitalisations (>80% reduction in infants) (227), all cause AGE hospitalisations 
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(26% in infants),(223) and GP attendances for diarrhoea related illness (20-30% in 
under 5 year olds) (228).  
This study aimed to assess the effect of rotavirus vaccination on multiple levels of 
the UK healthcare system simultaneously, by examining the trends in 
hospitalisations, ED attendances, community health consultations and GP 
consultations for outcomes of gastroenteritis, diarrhoea and rotavirus gastroenteritis 
(RVGE) in a defined population before and after vaccine introduction. This approach 
will for the first time provide estimates of rotavirus vaccine impact in a “total health 
economy”. Secondly, within the UK, children under five years of age are over 
represented in the most socioeconomically deprived populations (229,230), and 
experience significantly higher incidence of all-cause AGE hospitalisations than 
more affluent populations (159). It is known that in the UK, uptake of routine 
childhood vaccines (e.g. vaccines for measles, mumps and rubella, human 
papillomavirus, influenza) is lower in socioeconomically deprived populations 
(160,161,163). Thus we examined the uptake and impact of rotavirus vaccination in 
Merseyside, an area with wide variation in socioeconomic deprivation, in order to 
assess whether vaccine uptake and impact is equitable. 
6.3 Methods 
6.3.1 Study setting 
The study population was the metropolitan area of Merseyside, England with an 
estimated resident population of 1.4 million and an annual birth cohort of 
approximately 16 000. In 2016, 80,000 of the population were under 5 years of age 
(230). Merseyside contains five local authorities (Knowsley, Liverpool, Sefton, St 
Helens and Wirral), containing multiple National Health Service (NHS) trusts / 
organisations. Healthcare for the population is provided in the community by GP 
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practices and walk-in centres (WICs) offering both primary and urgent care; there 
are five hospitals with emergency and secondary care facilities including a large 
paediatric hospital (Alder Hey Children’s NHS Foundation Trust). Further 
description of the organisations and facilities has been previously described (214). 
6.3.2 Data sources and case definitions for outcome measures 
Data sources and full case definitions have been previously published (214).  Table 
6-1 summarises these details, and amends any discrepancies. Notably, data on GP 
consultations were obtained through the NHS clinical commissioning groups 
(CCGs). Coding for non-infectious gastroenteritis (ICD10 K52.9) was included in 
the all-cause AGE hospitalisation outcome measure, since unspecified gastroenteritis 
was classified under this code until April 2012 (231). 
6.3.3 Area of residence and socioeconomic deprivation 
In each of the health datasets accessed, an indicator for neighbourhood area of 
residence (Lower Super Output Area [LSOA]) was included. English LSOAs are 
small statistical boundaries defined following the 2001 and 2011 censuses and 
consist of approximately 1,500 people. A standardised measure of socioeconomic 
deprivation was assigned to each participant, using the LSOA of their residence and 
the English indices of deprivation 2015, the Index of Multiple Deprivation (IMD) 
(229).
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Table 6-1. Details of each outcome measure and data source 
Data source Population Outcome Denominator / offset Age in 
months 
(m) or 
years (y) 
Time 
period 
Alder Hey 
Children's 
NHS 
Foundation 
Trust -
laboratory 
reports 
Hospitalisations. 
Alder Hey's 
footprint covers the 
majority of 
Merseyside's 
children 
Laboratory confirmed rotavirus 
gastroenteritis. Rotavirus antigen 
detected by 
immunochromatography test or by 
enzyme immunoassay in a faecal 
specimen of a child with 
acute gastroenteritis 
Total hospitalisations per 
month by age group  
0-14y: 
<12m; 
12-23m; 
24-59m; 
5-14y 
July 
2002 
to June 
2016 
Hospital 
episode 
statistics - 
Admitted 
Patient Care 
 
Merseyside 
residents attending 
any hospital in the 
UK 
Hospitalisation for all cause acute 
gastroenteritis. Identified by 
ICD10 codes: A00-A09) or as 
non-infectious gastroenteritis 
(K52.9), in any diagnosis field 
Yearly estimated age 
specific population of 
Merseyside. Source: 
Office for National 
Statistics; accessed 
through Public Health 
England [17] 
All ages: 
<12m; 
12-23m; 
24-59m; 
5-14y; 
15-64y; 
65+ 
July 
2000 
to June 
2016 
 
Hospital 
episode 
statistics – 
Accident and 
Emergency 
Merseyside 
residents attending 
three major 
emergency 
departments in 
Merseyside 
Emergency department attendance 
for gastrointestinal conditions (AE 
diagnosis code 26); excluding 
subsequent admissions. Missing 
diagnosis data was imputed for 
one emergency department 
between November 2010 and 
March 2011 
Total emergency 
department attendances 
(excluding subsequent 
admissions) per month 
by age group 
All ages: 
<12m; 
12-23m; 
24-59m;  
5-14y; 
15-64y; 
65+ 
July 
2008 
to June 
2016 
Walk-in-
Centre 
attendance 
records 
 
Attendances to a 
Walk-in-Centres in 
Wirral, covering an 
estimated resident 
population of 
320,000 
Walk-in-Centre attendance for 
infectious gastroenteritis (Read 
Codes: gastroenteritis—presumed 
infectious origin (A0812), 
diarrhoea of presumed infectious 
origin (A083); infantile viral 
gastroenteritis (A07y1); infectious 
gastroenteritis (A0803); enteritis 
due to rotavirus (A0762); and 
infectious diarrhoea (A082)  
All Walk-in-Centre 
attendances per month 
by age group 
 
All ages: 
<12m; 
12-23m; 
24-59m; 
5-14y; 
15-64y; 
65+ 
July 
2011 
to June 
2016 
 
GP practice 
records 
 
Consultations at 
136 GP practices in 
Merseyside, 
covering an 
estimated 
population of 
790,000 
Consultations for infectious 
gastroenteritis (Read Codes: as 
above for Walk-in-Centre) 
Yearly estimated GP 
registered population by 
age group. Data were 
available from 2010 to 
2016, therefore estimates 
for 2007/2008 and 
2008/2009 were 
synthetically estimated 
using predictions from 
linear regression models. 
Source: Public Health 
England and 
participating GP 
practices 
All ages: 
<12m; 
12-23m; 
24-59m; 
5-14y; 
15-64y; 
65+ 
July 
2007 
to June 
2016 
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6.3.4 Uptake of rotavirus vaccination 
Pseudo-anonymised vaccine status data were extracted from the Child Health 
Information Service (CHIS) (232,233). The CHIS is managed locally by NHS Trusts 
and holds a unique record on each child born in these areas until the age of 18 years. 
We obtained a CHIS data extract on children eligible for rotavirus vaccination born 
from May 2013 to June 2016. The extract included a unique identifier, year and 
month of birth; year and month of first and second dose of rotavirus vaccine, and 
LSOA of residence. CHIS could be accessed for four out of the five local authorities 
in Merseyside. Data for Wirral could not be extracted due to lack of access to the 
CHIS database during the study period, related to organisational restructuring. We 
used codes in the CHIS dataset to exclude deaths, stillbirths and children who were 
born in Merseyside during the study period but subsequently moved out from the 
area. 
6.3.5 Statistical analyses 
Impact 
We examined monthly hospitalisations / attendances to healthcare providers using an 
interrupted time-series design. Firstly, to predict counterfactual numbers of 
hospitalisations and attendances that would have been expected in the absence of 
vaccination for the vaccine period, we fitted generalised linear models with Poisson 
or negative binomial distributions (to account for over-dispersion in the data) to pre-
vaccine introduction monthly counts, offset for dataset specific denominator (Table 
6-1). We adjusted for seasonal trends by including a categorical term for calendar 
month and secular trends by including a linear term for surveillance year (July to 
June) as explanatory variables in the models. Secondly, to quantify the percentage 
reduction in monthly attendances / hospitalisations, we included all data pre- and 
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post-vaccine introduction in a second model with a binary indicator variable 
denoting the post-vaccine period. This second model also included the same terms to 
adjust for seasonal and secular trends and allowed the calculation of incident rate 
ratios (IRRs). Percentage reduction was calculated as: 100 × (1 − 𝐼𝑅𝑅). The RVGE 
“season” in the UK in the pre-vaccine period was consistently between the months of 
January and May with the peak occurring in early to mid-March in most years;(36) 
for sensitivity analysis we examined specificity of end-point by stratifying by events 
which occurred in-season (January-May) and out-of-season (June-December). To 
investigate vaccine impact by age, the analysis was stratified by age group (<12 
months, 12-23 months, 24-59 months, 5-14 years, 15-64 years, 65+ years and 0-59 
months).  
Socioeconomic deprivation, vaccine uptake and hospitalisations 
Firstly, we wished to assess whether the incidence of all-cause AGE hospitalisations 
varied by level of socioeconomic deprivation. To achieve this we fitted negative 
binomial generalised linear models with the number of hospitalisations as the 
dependent variable and quintile of deprivation as the independent variable, offset for 
population denominator and adjusting again for seasonal and secular trends (model 
Y). Quintile of deprivation was calculated using the IMD scores for LSOAs 
nationally, whereby quintile five is the least deprived and quintile one the most 
deprived. Since the population of Merseyside is skewed towards the most deprived 
national quintiles, we combined the two least deprived quintiles into category “4/5 
(least deprived)”. The models allowed calculation of IRR for socioeconomic 
deprivation group by comparing the least deprived “4/5 (least deprived)” to the other 
quintiles, stratified by age group.  
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Secondly, we describe uptake of 1st and 2nd dose of rotavirus vaccine by month of 
birth for children born between May 2013 and December 2015. December 2015 was 
selected as the cut-off to allow all children in the cohort to reach 25 weeks of age, 
the upper time limit for rotavirus vaccination.(234) To investigate associations 
between socioeconomic deprivation and vaccine uptake, we fitted logistic regression 
models where the dependent variable was vaccine status and independent variable 
was national quintile of IMD and adjusted for gender, year and month of birth. The 
models allowed calculation of risk ratios (RRs) for socioeconomic deprivation group 
by comparing the least deprived “4/5 (least deprived)” to the other quintiles. 
Finally, we estimated the all-cause AGE hospitalisations averted per 1,000 vaccine 
first doses delivered in the 2014/15 and 2015/16 seasons for vaccine eligible cohorts 
aged <12 months and 12-23 months. We define the rate of hospitalisations averted 
per 1,000 vaccine first doses delivered as: 
𝑅𝐷𝐴𝑖𝑗𝑘 =
𝑋𝑖𝑗𝑘 − 𝑌𝑖𝑗𝑘
𝑃𝑖𝑗𝑘𝑉𝑖𝑗𝑘
 
where: RDA is the rate of hospitalisations averted per 1,000 vaccine first doses 
delivered; X is the model predicted counter-factual number of hospitalisations that 
would have been expected in absence of vaccination for the vaccine period; Y is the 
observed number of hospitalisations in the vaccine period; P is the population 
denominator; V is the proportion of the population vaccinated with one dose of 
vaccine; i is the deprivation group; j is the age group; k is the surveillance year. 
We used the RDA in the Merseyside population in this study to provide an estimate 
of the number of all-cause AGE hospitalisations averted at a national level if the 
95% vaccine uptake targets set by the World Health Organization (WHO) were 
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achieved across all deprivation strata (235,236). We define the total number of all-
cause AGE hospitalisations averted at a national level in 2015/16 at uniform 95% 
uptake as: 
𝑁𝐷𝐴 = ∑
𝑅𝐷𝐴𝑖𝑗𝑘
1000
× (𝑁𝑖𝑗𝑘 × 0.95) 
where: NDA is the number of all-cause AGE hospitalisations averted; RDA is the rate 
of hospitalisations averted per 1,000 vaccine first doses delivered in the Merseyside 
population; N is the national population denominator, derived from mid-year LSOA 
population estimates 2015 (230); i is the deprivation group; j is the age group; k is 
the surveillance year. 
Data handling and analysis was conducted in R version 3.3.0 or later (224). 
6.4 Results 
6.4.1 Vaccine uptake  
Rotavirus vaccine uptake (at least one dose of vaccine) in children born between 
May 2013 and December 2015 was 91.4% (29108/31,836); completion of full 
rotavirus vaccine schedule (i.e. two doses) was 86.7% (27,594/31,836). In the least 
deprived population, vaccine uptake for at least one dose was 93.6% (4,135/4,420) 
and 90.2% (3,989/4,420). For completion of the two dose schedule; in the most 
deprived population uptake was 90.6% (16,550/18,259) and 84.9% (15,505/18,259), 
respectively (Figure 6-1). The most deprived populations had a 54% (RR 1.54; 95% 
CI 1.34-1.75) increased risk of non-vaccination compared the least deprived 
populations. Furthermore, the most deprived populations had almost twice the risk 
(RR 1.97: 95% CI 1.62-2.41) of non-completion of the two dose schedule compared 
to the least deprived. 
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Figure 6-1. Rotavirus vaccine uptake in 4/5 areas of Merseyside for children 
born between May 2013 and December 2015 by deprivation quintile 
6.4.2 Vaccine impact by age 
Impact in under 5 year olds 
In children less than 5 years of age a clearly defined rotavirus season was observed 
prior to vaccine introduction, with the peak predominately occurring in March across 
all outcome measures for all years prior to vaccine introduction (Figure 6-2). The 
incidence of gastrointestinal disease fell across all health outcomes following 
vaccine introduction (Figure 6-2; Table 6-2). The greatest proportional reduction, 
80% (95% CI 70-87%), was for RVGE hospitalisation. All-cause AGE 
hospitalisations fell by 44% (95% CI 35-53%), ED attendances for gastrointestinal 
conditions by 23% (95% CI 11-33%); and WIC and GP consultations for infectious 
gastroenteritis by 32% (95% CI 7-50%) and 13% (95% CI -3 to 26%), respectively. 
Reductions were greatest in the rotavirus season for all outcomes; all-cause AGE 
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hospitalisations fell by 58% (95% CI 45-67%) and GP consultations by 29% (95% 
CI 8-45%).  
Disease reductions were highest in vaccine eligible age groups. RVGE 
hospitalisation fell by 87% (95% CI 78-93%) in infants age <12 months and 84% 
(95% CI 73-91%) in children 12-23 months; all-cause AGE hospitalisations fell by 
46% (95% CI 36-54%) in infants <12 months and 50% (95% CI 40-59%) in children 
12-23 months. In GP practices, infectious gastroenteritis consultations fell by 19% 
(95% CI 4-33%) in infants, averting 136 consultations per 10,000 registered 
population. There were also significant reductions in gastrointestinal disease 
outcomes in vaccine age ineligible children age 24-59 months; RVGE 
hospitalisations decreased in this age group by 66% (95% CI 44-81%) and all-cause 
AGE hospitalisations decreased by 26% (95% CI 11-39%). However, in the 2014/15 
season a peak of incidence was detected in May across all primary outcome 
measures that was comparable in magnitude to the pre-vaccine rotavirus peak 
observed in March. Disease rates by surveillance year and pre- and post-vaccine 
introduction are provided in Appendix C: Table S3. 
Impact in children aged 5 to 14 years 
In the pre-vaccine period, children aged 5-14 years had the lowest yearly rates of 
hospitalisation for all-cause AGE (18 per 10,000 population) (Table 6-2). Rotavirus 
seasonality in children aged 5-14 years, was less pronounced and inconsistent across 
all outcome measures in the pre-vaccine period (Figure 6-2). In this vaccine-
ineligible age group, between July 2013 and June 2016 there were only two 
laboratory confirmed detections of RVGE at Alder Hey Children’s hospital. 
Furthermore, all-cause AGE hospitalisations and ED attendances for gastrointestinal 
conditions also fell (Table 6-2). General Practice consultations (-3%, 95% CI -21 to 
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12%) and WIC attendances (0 %, 95% CI -52 to 34%) for infectious gastroenteritis 
remained similar to pre-vaccine levels. There were no differences between changes 
in incidence in the rotavirus-season and out of the rotavirus-season. 
Impact in persons aged 15-64 years 
Data were available for four out of five of the primary outcomes. There was no 
clearly identified seasonality in the pre-vaccine period for the non-specific outcome 
measures in this age group (Figure 6-3). Moderate reductions were seen in persons 
aged 15-64 years across all outcome measures (Table 6-2). In the post-vaccine 
period hospitalisations for all-cause AGE fell by 8% (95% CI 2-14%), ED 
attendances for gastrointestinal conditions by 29% (95% CI 16-40), and WIC and GP 
consultations for infectious gastroenteritis by 24% (95% CI 16-40%) and 26 % (95% 
CI 18-33%), respectively. There were no significant differences in the level of 
percentage change when comparing in season and out of season periods.  
Impact in 65+ year olds 
There were significant, moderate reductions in all-cause AGE hospitalisations, ED 
attendances for gastrointestinal conditions and GP consultations for infectious 
gastroenteritis (Figure 6-3; Table 6-2). The reduction in attendances to WICs for 
infectious gastroenteritis was non-significant (47%, 95% CI -15 to 75%). The 
absolute rate of consultations prevented was 19 per 10,000 registered population for 
GPs and 34 per 10,000 for WICs (Table 6-2). During the rotavirus season, 
proportional reductions were slightly higher than out of season, although the 
difference was not significant. 
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Figure 6-2. Trends in five study outcome measures for children aged 0-14 years 
in Merseyside, UK, July 2008 to June 2016 [Each analysis examines trends, including 
comparison of observed incidence (blue line) after rotavirus vaccination (July 2013 to June 2016) in the UK with 
expected incidence (red line) and associated 95% confidence intervals (red shaded area) in the absence of 
vaccination. Expected incidence and 95% confidence intervals are based on predictions from regression models 
fitted to available historic data for each outcome measure. The black hashed line represents the introduction of 
rotavirus vaccine in the UK in July 2013] 
Rotavirus vaccine impact and socioeconomic deprivation 
Measuring the effect of rotavirus vaccination on primary and secondary care 116 
 
Figure 6-3 Trends in four study outcome measures for older children and adults 
aged 15+ years in Merseyside, UK, July 2008 to June 2016 [Each analysis examines 
trends, including comparison of observed incidence (blue line) after rotavirus vaccination (July 2013 to June 
2016) in the UK with expected incidence (red line) and associated 95% confidence intervals (red shaded area) in 
the absence of vaccination. Expected incidence and 95% confidence intervals are based on predictions from 
regression models fitted to available historic data for each outcome measure. The black hashed line represents the 
introduction of rotavirus vaccine in the UK in July 2013]
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Table 6-2. Changes in rates of hospitalisation / attendances to different levels of 
the health system post rotavirus vaccine introduction in Merseyside, UK 
Age group Mean yearly rate of hospitalisations / 
attendances (per 10,000)¥ 
Percent reduction in hospitalisations / attendance 
rates (95% CI)† 
pre-vaccination post vaccination 
Observed Observed Expected* Full year Jan-May Jun-Dec 
Hospitalisations for laboratory confirmed rotavirus to Alder Hey 
<12m 129 14 122 87 (78 - 93) 94 (86 - 97) 57 (10 - 81) 
12-23m 123 16 106 84 (73 - 91) 87 (76 - 94) 70 (19 - 91) 
24-59m 33 10 29 66 (44 - 81) 74 (52 - 87) 35 (70 - 77) 
5-14y 7 0.3 9 95 (84 - 99) 96 (80 - 99.7) 94 (71 - 99.7) 
Total 0-59m 87 12 81 80 (70 - 87) 88 (80 - 94) 58 (25 - 77) 
Hospitalisations for all cause acute gastroenteritis 
<12m 402 230 468 46 (36 - 54) 60 (49 - 69) 35 (20 - 46) 
12-23m 271 128 311 50 (40 - 59) 66 (56 - 74) 37 (19 - 50) 
24-59m 72 54 78 26 (11 - 39) 33 (10 - 50) 22 (1 - 38) 
5-14y 18 20 28 32 (21 - 41) 35 (19 - 48) 29 (13 - 42) 
15-64y 39 60 66 8 (2 - 14) 11 (1 - 19) 6 (1 - 13) 
65+ 135 157 210 25 (19 - 30) 28 (19 - 36) 22 (15 - 29) 
Total 0-59m 178 104 213 44 (35 - 53) 58 (46 - 67) 35 (22 - 46) 
ED attendances for gastrointestinal conditions (no admission) 
<12m 2034 1855 2816 22 (11 - 33) 30 (15 - 42) 16 (2 - 29) 
12-23m 1146 892 1650 31 (15 - 43) 41 (19 - 57) 23 (4 - 38) 
24-59m 759 759 1054 12 (-4 - 25) 14 (-15 - 36) 10 (-6 - 24) 
5-14y 552 661 1038 22 (11 - 31) 17 (-2 - 33) 25 (12 - 36) 
15-64y 405 503 993 29 (16 - 40) 30 (4 - 49) 28 (14 - 40) 
65+ 341 438 788 21 (4 - 34) 25 (-5 - 46) 18 (-3 - 34) 
Total 0-59m 1235 1124 1795 23 (11 - 33) 31 (12 - 45) 18 (4 - 29) 
Walk-in centre attendances for infectious gastroenteritis 
<12m 574 373 644 37 (6 - 58) 51 (12 - 73) 25 (-26 - 55) 
12-23m 463 256 606 39 (0 - 63) 67 (38 - 83) 5 (-86 - 52) 
24-59m 196 153 167 18 (-20 - 44) 36 (-12 - 64) -5 (-79 - 38) 
5-14y 79 71 68 0 (-52 - 34) 6 (-77 - 49) -6 (-86 - 39) 
15-64y 55 51 61 24 (7 - 38) 29 (0 - 49) 21 (-4 - 40) 
65+ 22 18 52 47 (-15 - 75) 56 (-43 - 86) 38 (-72 - 78) 
Total 0-59m 362 231 363 32 (7 - 50) 51 (22 - 69) 12 (-27 - 39) 
GP consultations for infectious gastroenteritis 
<12m 674 492 628 19 (4 - 33) 40 (27 - 51) 3 (-20 - 21) 
12-23m 590 418 498 13 (-10 - 31) 38 (11 - 56) -11 (-44 - 14) 
24-59m 184 166 172 8 (-14 - 26) 7 (-29 - 33) 9 (-20 - 31) 
5-14y 53 56 51 -3 (-21 - 12) -7 (-38 - 17) 0 (-23 - 19) 
15-64y 41 30 41 26 (18 - 33) 29 (17 - 40) 23 (13 - 32) 
65+ 35 29 48 36 (25 - 45) 43 (30 - 54) 30 (13 - 43) 
Total 0-59m 363 282 331 13 (-3 - 26) 29 (8 - 45) 0 (-20 - 17) 
*Expected in the absence of vaccination using negative binomial or Poisson model adjusting for month and 
rotavirus year for the pre-vaccine years. †percent change is calculated as 1-risk ratio. Risk ratio was calculated 
using a negative binomial model adjusting for month and rotavirus year. ¥Table 6-1 provides specific 
denominators for each outcome measure 
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6.4.3  Vaccine impact by socioeconomic deprivation status 
Burden of gastrointestinal infection prior to vaccine introduction 
Prior to vaccine introduction the risk of being admitted to hospital for all-cause AGE 
was 57% higher (IRR=1.57, 95% CI 1.51-1.64) in the most socioeconomically 
deprived populations of Merseyside compared to the least (Figure 6-4). Age group 
stratified analyses showed that in all age groups apart from those 5-14 years of age 
(IRR=1.08, 95% 0.96-1.21), the risk of hospitalisation with all-cause AGE was 
significantly greater in the most socioeconomically deprived populations of 
Merseyside compared to the least. Children <12 months of age in the most 
socioeconomically deprived quintile had the highest rate of hospitalisation (47 per 
1,000 person years), compared with 36 per 1,000 person years in the least deprived 
(IRR=1.31, 95% 1.16-1.47). Among 12-23 month olds, the age group with the 
second highest rates of hospitalisation, the difference between the most deprived (30 
per 1,000 person years) and least deprived (26 per 1,000 person years) was less 
pronounced (IRR=1.15, 95% CI 1.01-1.31). 
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Figure 6-4 Incidence rate ratios of hospitalisation with acute all cause-
gastroenteritis prior to vaccine introduction, by age group and deprivation 
quintile, July 2004 to June 2013, Merseyside UK   
Hospitalisations averted per child vaccinated 
We estimated the number of all-cause AGE hospitalisations potentially averted in 
Merseyside due to rotavirus vaccination in two vaccine eligible age cohorts, <12 
months and 12-23 months of age. In children aged <12 months living in the most 
deprived populations it was estimated that in 2014/15 and 2015/16, 28 (95% CI 25-
31) and 26 (95% CI 23-30) all-cause AGE hospitalisations were averted per 1,000 1st 
dose rotavirus vaccines delivered, respectively. In the least deprived populations 15 
(95% CI 12-17) and 13 (95% CI 11-16) all-cause AGE hospitalisations were averted 
per 1,000 rotavirus vaccine 1st dose delivered, in 2014/15 and 2015/16 respectively 
(Figure 6-5). For the cohort aged 12-23 months it was estimated that there were 18 
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(95% CI 15-20) all-cause AGE hospitalisations averted per 1,000 persons vaccinated 
with at least one dose of rotavirus vaccine in 2015/16 in the most deprived 
populations, and 13 all-cause AGE hospitalisations averted (95% CI 11-16) in the 
least deprived populations.  
 
Figure 6-5 Estimated all-cause acute gastroenteritis hospitalisations averted per 
1,000 vaccine first doses delivered in the 2014/15 and 2015/16 seasons for 
vaccine eligible cohorts aged <12 months and 12-23 months [AGE, acute 
gastroenteritis] 
If the WHO target for primary childhood immunisations of 95% uptake were 
attained in each deprivation strata nationally (England), 10,810 all-cause AGE 
hospitalisations in infants would have been averted in 2015/16, with 41% (4,395, 
95% CI 3,898-4,925) of those averted in the most deprived population (Table 6-3). 
Among 12-23 month olds 9,472 all-cause AGE hospitalisations would be expected 
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to be averted, with 31% (2,940, 95% CI 2,570-3,330) of those averted in the most 
deprived population. 
Table 6-3 Predicted all-cause acute gastroenteritis hospitalisations averted 
nationally in children under 2 years of age in 2015/16 at 95% vaccine uptake 
Age group Index of Multiple 
Deprivation 
Estimated 
national 
population (2016) 
Hospitalisations averted at 95% vaccine 
uptake 
N 95% LCI 95% UCI 
<12months 1 (most deprived) 174784 4395 3898 4925 
2 149462 2185 1795 2603 
3 126372 1597 1292 1924 
4/5 (least deprived) 212359 2634 2156 3147 
Total 662977 10810   
12-23 months 1 (most deprived) 176129 2941 2579 3330 
2 149862 2397 2080 2740 
3 126517 1363 1124 1621 
4/5 (least deprived) 218485 2771 2359 3218 
Total 670993 9472 
  
 
6.5 Discussion 
In this study to simultaneously evaluate the impact of rotavirus vaccine introduction 
across all levels of the healthcare system in a defined geographic area, we have 
demonstrated reductions in gastrointestinal disease burden across all levels of 
healthcare and across all ages. Reductions were greatest for the most specific and 
severe disease outcomes (rotavirus and hospitalisations), during the rotavirus season, 
and for the youngest children who were vaccine age-eligible. Smaller reductions 
among older, unvaccinated populations suggest herd protection. The impact of 
vaccination was also greater in the most socioeconomically deprived populations, 
despite lower vaccine coverage.  
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Most previous studies that evaluated rotavirus vaccine impact in high income 
countries focussed on severe disease outcomes, with magnitude of reductions similar 
to those described here in both vaccine eligible and ineligible children 
(134,141,145,147–149,223,237–244). The reduction in all-cause AGE of 46% (36-
55%) for infants and 50% (38-60%) for children 12-23 months of age was also 
similar to that reported in earlier UK studies, as was the indication of herd protective 
effects in older adults and children (223,239). 
For less severe disease outcomes (disease presenting to GPs and WICs) we 
demonstrated smaller relative reductions compared to more-specific or severe 
disease outcomes. However, these reductions constitute a substantial contribution to 
the absolute number of healthcare contacts averted through vaccination. The impact 
on non-specific outcome measures was consistently highest during the rotavirus 
season for children under five years, suggesting that the observed reduction in 
incidence of AGE is likely to be due to a real reduction in rotavirus disease. The 
smaller reductions in consultations in primary care (WICs and GP practices) are 
likely explained by the non-specific gastroenteritis outcome measure and also 
because of the presumed lower effectiveness of rotavirus vaccine against milder 
disease (98,203). Furthermore, the reductions in GP consultations for infectious 
gastroenteritis observed in vaccine age-eligible children (19% for infants and 13% 
for 12-23 months) are epidemiologically plausible, since a study from the pre-
vaccine period estimated that rotavirus was detected by enzyme-linked 
immunosorbent assay (ELISA) in 14%, and by ELISA and / or PCR in 
approximately 19% of infectious intestinal disease GP consultations in UK children 
under 5,(47,245) with this estimate likely to be higher in infants. Furthermore, the 
estimated reductions in WIC attendances and GP consultations are comparable to 
Rotavirus vaccine impact and socioeconomic deprivation 
Measuring the effect of rotavirus vaccination on primary and secondary care 123 
that reported from analysis of UK syndromic surveillance of GP consultations for 
gastroenteritis, diarrhoea, and vomiting (26% reduction in infants),(228) and are 
comparable with reductions in AGE outpatient attendances reported in Finland (13% 
reduction in infants) (146,148). 
We have shown that the most deprived populations were at the greatest risk of all-
cause AGE prior to vaccine introduction, with highest rates of disease occurring in 
infants in the most deprived populations. This supports previous findings from a 
lower resolution national study, which showed that the rate of hospitalisation with 
all-cause AGE increased with increasing deprivation.(159) The uptake of rotavirus 
vaccination in our study population was also associated with neighbourhood level 
deprivation, with significantly lower uptake of the 1st dose of vaccine and lower 
completion of the full 2 dose schedule in the most deprived populations. Similar 
findings have been shown in Merseyside for measles, mumps and rubella 
vaccination, and locally and nationally for childhood influenza vaccination (160,161). 
We were able to overlay a combination of small area level deprivation status, 
vaccine uptake and all-cause AGE hospitalisations to estimate the disease averted 
per 1st vaccine dose delivered for different deprivation strata. In infants, disease 
averted by vaccination was higher in the most deprived, suggesting that even with 
lower vaccine uptake the most deprived populations benefit the most from the 
vaccination programme. The higher rates of disease averted in infants <12 months of 
age living in the most deprived populations is likely to reflect the higher baseline 
burden of disease in this group and the relative inequity of hospitalisation rates prior 
to vaccine introduction. However, in the 12-23 month olds there a smaller difference 
in disease averted between the least deprived and the most deprived reflecting the 
lower baseline inequity in disease burden between the deprivation strata.  
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Nationally there are disproportionately more infants and young children living in the 
most deprived quintile (26%) compared to the least deprived (15%).(229,230) With 
individual level vaccine effectiveness known to be lower in persons with lower 
socioeconomic status in studies conducted in high income settings,(174,246) 
improving vaccine uptake in the most deprived populations will have the biggest 
impact towards reducing rotavirus associated disease. We estimate that over 41% of 
all-cause AGE hospitalisations averted in infants due to rotavirus vaccination would 
be averted in the most deprived populations if vaccine uptake was equitable across 
deprivation strata at the WHO vaccine uptake target of 95% (235,236). 
6.5.1 Strengths and Limitations 
This ecological study using routine health service data is subject to a number of 
limitations. There is an inherent problem with clinical coding of RVGE in UK 
hospitals; quality analysis at Alder Hey Children’s hospital showed that only 39% of 
laboratory confirmed rotavirus hospitalisations were coded as ICD10 rotaviral 
enteritis (A08.0), and this figure is lower in other UK based hospitals (247). 
Since rotavirus detection is not routinely undertaken in community settings such as 
GP and WICs, syndromic and non-specific outcomes related to gastroenteritis were 
used, and we were therefore unable to account for the contribution of other 
pathogens causing AGE. However, the predictable seasonality of rotavirus infection 
allowed analysis to focus on the rotavirus season, which should improve the 
robustness of reduction estimates in age-eligible children. In older children and 
adults the estimates are more uncertain because there is limited laboratory testing 
and surveillance data on rotavirus seasonality and disease burden in these age groups 
in the pre-vaccine period. The lack of routine testing is evidenced by the 
recommendation in the Standards for Microbiology Investigation S7: gastroenteritis 
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and diarrhoea (PHE) that rotavirus testing is only standard for sporadic cases of 
gastroenteritis under the age of 5 years and immunocompromised cases (26). 
Because of these limitations, model fit was less good for older populations due to the 
less seasonal and more random incidence of gastroenteritis disease, and in these 
situations the analysis may have overestimated the impact of vaccination. 
Furthermore, we used non-dynamic regression fit and so were not accounting for 
changes in force of infection due to reduction in number of cases. We were therefore 
not able to adjust the predicted incidence to account for current levels of infection. A 
full transmission model would be required to fully describe the reduction in 
transmission rate and associated case reduction due to vaccination. Despite these 
limitations, studies in the UK, Australia, Europe and the US also show impact in 
older populations (134,143,223,239,240,248,249). The number of hospitalisations 
averted nationally under uniform 95% vaccine uptake was made using two main 
assumptions. Firstly, that the population of Merseyside is representative of the 
population nationally and secondly, that the relationship between vaccine uptake and 
the herd protective effect of vaccination is linear. Therefore the estimates are likely 
to be conservative as a consequence of assuming a linear relationship, particularly if 
the level of rotavirus vaccine uptake required for population protection is reached 
before 95% uptake.  
Finally, the novelty of measuring vaccine impact on multiple levels of a health 
system simultaneously in a defined population provides robustness that any detected 
changes are due to rotavirus vaccination rather than idiosyncrasies of one particular 
dataset. For example we detected delayed peak activity (April / May) in children 
aged 24-59 months across all primary outcome measures in season 2014/15 
strengthening the evidence that the datasets used in this study were useful in 
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detecting rotavirus activity in non-specific outcomes. This delayed peak is also 
observed in laboratory confirmed rotavirus detections nationally. 
6.5.2 Conclusions and policy implications 
This analysis identified the effect of rotavirus vaccination on healthcare utilisation 
for acute gastroenteritis in the four major levels of the UK health system for five 
outcomes of varying specificity. The study strongly indicates that rotavirus 
vaccination has reduced the incidence of acute gastroenteritis across the healthcare 
system in both vaccine eligible and ineligible populations. Rotavirus vaccination will 
therefore contribute to alleviating the increasing pressures on acute services across a 
health system. With impact greater than that predicted through cost effective 
modelling in the UK (222), these data strongly support the sustained use of the 
vaccine in the UK and continued expansion to other European countries. 
We have also shown that prioritising vaccine uptake in the most socioeconomically 
deprived communities is likely to give the greatest health benefit in terms of 
population disease burden and can contribute to reducing health inequalities. Further 
studies are required to disentangle which factors related to socioeconomic 
deprivation have greatest influence over vaccine acceptance, so that interventions to 
improve vaccine uptake can be effectively targeted.
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7 Mitigating confounding in observational vaccine 
effectiveness studies: a novel methodology using 
propensity score estimation to balance comparator 
populations in a rotavirus vaccine evaluation  
7.1 Abstract 
Background: Measuring real world vaccine effectiveness (VE) relies on the use of 
observational study designs. However, achieving robust estimates of direct and 
indirect VE is frequently compromised by bias, particularly when using syndromic 
diagnoses of low-specificity.  
Methods: In order to mitigate confounding between the measured outcome and the 
likelihood of being vaccinated we developed a method to balance comparator 
populations using individual-level propensity scoring derived from the vaccine-
exposed population, and applied it to the unexposed comparator population. Indirect 
VE was estimated by comparing the unvaccinated vaccine-exposed group with a 
propensity score-simulated unvaccinated, unexposed group. Direct VE was derived 
by removing indirect VE from the overall VE. We applied this method we applied it 
to data collected for evaluation of rotavirus vaccine introduction in the UK in July 
2013. In a general practice birth cohort covering the period May 2010 and June 2016 
and including 54,548 births, we calculated indirect and direct VE against 
consultations for acute gastroenteritis using conventional and vaccination-propensity 
adjustment comparator populations. 
Results: The overall VE calculated using mixed effects Cox regression was 11% 
[95% confidence intervals (95% CIs): 7-16%]. Use of traditional comparator 
populations resulted in implausible VE estimates of -46% (95% CIs: -70 to -26%) 
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for direct and 34% (95% CIs: 23-43%) for indirect effects. Applying our alternative 
method and estimating VE at a range of propensity scores, direct VE ranged between 
8 and 11% and indirect VE between 1% and 4%.  
Conclusions: Estimating VE using propensity score simulated comparator 
populations, particularly for those studies using routine health data with syndromic, 
low-specificity endpoints will aid accurate measurement of the broader public health 
impact of a vaccine programme. 
7.2 Background 
Vaccine efficacy is best measured by randomised controlled clinical trials (RCTs); 
such trials are considered to be the gold standard and are often conducted prior to 
vaccine licensing. However, efficacy studies have rigorously controlled conditions 
and are only generalisable if the study population is comparable to the wider 
population. In contrast, vaccine effectiveness (VE) is a measure of vaccine 
performance under real world conditions (80). Commonly a case-control or cohort 
design is used for calculating VE. These designs have the benefit of being cheaper 
than RCTs. Whilst RCTs with individual randomisation allow the calculation of 
direct vaccine efficacy, VE studies enable the calculation of the overall VE as an 
indicator of the public health benefit of a vaccine. Overall VE is a composite of the 
direct effect on those vaccinated and indirect effect / herd protection conferred by the 
vaccine on the unvaccinated; the total effect combines the direct and indirect effect 
in only those that are vaccinated (Figure 7-1). The overall VE and the indirect effect 
are important for the measurement of the broader public health impact, allowing 
health authorities to calculate realistic vaccine cost-effectiveness, informative to 
vaccine programmes (77,74,76,250).  
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Halloran et al., provide a framework for study design to allow calculation of the 
constituents of overall VE in observation studies (Figure 7-1) (77). This 
methodology has been referenced in a number of observational VE studies 
(85,106,251) In Halloran’s approach two populations are compared, population 𝐴-
‘vaccine-exposed’ and comparator population 𝐵-‘unexposed’. Population 𝐴 and 𝐵 
must be separate in space and/or time to ensure no transmission between populations. 
Population A is divided according to individual vaccination status into 𝐴1 
(vaccinated) and 𝐴0 (unvaccinated). Furthermore, this method requires that 
populations 𝐴1, 𝐴0, and 𝐵 are similar in base-line population and individual level 
characteristics and be distinguished only by vaccine receipt. In observational post-
licensure studies particularly those that utilise healthcare databases for VE 
estimation, are subject to selection bias: confounding introduced through different 
baseline characteristics of the population sampled, such as differences in healthcare 
access, health-seeking behaviour and social-mixing rates (80,252–254). Hence, an 
accurate calculation of the direct VE using post-vaccine population 𝐴, requires that 
the unvaccinated and vaccinated populations (𝐴0 and 𝐴1, respectively) are 
comparable; indistinct in every aspect except vaccine receipt, if confounding is to be 
minimised (Figure 7-1). However, there is clear potential for confounder-dependent 
association between the outcome of interest and likelihood of being vaccinated 
(80,254). For example, those vaccinated (𝐴1) are likely to have different health-
seeking behaviours and better healthcare access than those unvaccinated (𝐴0), 
particularly in outpatient or general practice (GP) settings (80,253). This will 
introduce ascertainment bias which may cause under-estimation of the direct effect 
(254). Additionally, due to social-mixing and transmission within the community, 
individuals in each population (𝐴0 and 𝐴1) may not have fully independent infection 
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risks. Thus direct effect estimates from comparison between these groups is prone to 
error.  
Estimating indirect and total effects by comparing either an unvaccinated post-
vaccine population (𝐴0) or a vaccinated post-vaccine introduction population (𝐴1) 
with a temporally or geographically separate population 𝐵 will not be appropriate. 
This is because population 𝐴 has been conditioned on vaccine uptake, allowing for a 
distinction between populations 𝐴0 and 𝐴1. This is not the case for population 𝐵, 
which remains mixed, and incorporates residual confounding (76,80). Categorising 
population B into virtual groups, those that probably would and would not have 
received vaccine, offers a potential solution. 
 
Figure 7-1 Calculation of vaccine effectiveness based on different comparison 
populations [Adapted from Halloran et al. 1997 and Panozzo et al. 2014 (77,85). Abbreviations: VE, 
vaccine effectiveness; λ, hazard rate of infection] 
The limitations affecting accurate calculation of VE in many observational studies 
can be minimised through the use of propensity scores (PSs). The PS is traditionally 
used in observational studies to reduce the effect of confounding and is the 
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conditional probability of receiving treatment or of being exposed in relation to 
known baseline characteristics (255–258). We therefore propose the use of PS 
analysis to establish propensity for vaccine uptake in population 𝐴 and then applying 
PS to population 𝐵. This enables the simulated splitting of population 𝐵 into two 
groups; those who would have been likely to receive vaccine were it available (𝐵1) 
and those likely to remain unvaccinated despite vaccine availability (𝐵0) (Figure 
7-2). Comparing 𝐴0 with 𝐵0 provides an estimate of indirect VE. Direct VE is then 
derived by removal of the indirect VE from the overall VE estimates. This method is 
particularly applicable to observational studies measuring the broader public health 
effect of a well utilised vaccine using non-pathogen specific syndromic endpoints 
where risk of bias is magnified. To provide an example of this methodology in 
practice we applied it to an evaluation of rotavirus vaccination in the UK. 
 
7.2.1 Applied use of vaccination-propensity adjustment  
Rotavirus vaccination was introduced into the childhood immunisation schedule for 
the UK in July 2013. Children born from 1st May 2013 were eligible to receive the 
live-attenuated, two dose oral monovalent rotavirus vaccine (RV1, Rotarix™, 
GlaxoSmithKline Biologicals S.A., Belgium) with doses given at two and three 
months of age (158). Rotavirus vaccination  rapidly achieved high uptake, at over 
92% for one dose and 88% for two by early 2014 (259). Impact studies in the UK 
have estimated reductions of over 70% in laboratory detections of rotavirus and 
>80% for rotavirus gastroenteritis hospitalisations since vaccine introduction 
(223,227,260). Although high-specificity disease endpoints (e.g. rotavirus 
gastroenteritis) are important, low-specificity endpoints (e.g. all-cause 
gastroenteritis) pose a significant burden to health systems because of their greater 
number. We therefore conducted a birth cohort study to assess VE against milder, 
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non-specific gastroenteritis presenting at GP. We firstly examined rotavirus VE 
using the study design comparator populations used in Figure 7-1 (Method One) and 
subsequently applied novel methodology to measure VE utilising PS analysis 
(Method Two) (Figure 7-2).  
 
Figure 7-2. Calculation of vaccine effectiveness based on simulated comparison 
populations generated through the use of vaccination-propensity adjustment 
[Population A and B are separate through inter alia, geographical or temporal separation. Panel I represents VE 
calculations under rigorously controlled or “idealised“ real world conditions, with no difference other than 
receipt of vaccine between populations. Panel II represents vaccination-propensity adjustment for identifying 
comparator populations under observational conditions. (Panel I: adapted from Halloran et al. 1997 and Panozzo 
et al. 2014). Abbreviations: VE, vaccine effectiveness; λ, hazard rate of infection]  
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7.3 Study population and data 
7.3.1 Setting 
Merseyside is a large metropolitan area in England, with an estimated resident 
population in 2015 of 1.4 million persons, of whom 50,000 are under 3 years of age 
(261).   
7.3.2 Design, Data and Population 
In the UK, GPs electronically record consultations and patient notes for each patient 
registered. Children are routinely registered with a GP in the first months of life. We 
created a birth cohort dataset that included all children born between May 2010 and 
June 2016 and who were registered with any of the participating GPs. Data were 
extracted from GP records by practice or centrally via a National Health Service 
(NHS) Clinical Commissioning Group (CCG). Agreement to participate was first 
sought from the CCGs information governance and then GPs within the participating 
CCGs. Children entered the study at 6 months of age, beyond which no further 
rotavirus vaccination is given in the UK. Due to patient confidentiality data were not 
extracted from children that had died or children for whom there was no consent to 
share data. 
7.3.3 Outcomes, exposures and covariates 
Outcome measures were consultations for acute gastroenteritis including rotavirus 
gastroenteritis. Rotavirus coded consultations are rare because laboratory testing for 
rotavirus is not routinely undertaken in primary care. We therefore used coding 
indicating acute gastroenteritis and associated syndromes (e.g. diarrhoea), excluding 
those for specific non-rotavirus infections, as previously reported (214).   
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Vaccine status was extracted including date of vaccination (214); vaccine status was 
taken at six months of age. Six months was selected because the cut-off for receipt of 
the second dose of the vaccine in the UK is 24 weeks of age (262).  
To account for geographical variation, we included an indicator for neighbourhood 
area of residence (Lower Super Output Area [LSOA]); in order to characterise 
differences in care seeking or access to healthcare we also included GP for which 
each child was registered. English LSOAs are small statistical boundaries consisting 
of approximately 1,500 people. Using LSOA of residence, a measure of 
socioeconomic deprivation was assigned to each participant, measured using English 
indices of deprivation, Index of Multiple Deprivation (229). 
7.4 Statistical analysis 
7.4.1 Method One 
For time to first event analysis we used mixed-effects Cox proportional hazards 
regression models to estimate hazard ratios, comparing the hazard of acute 
gastroenteritis consultations in the pre-vaccine introduction cohort (B) to that in the 
post-vaccine introduction cohort (A) (Figure 7-1 and Figure 7-3). Overall VE 
(𝐴 𝑣𝑠 𝐵) was calculated using 1 − 𝐻𝑅. The time variable started at 0 days when 
children entered the cohort at 6 months of age and were censored following a 
consultation for acute infectious gastroenteritis or at the end of the study period; June 
30th 2013 for the pre-vaccine cohort and June 30th 2016 for the post-vaccine period, 
whichever occurred first. The model included a random effect for registered GPs and 
was adjusted for gender and Index of Multiple Deprivation score. We also estimated 
the direct (𝐴0𝑣𝑠 𝐴1), indirect (𝐴0𝑣𝑠 𝐵) and total effects (𝐴1𝑣𝑠 𝐵), changing the 
comparison cohorts as described above (Figure 7-1). By way of sensitivity analysis, 
we examined the effect of specificity of endpoint by also fitting models which only 
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included events that occurred in peak rotavirus-season (January to May) because of 
the distinct seasonality of rotavirus disease in children in the UK prior to vaccine 
introduction (36).  
 
Figure 7-3 Population cohort groups for this study [𝐴 and 𝐵 are separate in time.] 
Cohort characteristics were compared between children from the pre- and post-
vaccine periods. Continuous variables were tested by Student’s t-test or Wilcoxon 
rank-sum test if not normally distributed and χ2-test or Fisher's exact-test for 
categorical variables. All data analyses were performed using R Version 3.1.2 (224). 
7.4.2 Method Two: alternative VE estimation 
Selection of comparator populations using vaccination-propensity adjustment 
Using population A where vaccination uptake is known, we generated a PS for the 
predicted probability of vaccine uptake based on known associations. Vaccine 
uptake with any dose was the binomial outcome variable, and registered GP practice 
and LSOA of residence were used as categorical predictors. These predictors were 
identified a priori based on the availability of data, previously unpublished local data 
analysis and published literature on risk factors for non-vaccination (20–24). 
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Often a PS is estimated using parametric model such as logistic regression model. 
Here we used a machine learning non-parametric regression model known as 
Generalised Boosting Model (GBM). A number of studies suggest GBM outperform 
PS estimation from simple logistic regression, providing a more flexible approach 
that may model nonlinear relationships using an iterative process with multiple 
regression trees (256,265). We used the “gbm” package in R to generate the PS 
(224,266). Although assessing PS performance with area under the receiver operator 
characteristic curve (AUC) or c-statistics is questionable,(267) in this study we used 
PS for predictive modelling rather than its traditional use. Therefore, using AUC was 
considered appropriate and a value of 0.87 indicated good predictive power.  
We then applied the PS to population 𝐵, enabling 𝐵 to be split into 𝐵0which would 
have the lowest probability of being vaccinated (lower PS) if they were offered the 
rotavirus vaccine, and 𝐵1 the highest probability of being vaccinated (Figure 7-4). 
The populations 𝐵0 and 𝐵1 were generated using a range of PSs including the 80
th-
90th-95th-99th percentiles for non-vaccination.  
 
Figure 7-4 Conceptualised population cohort groups and sub-population 
comparators, utilising a vaccination-propensity adjustment for identification of 
population B0
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Estimating the indirect VE 
An indirect VE can be estimated using a range of PSs to identify population B0 
(Figure 4) and can be written as  
𝑉𝐸𝐼𝐷𝑃𝑆𝑥 = 1 −
𝜆𝐴0(𝑡)
𝜆𝐵0𝑃𝑆𝑥(𝑡)
 
Abbreviations: 𝑉𝐸, vaccine effectiveness; 𝐼𝐷, indirect effect; 𝑃S, propensity 
score range for selecting the comparator population.  
Because GP and residence information were used to generate the PS they could not 
be used for modelling VE. Therefore, a fixed-effects Cox regression model adjusting 
for gender and Index of Multiple Deprivation score was used to calculate VE for the 
indirect and total effects at a range of PS scores. 
Estimating direct VE 
Direct VE cannot be calculated robustly estimated using the comparator populations 
𝐴1 and 𝐴0 because as discussed previously it is likely that differences in healthcare 
seeking behaviour between vaccinated (𝐴1) and unvaccinated groups (𝐴0) could 
cause substantial confounding. We therefore established the following mathematical 
formula for calculating direct VE. 
Overall disease averted (𝑂𝐷𝐴) is a composite of the indirect and direct effect on three 
different populations: 1) those that are vaccinated (𝑉) and receive a direct effect of 
vaccination; 2) those that have been vaccinated but in whom the vaccine has failed to 
exert a direct immune response / vaccine failures (𝑉𝑓) but may still receive an 
indirect effect; 3) the unvaccinated population (𝑈𝑉) that may achieve an indirect 
effect through herd protection. The estimate of overall disease averted in a 
population can be written as:  
O𝐷𝐴 = V𝐷𝐴 + 𝑉𝑓𝐷𝐴 + UV𝐷𝐴 
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Abbreviations: 𝑂𝐷𝐴, overall disease averted by population vaccination; 𝑉𝐷𝐴, 
disease averted in the vaccinated population; 𝑉𝑓𝐷𝐴 , disease averted in the 
population of vaccine failures; 𝑈𝑉𝐷𝐴, disease averted in the unvaccinated. 
Components calculated by: 
O𝐷𝐴 = 𝑉𝐸𝑂 × 𝑃𝐴 × 𝑅 
𝑉𝐷𝐴 = 𝑉𝐸𝐷 × 𝑅 × 𝑃𝐴1 
𝑉𝑓𝐷𝐴 = 𝑉𝐸𝐼𝐷 × 𝑅 × (𝑃𝐴1 × (1 − 𝑉𝐸𝐷)) 
𝑈𝑉𝐷𝐴 = 𝑉𝐸𝐼𝐷 × 𝑅 × 𝑃𝐴0 
Abbreviations:  𝑉𝐸𝐷 ,direct vaccine effectiveness; 𝑉𝐸𝐼𝐷 , indirect vaccine 
effectiveness; 𝑃𝐴 , cohort 𝐴 population; 𝑃𝐴1,  number vaccinated; 𝑃𝐴0number 
unvaccinated; R, rate of disease in the pre-vaccine era. 
Full equation to estimate Overall disease averted: 
𝑉𝐸𝑂 × 𝑃𝐴 × 𝑅
= (𝑉𝐸𝐷 × 𝑅 × 𝑃𝐴1) + 𝑉𝐸𝐼𝐷 × 𝑅 × (𝑃𝐴1 × (1 − 𝑉𝐸𝐷)) + (𝑉𝐸𝐼𝐷 × 𝑅 × 𝑃𝐴0) 
Therefore the indirect VE and overall VE estimates can be used in a rearranged 
equation to produce direct VE estimate and can be written as: 
𝑉𝐸𝐷 =
(𝑉𝐸0 − 𝑉𝐸𝐼𝐷)𝑃𝐴
𝑃𝐴1(1 − 𝑉𝐸𝐼𝐷)
 
Once indirect VE estimates were produced for different comparator populations 
selected using PS at 80th-90th-95th-99th percentiles for non-vaccination we were able 
calculate direct VE. We also specified what values within this range of percentiles 
would be considered epidemiologically and biologically plausible in context of 
rotavirus vaccination in a childhood cohort. This was pre-specified using the 
following criteria: 
 Indirect VE should not be higher than direct VE in a cohort of the same age. 
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 Indirect and direct VE should not be below zero. 
 Direct and indirect VE cannot be higher than the overall VE (maximum value 
at the 95% Upper CI). 
7.5 Results – method one 
7.5.1 Characteristics of the cohort 
Six of the seven NHS CCGs in Merseyside, agreed to participate in the study. 
Therefore, 232 GPs had the opportunity to participate, and of these 135 (58%) 
consented. There was no difference in the IMD score for GP practices participating 
and those that declined. Records on 54 548 children were extracted from 
participating GPs (Figure 7-5); approximately 0.1% of the total registered population 
could not be extracted due to patient confidentiality. We excluded 905 children that 
were born outside of Merseyside or were missing covariates (LSOA, Gender, GP); 
8336 children who were <6 months of age; and 48 children from the post-vaccine 
cohort (A) that had either received a dose of rotavirus vaccine after 6 months of age 
or had an invalid vaccination date. This left 45,259 in the cohort, comprising 23,020 
in the pre-vaccine period and 22,239 in the post-vaccine period. Of the children in 
the post-vaccine period 91% (20,289) had received one rotavirus vaccine dose and 
84% (18,733) received two doses (Table 7-1). In the post-vaccine period, children 
who were unvaccinated were more likely to have been from a socioeconomically 
deprived household (𝐴0 vs 𝐴1: P<0.001) and to have been older / in the cohort for 
longer (𝐴0 vs 𝐴1: P<0.001). Unvaccinated children were more likely to be older 
because vaccine uptake levels took several months after introduction to reach steady 
state (259). 
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Figure 7-5 Study population.  
[Abbreviations: NHS, National Health Service; GP, General Practice] 
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Table 7-1 Characteristics of the cohort Figures are n (%) (n=45,259)  
Variable 
Pre-vaccine 
period (𝐵) 
(n=23020) 
Post-vaccine period (𝐴) 
𝐴0 v 𝐴1  
(P 
value) † 
𝐵 vs 𝐴 
(P  
value)† 
 
Vaccinated 
(𝐴1) 
(n=20289) 
Unvaccinate
d (𝐴0) 
(n=1950) 
Total (𝐴) 
(n=22239) 
Male 11807 (51) 10489 (52) 1012 (52) 11501 (52) 0.866 0.371 
Time in cohort (days)     <0.001 0.041 
Median 412 412 504 412   
Lower quartile 177 170 261 182   
Upper quartile 685 682 777 685   
Number of vaccine doses        
0 
23020 
(100) 
0 1950 (100) 1950 (9) N/A N/A 
1 0 20289 (100) 0 20289 (91)   
2 0 18733 (92) 0 18733 (84)   
Index of Multiple 
Deprivation score 
    <0.001 0.001 
Median 34.390 34.20 44.16 35.13   
Lower quartile 16.94 17.27 22.61 17.44   
Upper quartile 55.26 55.26 60.22 55.85   
Quintile of deprivation≠ 
 
     
5 (least deprived) 1689 (7) 1381 (7) 79 (4) 1460 (7) <0.001 0.014 
4 2599 (11) 2313 (11) 154 (8) 2467 (11)   
3 3567 (15) 3261 (15) 241 (12) 3502 (16)   
2 3499 (15) 3065 (15) 279 (14) 3344 (15)   
1 (most deprived) 11666 (51) 10269 (51) 1197 (61) 11466 (52)   
† χ2-test and Wilcoxon rank-sum test 
≠ Index of Multiple Deprivation score divided into quintiles 
7.5.2 Direct, indirect, total and overall vaccine effectiveness 
The overall VE (𝐴 𝑣𝑠 𝐵) for one or more doses of RV1 for preventing GP 
consultations for acute gastroenteritis and its symptoms in this cohort was 11% (95% 
CI 7%, 16%) (Table 7-2). If only time and events in-season (January to May) were 
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included overall VE (𝐴 𝑣𝑠 𝐵) increased to 30% (95% CI 25%, 34%). Using 
comparator populations specified in Method One the direct VE (𝐴1 𝑣𝑠 𝐴0 ) in our 
cohort was -46% (95% CI -70%, -26%). The indirect effect (𝐴0 𝑣𝑠 𝐵) was 34% (95% 
CI 23%, 43%) and the total effect (𝐴1 𝑣𝑠 𝐵) 9% (95% CI 4%, 14%). Similar to 
overall VE in-season, the direct, indirect and total effects were all higher in the 
rotavirus season (Table 7-2). 
Table 7-2. Rotavirus vaccine effectiveness estimates against GP consultations 
for acute gastroenteritis: Method One   
 Time period 1 or more doses 
vaccinated (𝐴1) n 
Unvaccinated (𝐴0) n Pre-vaccine population 
(𝐵) n 
Vaccine 
effectiveness 
(95% CI) 
Events Population Events Population Events Population 
Direct Full year 2632 20289 191 1950 - - -46 (-70,26) 
Jan-May 1362 19653 109 1913 - - -30 (-58,6) 
Indirect Full year - - 191 1950 3287 23020 34 (23,43) 
Jan-May - - 109 1913 2146 22308 41 (28,51) 
Total Full year 2632 20289 - - 3287 23020 9 (4,14) 
Jan-May 1362 19653 - - 2146 22308 29 (24,33) 
Overall Full year 2632 20289 191 1950 3287 23020 11 (7,16) 
Jan-May 1362 19653 109 1913 2146 22308 30 (25,34) 
Abbreviations: CI, confidence interval. 
7.6 Results - method two 
Figure 7-6 presents the indirect and direct VE for a range of comparator populations 
selected using the PS; they are presented as 1-PS with percentiles towards non-
vaccination. The 95th percentile fell at 1 − 𝑃𝑆 ≥ 0.32 (population 𝐵0: n=1,008) 
giving an indirect vaccine effect of 2% and an associated direct effect of 10%; at the 
99th percentile population where 1 − 𝑃𝑆 ≥ 0.52 the population size of 𝐵0 was very 
low (n=164) and gave an indirect vaccine effect of 25% and direct effect of -21%.  
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Figure 7-6. Indirect and direct vaccine effectiveness against GP consultations 
for acute gastroenteritis; for a range of comparator populations selected 
through vaccination-propensity adjustment [The values on the x axis include populations ≥
 𝟏 − 𝑷𝑺. The grey box represents a plausible range of values given prior knowledge of rotavirus and the vaccine. 
Abbreviations: VE, vaccine effectiveness] 
The 95th percentile for non-vaccination fell within a range of values which were 
plausible. Following the specified criteria, plausible estimates for direct VE ranged 
from 8-11% and the indirect VE ranged from 0-4%  
We also estimated indirect and direct VE for the rotavirus season only. Figure 7-7 
shows the indirect and direct effects for in-season (January to May). At the 95th 
percentile indirect VE was 8% and direct VE 26% (population 𝐵0: n=982), whereas 
at the 99th CI the indirect VE estimate was 38% giving a direct VE of -14% 
(population 𝐵0: n=194). Within the plausible range of estimates (grey box), the 
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direct VE was calculated at between 17% and 29% for indirect VE estimated at 
between 5% and 17%.  
 
Figure 7-7 Indirect and direct vaccine effectiveness against GP consultations for 
acute gastroenteritis during the rotavirus season, for a range of comparator 
populations selected through vaccination-propensity adjustment (January to 
May) [The values on the x axis include populations ≥  1 − 𝑃𝑆. The grey box represents a plausible range of 
values given prior knowledge of rotavirus and the vaccine. Abbreviations: VE, vaccine effectiveness] 
7.7 Discussion 
We have presented two methods for calculating direct and indirect VE in 
observational studies. The first, established method (Method One) is commonly cited 
in the literature for measurement of rotavirus vaccine impact and effectiveness 
(77,85,251). However, in order to provide accurate VE estimates it requires a study 
design with little to no bias and rigorous control over study participants that is often 
not afforded in effectiveness studies. The second methodology (Method Two) 
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attempts to mitigate for design limitations such as selection bias and confounding via 
the use of PS analysis.  
Regardless of the two methods used, overall VE was estimated as 11% (95% CI 7%, 
16%). When analysis was restricted to rotavirus season, thereby increasing 
specificity, the overall VE increased substantially to 30% (95% CI 25%, 34%). The 
overall estimates of VE compare well to those from the ecological study of the same 
population which used an interrupted time-series approach for analysis (Chapter 6). 
Thus rotavirus vaccination appears to be effective at reducing attendances to GPs, 
supporting findings from other studies  assessing rotavirus VE against community 
attendances for acute gastroenteritis (174,175,177). 
When estimating the components of overall VE, Method One produced estimates for 
direct (-46%) and indirect (34%) VE that were implausible, suggesting confounding, 
typical for this type of study design. For instance, the outcome measure depends on 
comparable healthcare seeking behaviour for each comparator group. However, by 
definition, those in the post-vaccine introduction vaccinated group (𝐴1) are more 
likely to access healthcare than the unvaccinated. Therefore, for mild disease which 
is more likely to be seen by GPs than at hospitals it may be assumed that the 
vaccinated (𝐴1) are more likely to seek healthcare contact when ill than the 
unvaccinated (𝐴0), resulting in a negative direct VE. This issue is also true of the 
pre-vaccine introduction cohort (𝐵) using Method One, as this group will include 
persons that would either have been vaccinated or unvaccinated had rotavirus 
vaccine been available. Therefore under Method One a large positive indirect VE 
could be expected if direct VE is negative and the comparator population 𝐵 is more 
likely to access healthcare than population 𝐴0.  
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Method Two attempts to control for the confounding and bias in healthcare seeking 
behaviour by using a PS score to balance comparator populations. Method Two 
provided a range of direct (8% to 11%) and indirect VE (0 to 4%) estimates which 
are plausible given logical criteria based on epidemiological and biological 
knowledge of rotavirus disease and vaccination. Whilst point estimates of direct and 
indirect VE are difficult to specify using this method because they depend on 
selection of the most representative comparator populations, estimates at the 95th 
percentile were plausible for both full year and in-season VE estimates. Estimates at 
the 99th percentile were implausible and were generated using a very small 
comparator population for 𝐵0. We opted not to calculate total VE in Method Two 
because of its limited public health relevance relative to the overall VE and because 
it is a composite of the direct and indirect effects. 
To put our findings into context, a longitudinal cohort study conducted in the UK 
prior to rotavirus vaccine introduction identified rotavirus in 14% of stool samples 
obtained from children under five attending GP practices with infectious intestinal 
disease, with this figure likely to be higher in children under 2 years of age, and 
during the season when rotavirus activity is higher (36,227,245). Given the direct 
effects (8-11%) reported from Method Two and assuming rotavirus was the 
causative agent in 14% of gastroenteritis cases this would suggest an efficacy of 
between 57% and 78%. This is lower than that reported for severe disease in 
developed countries, but the cases in this cohort are likely to represent mild or 
moderate disease against which rotavirus vaccines are less efficacious (203,67).   
This study was subject to limitations which are often associated with secondary 
routine healthcare data. We needed to consider the potential for clinical coding to 
lead to misclassification of disease, and this misclassification may vary by different 
Mitigating confounding in observational vaccine effectiveness studies 
Measuring the effect of rotavirus vaccination on primary and secondary care 147 
GP practice. We tried to account for any GP level effect through mixed effects 
models with GP practice as a random effect. We also investigated any temporal 
changes in coding with the NHS CCGs and there had been no recorded changes in 
practice during the dates of interest.   
There are number of considerations and assumptions required for Method Two to be 
successful. Firstly, it requires data such as population level parameters or individual 
level characteristics for the generation of the PS. In this study using healthcare data 
from a clinical database, we had access to few individual and population level 
indicators. However, even with this level of data we were able to generate a PS with 
excellent discrimination based on a strong association between the covariates and the 
exposure (AUC=0.87). In order to utilise this method in other studies it is imperative 
that individual and population characteristics which are associated with exposure are 
available. However, in generating a PS the complexity of any covariates included 
need to be balanced with the need to keep the PS generalisable to the population. A 
trade-off between specificity and sensitivity is required. Secondly, applying a PS to 
population 𝐵 requires an assumption that the populations 𝐴 and 𝐵 are comparable in 
the variables used to generate the propensity score. This assumption was appropriate 
in this study as we compared the same population at two periods that were 
temporally not too distant. Finally, the criteria used to identify the plausible range in 
this study are specific to the population and pathogen. Nonetheless, provided that 
indirect VE is measured in the same sub-set of the population as the direct VE, the 
criteria are likely to be applicable to rotavirus vaccination in other settings and 
pathogens with similar infectious disease dynamics, such as, short carriage and rapid 
acute symptoms. However, these criteria would be inappropriate for measuring 
indirect VE in sub-populations which are ineligible for vaccination but have high 
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incidence of disease, for example, the indirect effect of vaccination of children with 
Pneumococcal Conjugate Vaccine on Incidence of pneumococcal disease in older 
adults, where indirect may exceed direct VE (268). 
In summary, although Method Two will not remove the temporal bias of ecological 
studies, it does provide a robust solution to dealing with selection bias caused by 
differences in healthcare access and health- seeking behaviour between vaccinated 
and unvaccinated groups. The method is particularly applicable to vaccine 
effectiveness studies using routine health data that wish to measure the broader 
public health impact of a vaccine through the use of non-pathogen specific 
syndromic endpoints. We envisage that this method will be immediately applicable 
to respiratory diseases such as influenza where there are multiple non-pathogen 
specific syndromic outcomes from influenza infection. 
Summary, recommendations and further research 
Measuring the effect of rotavirus vaccination on primary and secondary care 149 
8 Summary, recommendations and further research 
8.1 What this thesis adds to the knowledge base 
I have used routine health data for a defined population to evaluate the effect of 
rotavirus vaccination on a range of health outcomes. To achieve this aim a series of 
inter-linked studies / analyses were conducted using ecological and cohort study 
designs. The effect of vaccination on gastrointestinal disease presentations at 
primary and secondary care in relation to vaccine uptake and deprivation has been 
described.  
In the studies that make up this thesis a number of novel findings were identified. 
Whilst the impact of rotavirus vaccination on severe disease outcomes in high 
income countries has been well described, the impact across an entire healthcare 
economy for a defined population has not been described before. Importantly in 
vaccine eligible children, impact was shown across all outcome measures, in primary 
care and secondary care. The level of impact varied depending on the setting and the 
specificity of the outcome definition but was comparable with other studies 
conducted in high income settings. 
In Merseyside uptake of rotavirus vaccine reached over 90% rapidly mirroring 
national trends (226). Like other routine childhood vaccines, uptake was not 
equitable across deprivation strata. First dose vaccine uptake and completion of the 
full dose schedule was significantly lower in the most socioeconomically deprived 
populations compared to the least deprived. Findings from this Merseyside based 
study also supported that of Pockett et al, 2011, that those living in the most 
deprived populations had the highest baseline incidence of all-cause acute 
gastroenteritis (AGE) admissions (159). These findings suggest that the most 
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deprived populations have the most to gain from rotavirus vaccination. Indeed this 
study shows that infants from the socioeconomically deprived populations derived 
the greatest benefit from rotavirus vaccination despite lower vaccine uptake. This is 
the first time an ecological study design has described rotavirus vaccine impact in 
relation to socioeconomic deprivation in a high income country. 
The impact of vaccination on milder disease across all-age groups is 
underrepresented in the literature (240). This study presents evidence that in children 
<2 years of age where the burden of rotavirus disease is highest, vaccination is 
having a substantial impact on healthcare attendances for mild disease. Furthermore, 
results indicate that herd protection is also reducing mild disease in older adult 
populations, likely through the reduced transmission of rotavirus from children. This 
is an important finding as the majority of rotavirus related disease in healthy adults is 
likely to be mild and either result in home care or contact with primary care.  
The novelty of measuring vaccine impact across primary and secondary care in 
parallel in a defined population provides robustness that any detected changes are 
due to rotavirus vaccination rather than the peculiarities of one particular data source. 
The delayed peak of rotavirus in 2-4 year olds in season two (2014/15) post-vaccine 
introduction detected nationally, in rotavirus laboratory detections and locally, at 
Alder Hey Children’s NHS Foundation Trust was detected across all study outcome 
measures, strengthening the evidence that the datasets used in this study were useful 
in detecting rotavirus gastroenteritis for non-specific outcomes. These findings could 
potentially provide confidence for using similar datasets for other regional vaccine 
evaluation studies. However, the use of an ecological study design with multiple 
non-specific endpoints still means that we can still only infer vaccine impact and 
cannot prove a causal link. The reduction in rotavirus and non-specific AGE 
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outcomes could be related to unmeasured population changes, virus variance and 
environmental factors such as: changes to birth rates (affecting the number of 
immunological naïve susceptible infants); climate; and / or natural shifts in rotavirus 
genotype distribution. Although, these factors cannot be ruled out, they seem 
unlikely to be causing the significant reductions reported in this thesis. Particularly 
since, birth rates in Merseyside have stayed constant (230) and seasonal rotavirus 
genotype distributions in the UK pre-vaccine introduction were stable for decades 
(36,269–271).  
The retrospective general practice (GP) birth cohort using routine data from primary 
care was an original approach to measuring rotavirus vaccine effectiveness (VE) 
against GP consultations for infectious gastroenteritis. This study was intended to 
allow a methodologically rigorous analysis of individual level rotavirus vaccine VE 
against milder non-specific disease. However, there were a number of issues with 
confounding associated with the use of a retrospective healthcare database. 
Therefore, these issues necessitated the development of a new methodology for 
designing and analysing VE in studies suffering from confounding, related to 
healthcare access / health-seeking behaviour. Use of an adaptive study designs, like 
that used here, are gaining prominence in case-control, cohort and ecological studies 
measuring VE and impact, as epidemiologists continually look to reduce study bias, 
maintain generalisability and ethics, whilst conducting cost-realistic studies 
(254,272). This methodology should therefore be useful to epidemiologists assessing 
the effect of interventions; specifically VE studies measuring multiple non-pathogen 
specific syndromic outcome. However, it requires application under different 
conditions, such as vaccines with lower vaccine uptake, (e.g influenza vaccine) to 
assess the generalisability of this method. 
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8.2 Recommendations arising from thesis 
8.2.1 Data access and quality 
As the studies included in this thesis were entirely based on analysis of routine 
health data, there has been the opportunity to assess the accessibility and usefulness 
of these data sources for infectious disease epidemiological research. Access to data 
is incredibly complex and time consuming, largely due to the complexities of NHS 
organisational structures across multiple local authorities (Figure 8-1).  
There are aspects of this study that require improvement, firstly, there were 
substantial inconsistencies in clinical / symptomatic coding across services which 
provide similar if not identical functions but are commissioned by different 
organisations. For instance Read Codes, accident and emergency NHS codes or free-
text were used by walk-in-centres (WIC) across Merseyside to record a patient’s 
symptoms / clinical presentation. Secondly, there has been multiple instances of the 
organisations responsible for commissioning services not having access to full 
datasets for the services they commission, either because of restrictions in access 
caused by IT data provider contracts, organisation restructure or gaps in staff training. 
These experiences have led to the following specific recommendations: 
 Data for this study came from multiple NHS organisations and was provided 
to the study team without financial remuneration. Access was only possible if 
NHS organisations could see the value of the study. The success of this study 
has therefore largely been facilitated by strong partnership working between 
the research team and partner agencies and a commitment to using an 
evidenced-based approach. Therefore identifying key individuals and 
fostering strong relationships early on in study design is crucial for a 
successful study. 
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 Regular contact with data providers including sites visits by researchers to 
observe data input and database storage is critical to understanding the 
complexities and idiosyncrasies of secondary clinical data. This effort will 
help to minimise study bias and the potential of erroneous findings. 
 For anonymous data research / surveillance GPs and NHS CCGs should 
consider employing an opt out method for data sharing between GPs and 
NHS CCGs. NHS CCGs should act as the data custodian on behalf of GPs.  
 IT systems procured for use by healthcare providers, should allow 
compatibility with legacy systems. Contracts with IT providers should not 
include costs for data access incurred by providers and commissioners. 
 All anonymous data collected within the NHS on patients should be freely 
accessible to the organisations that commission the service in question and to 
the service providers.  
 Permissions for data sharing for research purposes could be streamlined if 
multiple NHS Trusts and CCGs utilised a cross-organisation team for 
research governance and data protection. 
 Study investigators should organise a regional event to feedback research 
finding and recommendations. Those invited should include: NHS Trusts; 
NHS CCGs; Public Health Departments at local authorities; Regional Public 
Health England; and NHS England Screening and Immunisation team. Lay 
members of these organisations should be invited. The event should also 
provide an opportunity for sharing future research priorities. 
In the longer term many of the specific recommendations above would be redundant 
in secondary data studies if primary, secondary and community health data were 
linked as routine practice to create an anonymised unique record for each GP 
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registered patient. Access could then be governed on a study specific basis by the 
NHS Health Research Authority Confidentiality Advisory Group (CAG) (273). 
8.2.2 Research design and analysis 
The rotavirus vaccine programme was introduced universally across the UK in July 
2013, therefore population-level vaccine impact studies have been limited to a cohort 
or time-series design with ‘before and after’ comparator populations. The use of 
more robust pragmatic study designs and analysis could be utilised for this and other 
vaccines. For example, although not feasible for evaluating rotavirus vaccination in 
the UK, a cluster randomised stepped wedge design could be both politically, 
analytically and logistically appealing for a new vaccine programme (109,274). 
Alternatively, novel analytical methods could be used to minimise unmeasured bias 
and confounding, helping to disentangle changes in outcome measures that are 
related to the vaccine and changes that are caused by extraneous factors. In this 
thesis propensity score analysis was utilised in an original methodology to balance 
comparator populations in a birth cohort through minimising confounding related to 
healthcare seeking behaviour. Other methodologies may also have been applicable 
and may warrant investigation for future analyses. One such method uses synthetic 
controls for adjusting interrupted time-series models (272,275). In this approach 
multiple control time-series are weighted based on their fit to the pre-vaccine 
introduction time-series of the outcome of interest and combined into one control 
time-series. Unmeasured bias and confounding is effectively adjusted for, using the 
synthetic control’s predicted counterfactual estimates of what would have occurred 
in the post-intervention period if the vaccine had not been introduced (272).  
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8.2.3 Microbiology standards 
The significant reduction in laboratory confirmed rotavirus at Alder Hey Children’s 
NHS Foundation Trust and mirrored at other acute hospitals may encourage 
rotavirus diagnostic and genotypic testing practices to change. The decrease in 
RVGE is likely to mean the relative prevalence of other AGE causing pathogens, 
such as norovirus and adenovirus increases. It may be sensible and cost-effective for 
paediatric hospitals to begin testing for these pathogens if not already doing so. 
However, as it is only four years since rotavirus vaccine introduction, routine 
paediatric testing should continue, so that the long term effect of vaccination on 
paediatric RVGE epidemiology can be monitored, especially genotype distributions 
and prevalence. 
8.2.4 Vaccine policy 
Finally, the findings that vaccination in the most socioeconomically deprived 
communities has the largest impact on population disease burden despite lower 
vaccine uptake, further highlights the need for additional targeted immunisation 
campaigns in socioeconomically deprived populations to maximise vaccine impact 
and cost-effectiveness. Whilst identifying deprived areas at the micro-population 
level is relatively straightforward, understanding the enablers and barriers for 
vaccination in these communities is challenging; particularly since opinions are fluid. 
However, successfully increasing uptake of routine childhood vaccinations in the 
most deprived areas will contribute to reducing health inequalities and help “give 
each child the best start in life” (276,277). 
Summary, recommendations and further research 
Measuring the effect of rotavirus vaccination on primary and secondary care 156 
 
F
ig
u
re
 8
-1
 E
n
d
 o
f 
st
u
d
y
 s
ch
em
a
ti
c 
o
f 
d
a
ta
 s
o
u
r
ce
s 
a
n
d
 p
ro
v
id
er
s 
a
cr
o
ss
 M
er
se
y
si
d
e
 
Summary, recommendations and further research 
Measuring the effect of rotavirus vaccination on primary and secondary care 157 
8.3 Further research 
This study was conducted over only 3 years post-vaccine introduction on routine 
health data. Whilst there is strong evidence that rotavirus vaccination has 
significantly reduced healthcare use for AGE across both primary and secondary care, 
in vaccine eligible infants, and young children, the long-term impact of vaccination 
on these cohorts is as yet uncertain. Prior to vaccination in the UK, there was a well-
defined rotavirus season occurring between January and May each year with peak 
incidence in late March (36). Infections were predominately caused by the G1P[8] 
genotype (56%) and ~90% of RVGE was in children less than 5 years old. However, 
persons aged 5 years and over were more likely to be infected with non-G1P[8] 
genotypes. Odds of infection with less common non-G1P[8] strains also increased 
out of rotavirus season (June-December), as did the odds of infection in persons aged 
5 years and over. This pattern of a relative proportional increase in less common 
genotypes out-of-season and the associated reduction in rotavirus incidence are 
reflected in countries which have introduced vaccination (278,279). Furthermore, 
since vaccine introduction there is the potential that vaccinated children will have 
reduced exposure to both natural primary and secondary infections as a child because 
they are only being exposed to G1P[8] in the Rotarix® vaccine. Therefore, further 
work should explore the hypothesis that heterotypic immunity to non-G1P[8] 
genotypes in the vaccinated cohort will be lower than in the pre-vaccine era, leaving 
this cohort more susceptible to heterotypic infections as older children and adults, 
potentially increasing the risk of outbreaks in older children. 
To achieve these aims, serological data, cohort healthcare data from hospitals and 
primary care and mathematical models would be required to predict how routine 
childhood vaccination may alter the epidemiology of rotavirus infection. Specifically, 
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looking to investigate how rotavirus genotype distribution and risk of rotavirus 
infection changes as a vaccinated cohort ages. Then to validate the model predictions 
against routinely collected epidemiological data. Any changes to disease patterns 
will have implications for diagnostics, outbreak prevention and response and the 
public impact and societal cost. This study would therefore be important and unique; 
integrating detailed serology, genotyping and incidence data into mathematical 
models will allow us to understand, monitor and predict any changes in the 
epidemiology of rotavirus infections. This work would support vaccine programme 
policy and health protection preparedness going forward.  
It was not possible within the scope of this study to determine the economic cost of 
rotavirus ‘before and after’ vaccine introduction across a healthcare system in 
relation to socioeconomic deprivation and vaccine uptake. Economic evaluations of 
the impact of rotavirus vaccine exist but have mainly focussed on the effect on 
severe disease presentations and specific endpoints. What is lacking is an economic 
assessment of the impact on the wider healthcare system, taking into account less 
specific endpoints and societal costs. However, the data collected in this study along 
with previously published data could be used to parameterise an economic-cost 
model for direct medical and indirect patient / carer costs associated with an episode 
of acute viral gastroenteritis. For instance, these data would allow the medical costs 
of an episode to be extrapolated from resources such as the Unit Costs of Health and 
Social Care and the NHS reference costs (280,281). Whereas the indirect patient / 
carer costs could be estimated using data from the previously published Infectious 
Intestinal Diseases Study (IID2), UK. A cost saving per episode and a total cost 
saving could then be calculated, which can be further analysed for differential impact 
across socioeconomic strata.  
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In addition to the commonly associated symptoms of diarrhoea and vomiting, 
rotavirus infection is associated with childhood seizures. Prior to vaccine 
introduction, a large multi-centre study in Canada, showed that 7% of children 
hospitalised with laboratory confirmed rotavirus infection had seizures (282). 
Rotavirus vaccine introduction in the United States has been associated with a 18-
21% reduction in emergency department or hospital diagnosed seizures (283). In 
Australia there has been a 35-38% reduction in febrile seizure hospitalisations in 
children under 2 years of age, since rotavirus vaccine introduction.  
As yet, no study has been conducted in the UK to assess the population impact of 
rotavirus vaccination on afebrile and febrile seizures. However, preliminary analysis 
by this research team suggest a 34% reduction in hospitalisations for all-cause AGE 
with a co-diagnosis of febrile seizure in children under 5 years of age since 
introduction of rotavirus vaccination. Therefore an ecological study to assess the 
impact of rotavirus vaccination in children under 5 years of age on seizure 
hospitalisations; and, to estimate the unmeasured incidence of seizures associated 
with rotavirus infection would be welcome.  
In this thesis a novel method for dealing with bias in observational vaccine 
effectiveness studies is described and tested using rotavirus vaccination in a GP birth 
cohort. However, it is now necessary to test the applicability of the novel method in 
other relevant studies. An adapted application of the methodology is planned for 
investigating the impact of pneumococcal conjugate and rotavirus vaccine over time 
in Malawi, using all-cause mortality as the outcome and population level 
demographic survey data for reducing confounding through balancing comparator 
groups (284). 
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Lastly, ongoing work is required to understand the underlying barriers and enablers 
to childhood vaccine uptake in socioeconomically deprived communities. The 
evidence included in this thesis has already supported a public engagement grant for 
understanding attitudes to vaccination in the Liverpool community and is supporting 
ongoing work to develop educational resources through an iterative process in the 
community.  
8.4 Conclusions 
In summary, this thesis has presented a wide body of evidence that rotavirus 
vaccination reduced healthcare use related to AGE, in young children in a defined 
geographic area; ranging from rotavirus specific hospitalisations to milder disease 
presenting to GPs and WICs. Furthermore, there is also indication that vaccination is 
offering herd protection particularly to older adults. The findings also offer evidence 
that rotavirus vaccination reduces severe disease burden in the most 
socioeconomically deprived populations, despite lower vaccine uptake. These data 
should support national measures to reduce health inequalities by improving vaccine 
uptake in the most deprived communities. Lastly, in the process of assessing 
rotavirus VE in primary care a novel methodology was developed to mitigate the 
often inherent bias in routine health data. This method will be particularly applicable 
to clinicians, epidemiologists and public health professionals that wish to measure 
the wider public health impact of a vaccine through syndromic endpoints in routine 
healthcare data. 
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Appendix C: Supplementary tables 
Table S1 study characteristics of seven cohort studies published between January 2006 and April 2014. 
Study Country Vaccine 
introduction 
year 
Vaccine 
coverage 
Study period Setting Outcome Cohort definition Vaccine 
status 
VE measure 
Eberly et 
al. 2011 
USA 2006 54% July 2003-
June 2009 
Military 
health 
system 
database 
Hospitalisation for RVGE Cohort of all US military dependents <5 years enrolled in 
Department of Defence’s  health care program 
Outpatient 
records 
contained 
within 
database 
1-RR x 100 (crude) 
Fontes-
Vieira et 
al. 2011 
Brazil 2006 (National 
immunisation 
programme) 
NR December 
2006-
December 
2008 
Monitored 
at home 
every 2 
weeks 
All-cause diarrhoea and RV (+) 
diarrhoea 
Cohort of 500 children under 1 year.    Reports cumulative 
incidence of all-cause diarrhoea and number of samples RV 
positive in vaccinated and unvaccinated groups. 
Vaccination 
card and 
health centre 
databases 
NR calculated by reviewers. 
Muhsen 
et al. 
2011 
Israel 2007 (partial 
reimbursement 
offered) 
55% September 
2008-January 
2009 
Health 
maintenance 
organisation 
(HMO) 
database 
AGE requiring a physician visit 
in infants < 1 year (Physician 
diagnoses coded as AGE 
according to ICD 9)  
Cohort of 34,642 infants analysed. Exposure variable: RV 
vaccine purchased before September 1st 2008 
Vaccine 
purchases 
(HMO 
database) 
1-RR x 100, stratified by 
number of doses purchased 
and socioeconomic status 
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Nolan et 
al. 2012 
USA 
(Philadelphia) 
2006 78.2% 
(1+) 65% 
(full) 
Feb 2006 – 
Feb 2008 
Electronic 
Health 
Record of a 
Paediatric 
Practice 
Based 
Research 
Network 
AGE community consultation, 
AGE after hours telephone 
calls, or AGE episode 
(combination of calls and 
consultations occurring within 
10 days of each other to 
estimate discrete episodes) 
A total of 24,679 children eligible for RVV.  
Cohort 1 -  children eligible in both 2007 & 2008 – 13951 
(9351 received vaccine). Further divided in to 1a – 2007 
season, and 1b 2008 season (mutually exclusive) 
Cohort 2 – children only eligible in 2008 – 10728 (9958 
received vaccine). 
Electronic 
Health 
Record 
1-IRR x 100, adjusted for 
age at start of season, race, 
practice location, presence 
of a chronic condition, well 
child visits up to date, non-
RV immunisations up to 
date, total sick-child visits, 
time in cohort. 
Panozzo 
et al. 
2014 
USA 2006 51% in 
2007 - 
86% I n 
2010 
Born May 
2000-April 
2005 and 
born May 
2006- April 
2010 
National 
Health 
Insurance 
Claims 
Database 
ICD9 Codes identifying RVGE & 
AGE hospitalisations 
Cohort of 905,718 children aged 8-20 months who had 
received at least 1 dose of DTaP. 
Coding in 
National 
Health 
Insurance 
Claims 
Database 
1-Hx100  Cox regression. 
Age was the time variable 
and  analyses were 
stratified by year and 
adjusted for birth month.  
Wang et 
al. 2010 
USA 2006 NR 2007 & 2008 
Rotavirus 
Seasons 
National 
Health 
Insurance 
Claims 
Database 
ICD10 Codes identifying RVGE 
& AGE outpatient 
consultations, hospitalisations 
and ED presentations. ED 
presentations and 
hospitalisations were 
combined into one outcome. 
A total of 42306 infants who had received at least one dose 
of RV5 and a concurrent group of 28,417 infants who had 
not received RV5 but had received a first dose of DTaP. 
Vaccination 
codes or 
National drug 
codes o 
health 
insurance 
claims. 
VE =  1- rate ratio 
comparing infants receiving 
RV5 to DTaP. AGE outcomes 
were adjusted for gender 
and calendar year. RVGE 
outcomes not adjusted due 
to small numbers 
Wang et 
al. 2013 
USA 2006 NR 2007 & 2008 
Rotavirus 
Seasons 
National 
Health 
Insurance 
Claims 
Database 
ICD10 Codes identifying RVGE 
& AGE outpatient 
consultations, hospitalisations 
and ED presentations. ED 
presentations and 
hospitalisations were 
combined into one outcome. 
A total of 33140 infants who had received a full course of 
RV5 and a concurrent group of 26167 infants who had not 
received RV5 but had received a full course of DTaP 
Vaccination 
codes or 
National drug 
codes o 
health 
insurance 
claims. 
1- RR x 100 AGE outcomes 
were adjusted for gender 
and calendar year. RVGE 
outcomes not adjusted due 
to small numbers 
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Table S2 study characteristics of twenty three case-control studies published between January 2006 and April 2014. 
Study Country Vaccine 
introduction 
year 
Vaccine 
coverage 
Study 
period 
Setting Outcome Case definition Control definition Vaccine status VE measure 
Case-Control studies 
Bellido-
Blasco et 
al. 2012 
Spain 
(Castellon) 
2006 (privately 
available) 
21.8% 
(control 
group) 
2009 Laboratory 
surveillance 
Laboratory 
detection 
Children 2-35 months of 
age with Diarrhoea and 
laboratory (+) RV. Mixed 
infections excluded 
Children 2-35 months of age with AGE with 
laboratory (-) RV 
Immunisation 
registry 
1-OR*100  adjusted for 
age, hospitalisation and 
time of year. Logistic 
regression. 
Braeckman 
et al. 2012 
Belgium 2006 (National 
immunisation 
programme, 
partially 
reimbursed) 
>90% February 
2008-June 
2010 
Random 
sample of 
39 hospitals 
Hospitalisation 
for RVGE 
Children with AGE aged 
3-59 months with 
laboratory (+) RV 
Non-AGE controls – matched to case’s DOB 
attending hospital or outpatient clinic. 
Vaccination 
card or 
medical record 
1-mOR*100 from logistic 
regression adjusting for 
sex, medical history, 
attendance at day care, 
maternal breast feeding, 
maternal education, 
attendance at preschool 
and household size 
Carvalho-
Costa et al. 
2009 
Brazil (Rio de 
Janeiro) 
2006 (National 
immunisation 
programme) 
58% 
(control 
group) 
February 
2005 to 
December 
2007 
A paediatric 
hospital 
Hospitalisation 
for RVGE 
Children<60 months of 
age with AGE and 
dehydration requiring IV 
fluid replacement with 
laboratory (+) RV 
Children<60 months of age with AGE and 
dehydration requiring IV fluid replacement 
with laboratory (-) RV 
Unknown 1-OR*100 (crude OR 
calculated by review 
team) 
Castilla et 
al. 2012 
Spain 
(Navarre) 
2006 (privately 
available) 
18% 
(control 
group) 
January 
2008- June 
2011 
Health 
service 
database 
RVGE or AGE 
health care 
contact or 
Hospitalisation 
Children with AGE aged 
3-59 months with 
laboratory (+) RV 
Children with AGE aged 3-59 months with 
laboratory (-) RV 
Immunisation 
registry 
1-OR*100, adjusting for 
age group, sex, birth year, 
major chronic conditions, 
health care setting and 
area 
Correia et 
al. 2010 
Brazil 2006 (National 
immunisation 
programme) 
>50% March 2006 
- September 
2008 
A paediatric 
hospital 
Hospitalisation 
or ED visit for 
RVGE 
Children under 60 
months of age  with 
severe diarrhoea defined 
as treatment with IV fluid 
replacement with 
laboratory (+) RV 
Two groups 
1) Children under 60 months of age  with 
severe diarrhoea defined as treatment with IV 
fluid replacement with laboratory (-) RV. 
2) Children hospitalised with ARI 
Vaccination 
card 
1-OR *100 unconditional 
logistic regression 
adjusting for month and 
year of birth 
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Cortese et 
al. 2011 
USA 
(Minnesota, 
Georgia and 
Connecticut) 
2006 In controls 
41-63% fully 
vaccinated 
December 
2006 – June 
2007, 
December 
2007- June 
2008, 
December 
2008 - June 
2009 
5 Hospitals Hospitalisation 
or ED visit for 
RVGE 
Children 56days and 
older with AGE 
laboratory (+) RV 
Two groups:  
1) Children with AGE with laboratory (-) RV. 
2) Matched controls from Immunisation 
registry. Matched on Zip code and birth date 
Hospital 
providers or 
immunisation 
registry 
1-OR*100 adjusting for 
site, season and birth 
quarter. Exact 
unconditional logistic 
regression 
Cortese et 
al. 2013 
USA (Georgia 
and 
Connecticut) 
2006 In controls 
72% fully 
vaccinated 
with RV1 
January 
2010-June 
2010 and 
January 
2011-June 
2011 
5 Hospitals Hospitalisation 
or ED visit for 
RVGE 
Children >7 months of 
age with AGE laboratory 
(+) RV 
Two groups:  
1) Children with AGE with laboratory (-) RV. 
2) Matched controls from Immunisation 
registry. Matched on Zip code and birth date 
Hospital 
providers or 
immunisation 
registry 
1-OR*100 adjusting for 
site, season and birth 
quarter. Exact 
unconditional logistic 
regression 
Cotes-
Cantillo et 
al. 2014 
Colombia 2009 
(Expanded 
programme of 
immunisation) 
>90% January 
2009 - 
January 
2011 
Health 
centres 
with EDs in 
six cities 
Hospitalisation 
or ED visit for 
RVGE 
Children aged <60 
months with diarrhoea 
and laboratory (+) RV. 
Children aged <60 months with diarrhoea and 
laboratory (-) RV. 
Vaccination 
card 
1-OR*100 adjusting for 
age and birth quarter, 
dehydration, and vomit. 
Unconditional logistic 
regression 
de Palma 
et al. 2010 
El Salvador 2006 In controls 
85%  
Jan 2007 to 
June 2009 
Seven 
hospitals 
based in 
cities 
Hospitalisation 
for RVGE 
Children under 60 
months of age  with 
dehydration with 
laboratory (+) RV 
For each case three controls from the  
community were matched on case date of 
birth  
Vaccination 
card or 
vaccination 
registry 
1-OR *100 conditional 
logistic regression 
adjusting for sex, medical 
history, attendance at day 
care, maternal breast 
feeding and SES 
Desai et al. 
2010 
USA 
(Connecticut) 
2006 In controls 
30%  
March 2006 
- July 2009 
A paediatric 
hospital 
Hospitalisation 
for RVGE 
Children 8 weeks to 3 
years of age  with 
laboratory (+) RV 
Two group 2 matched controls per group: 
1) Hospitalised children with AGE (-) RV or 
hospitalised for non-AGE. Matched on date of 
birth and date of hospitalisation. 
2) Non-hospitalised children registered at the 
same medical centre as case. Also matched 
for date of birth. 
Medical 
records 
1-mOR*100 from logistic 
regression adjusting for 
sex, race, ethnicity, day-
care attendance, breast 
feeding, chronic illness, 
premature birth, income 
and tobacco exposure. 
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Donauer et 
al. 2013 
USA 
(Rochester, 
Cincinnati, 
Nashville) 
2006 74% (≥ 1 
dose) 
December 
2006 – June 
2007 and 
December 
2007- June 
2008 
Prospective 
active 
population 
based 
surveillance 
at 3 sites 
Hospitalisation 
or ED visit for 
RVGE 
Lab-confirmed rotavirus 
in children < 3 years 
Three groups:  
1) Representative sub-cohort of children 
registered with primary care practices.  
2) Children with AGE negative for RV; 
3) Children with acute respiratory infection.  
(2&3 at same institutions as cases and 
matched by date of birth) 
Immunisation 
records, 
immunisation 
registries and 
review of 
medical charts 
(1) 1-HR*100 adjusted for 
DOB, insurance status, 
breast feeding and days 
spent at risk; (2&3) 1-
OR*100, adjusted for age, 
breastfeeding, insurance 
status and site 
Guh et al. 
2011 
USA 
(Connecticut) 
2006 In controls 
22% at least 
partially 
vaccinated  
July 2006-
December 
2008 
2 Paediatric 
specialty 
hospitals 
Hospitalisation 
for RVGE 
All infants aged ≥ 2 
months but < 3 years 
with laboratory (+) RV  
No hospitalisation for RV in study period. 
Matched by birth date and residence  
Connecticut 
immunisation 
registry and 
tracking 
system  
1-mOR*100 conditional 
logistic regression 
Ichihara et 
al. 2014 
Brazil  2006 (National 
immunisation 
programme) 
In controls 
90% at least 
partially 
vaccinated 
July 2008-
August 2011 
National RV 
Acute 
Diarrhoea 
Surveillance 
System 
Hospitalisation 
for RVGE 
Children aged 4-24 
months admitted with 
acute diarrhoea and (+) 
RV. Hospital stay at least 
24 hours and first 
hospitalisations only. 
Hospital controls recruited from same 
hospital as cases.  No previous history RV-A 
diarrhoea and no vaccine preventable 
disease.  Frequency matched for age and sex.   
Vaccination 
card 
1-OR*100, adjusting for 
sex and age, year of birth 
and robust variance 
estimation of Jackknife, 
with clusters being 
hospitals 
Justino et 
al. 2011 
Brazil 
(Belém) 
2006 (National 
immunisation 
programme) 
85% 
partially 
vaccinated 
(Community 
controls) 
May 2008-
May 2009 
Active 
surveillance 
at 4 large 
paediatric 
hospitals 
Hospitalisation 
for RVGE 
Children at least 12 
weeks of age hospitalised 
with lab-confirmed 
severe RVGE 
Two groups: 
1Community and 1 hospital control without 
gastroenteritis per case.  Matched by birth 
date. 
Vaccination 
card 
1-OR*100,adjusting for 
potential confounders 
including recruitment 
period, underlying medical 
conditions, diet and 
breastfeeding) 
Martinon-
Torres et 
al. 2011 
Spain (not 
reimbursed) 
2008 40% October 
2008-June 
2009 
Paediatric 
research 
network 
including 
primary, ED 
and 
hospital 
settings 
Any episode of 
RVGE and 
hospitalisation 
for RVGE 
Children under 2 years 
seeking care due to AGE 
with laboratory (+) RV 
Children with AGE with laboratory (-) RV Vaccination 
record 
1-OR*100 (crude) 
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Mast et al. 
2011 
Nicaragua 2006 (National 
immunisation 
programme) 
92% 
partially 
vaccinated 
(Community 
controls) 
February 
2007-
October 
2009 
Prospective 
active RV 
surveillance 
programme 
at 6 
hospital 
sites 
Hospitalisation 
or ED visit for 
RVGE 
Severe (Vesikari score ≥ 
11) wild type RVGE in 
children under 5 years 
Two groups 
1) Community controls, age and residence 
matched. 
2) Hospital controls, acute non-diarrhoeal 
infectious disease, age-matched 
Child health 
cards, health 
centre records 
if cards not 
available 
1-OR*100, Final model 
adjusted for income, 
potential confounders 
included in univariate 
analysis included maternal 
education, gender, 
Maternal employment; 
mothers age, income, 
breastfeeding birth 
weight, premature. 
Muhsen et 
al. 2011 
Israel 2007 (partial 
reimbursement 
offered) 
In controls 
36% at least 
partially 
vaccinated 
November 
2007-
December 
2009 
Active 
surveillance 
at 3 
hospitals in 
Northern 
Israel 
Hospitalisation 
for RVGE 
Children born August 
2007 or later hospitalised 
with laboratory (+) RV 
Children hospitalised with diarrhoea with 
laboratory (-) RV 
Parents’ report 1-OR*100, adjusting for 
season, age, hospital, 
socio-economic status, 
birth year and month 
Patel et al. 
2009 
Nicaragua 2006 In controls 
88% were 
at least 
partially 
vaccinated. 
2007-2008 4 hospitals 
in 
Nicaragua 
RVGE requiring 
overnight 
admission 
(other outcome 
measures 
included but 
not reported 
here) 
Children age-eligible to 
receive RV5 who were 
admitted with diarrhoea 
and laboratory (+) RV 
Two groups: 
1) Community - homes to left and right of 
case visited until 3 age matched controls 
identified 
2) Hospital - children seeking care at ED or 
outpatient clinic, unrelated to diarrhoea or 
vaccine preventable illness, and matched to 
DOB within 30 days. 
Obtained from 
parent and 
considered 
confirmed if 
vaccination 
card or clinic 
records 
completed. 
VE = 1 –mOR x 100 
Unadjusted findings 
presented, as adjusting for 
potential confounders did 
not change results 
Confounders tested 
included gender, 
underlying chronic illness, 
breastfeeding, day-care 
attendance, maternal 
education, no. of children, 
household size and 
socioeconomic status 
required to change 
estimate by more than 
10%. 
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Patel et al. 
2012 
Nicaragua 2006 <1 Year 79% 
average had 
1 dose over 
period of 
study.  
35% 
average had 
1 dose over 
period of 
study 
2007-2010 4 
community 
hospitals in 
Nicaragua 
Hospitalisation 
with diarrhoea, 
laboratory (+) 
RV (other 
outcomes e.g. 
IV hydration – 
not reported 
here) 
Children age-eligible to 
receive RV5 vaccine 
presenting with acute 
diarrhoea laboratory (+) 
RV. 
Three groups: 
1) Non-diarrhoea controls – matched to case’s 
DOB from 2 sources – hospital and 
community. Hospital -were seeking care at ED 
or clinic or admitted to same hospital as the 
case, with an illness unrelated to diarrhoea or 
a vaccine preventable condition.  
2) Community controls were found by visiting 
homes to left and right of case home until 3 
controls identified. 
3) Children hospitalised with diarrhoea 
laboratory (-) RV 
Obtained from 
parent and 
considered 
confirmed if 
vaccination 
card or clinic 
records 
completed. 
VE = 1-OR x 100 
VE calculations adjusted 
for month of birth, age at 
hospitalisation, and 
hospital. Confounders 
tested included gender, 
underlying chronic illness, 
breastfeeding, day-care 
attendance, maternal 
education, no. of children, 
household size and 
socioeconomic status 
required to change 
estimate by more than 
10%. 
Patel et al., 
2013 
Bolivia 2008 National 
coverage 
76% 2010, 
80% 2011 
March 2010 
– June 2011 
Six 
hospitals in 
Bolivia 
Hospitalisation 
with diarrhoea, 
laboratory (+) 
RV (other 
outcomes 
considered but 
not presented 
here). 
Children admitted 
overnight with acute 
diarrhoea testing positive 
for RV, eligible to receive 
at least one dose of RV1, 
Two groups: 
1) Hospital Controls – children admitted to 
same hospital for acute illness unrelated to 
diarrhoea or a vaccine preventable condition, 
eligible to receive at least 1 dose of RV1, with 
a DOB within 30 days of case. 
2) Children hospitalised with diarrhoea lab-
negative for RV 
Obtained from 
parent and 
considered 
confirmed if 
vaccination 
card or clinic 
records 
completed. 
1-adjusted OR x100 
non-diarrhoea controls 
matched on age and 
hospital, and adjusted for 
gender, number of 
children and rooms at 
home, a computer at 
home. Test negative 
controls adjusts for age in 
months, month/year of 
birth, gender, hospital, 
number of children and 
rooms in home, computer 
at home. 
Payne et 
al. 2013 
USA 2006 In controls 
fully 
vaccinated 
with: 
RV1 in 2010 
46%; 47% in 
2011: RV5 
53% in 2010 
and 63% in 
2011  
November 
2009 – June 
2011 
Range of 
surveillance 
hospital 
sites in 
USA. 
Rotavirus 
disease 
presenting to 
ED or requiring 
hospitalisation, 
age-eligible for 
vaccination. 
Children <5 years of age 
visiting ED or hospitalised 
with AGE laboratory (+) 
RV  
Those children enrolled in the study who 
were found to be laboratory (-) RV 
Contact with 
subject’s 
primary care 
provider and 
regional 
immunization 
systems. 
VE = (1-OR) x 100  
Presented stratified 
analysis across a range of 
factors. Adjusted for 
insurance status and 
clinical setting but results 
not presented. 
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Snelling et 
al. 2011 
Australia 2006 In controls 
72% fully 
vaccinated  
March – July 
2011 
Medical 
record 
review of 
all children 
admitted to 
Alice 
Springs 
hospital 
during an 
outbreak 
ICD10 codes for 
infectious 
gastroenteritis 
in medical 
records. 
Subgroup of 
those RVGE 
positive. 
All children aged <5 
admitted to Alice Springs 
Hospital with 
gastroenteritis during an 
outbreak, with ICD10 
codes for infectious 
gastroenteritis 
Retrospectively conducted matched controls 
from a record of central Australian births 
registered on hospital information database.  
Vaccination 
determined 
from central 
immunisation 
database. 
VE = 1-OR x 100 (Cases 
and controls matched for 
indigenous status and 
date of birth (within 7 
days). Adjusted for remote 
residence. 
Staat et al. 
2011 
USA 2006 In controls 
54% any 
dose 
2007-2009 
rotavirus 
seasons 
Prospective 
surveillance 
conducted 
in 3 US 
counties as 
part of New 
Vaccine 
Surveillance 
Network 
Hospitalisations 
and ED visits 
for RVGE in 
children 
attending the 
surveillance 
hospitals 
during the 
rotavirus 
seasons. 
All children attending the 
ED or hospitalised with 
AGE with laboratory (+) 
RV 
Two groups: 
1) Children with AGE with laboratory (-) RV. 
2) ARI controls: children with ARI symptoms 
who were residents of same study county. 
Parents 
documentation 
of vaccination. 
If not available, 
obtained from 
state registries. 
VE = (1-OR) x 100 
Cases were matched to 
controls according to DOB 
and symptom onset date. 
Adjusted for insurance 
status and clinical setting. 
VE= vaccine effectiveness; RVGE=rotavirus gastroenteritis; AGE=acute gastroenteritis; RR= relative risks / risk ratios; IRR=incidence rate ratio; ARI= acute respiratory infection; ED= 
emergency department; (+) RV =  laboratory confirmed positive rotavirus; (-) RV =  laboratory confirmed negative rotavirus; mOR = matched Odds Ratio; DTaP = diphtheria, tetanus, acellular 
polio; RV1= Rotarix vaccine; RV5= RotaTeq vaccine; HR= Hazard rate ratio
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Table S3 Yearly rates of hospitalisation/attendance for different levels of the health system pre- and post-rotavirus vaccine introduction 
in Merseyside, UK. 
 
Age group 
Yearly rate of hospitalisation / attendance (per 10,000)¥ 
Pre-vaccine Introduction Post-vaccine introduction 
2000/01 2001/02 2002/03 2003/04 2004/05 2005/06 2006/07 2007/08 2008/09 2009/10 2010/11 2011/12 2012/13 2013/14 2014/15 2015/16 
Hospitalisations for laboratory confirmed rotavirus to Alder Hey 
<12m - - 158 168 148 182 85 123 85 113 125 130 168 16 23 4 
12-23m - - 159 118 145 157 88 140 97 130 136 112 102 30 19 0 
24-59m - - 44 36 30 48 28 42 25 33 23 26 40 5 17 7 
5-14y - - 7 6 5 8 6 9 8 9 11 6 6 1 1 0 
Total 0-59m - - 106 98 93 121 62 94 63 84 84 82 96 14 19 5 
Hospitalisations for all cause acute gastroenteritis 
<12m 351 322 312 353 285 387 563 577 492 580 363 298 328 249 222 220 
12-23m 251 227 233 231 209 259 335 343 295 404 244 227 254 138 124 123 
24-59m 68 63 68 55 58 63 98 94 91 98 63 51 63 42 67 53 
5-14y 14 13 12 13 13 17 25 25 25 28 22 16 20 18 19 22 
15-64y 30 27 27 25 29 32 44 49 45 46 48 53 55 56 61 63 
65+ 82 87 111 101 117 120 169 173 158 155 140 160 172 151 159 159 
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Age group 
Yearly rate of hospitalisation / attendance (per 10,000)¥ 
Pre-vaccine Introduction Post-vaccine introduction 
2000/01 2001/02 2002/03 2003/04 2004/05 2005/06 2006/07 2007/08 2008/09 2009/10 2010/11 2011/12 2012/13 2013/14 2014/15 2015/16 
Total 0-59m 156 143 147 148 135 169 243 247 217 260 161 137 158 103 109 100 
ED attendances for gastrointestinal conditions (no admission) 
<12m - - - - - - - - 1654 1889 2101 2280 2240 1959 2115 1610 
12-23m - - - - - - - - 978 1003 1102 1314 1340 942 1050 758 
24-59m - - - - - - - - 650 691 750 828 887 800 945 604 
5-14y - - - - - - - - 406 456 584 656 711 698 712 601 
15-64y - - - - - - - - 286 304 375 525 630 606 507 432 
65+ - - - - - - - - 237 278 350 404 521 545 443 366 
Total 0-59m - - - - - - - - 1022 1105 1239 1395 1425 1180 1332 948 
Walk-in centre attendances for infectious gastroenteritis* 
<12m - - - - - - - - - - - 604 580 369 378 371 
12-23m - - - - - - - - - - - 468 488 249 325 206 
24-59m - - - - - - - - - - - 209 184 144 176 143 
5-14y - - - - - - - - - - - 81 78 66 89 60 
15-64y - - - - - - - - - - - 56 56 45 52 54 
65+ - - - - - - - - - - - 15 29 16 20 19 
Total 0-59m - - - - - - - - - - - 380 361 223 262 211 
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Age group 
Yearly rate of hospitalisation / attendance (per 10,000)¥ 
Pre-vaccine Introduction Post-vaccine introduction 
2000/01 2001/02 2002/03 2003/04 2004/05 2005/06 2006/07 2007/08 2008/09 2009/10 2010/11 2011/12 2012/13 2013/14 2014/15 2015/16 
GP consultations for infectious gastroenteritis 
<12m - - - - - - - 712 678 677 697 625 658 452 524 500 
12-23m - - - - - - - 692 567 652 500 558 582 335 488 429 
24-59m - - - - - - - 183 187 209 178 164 182 125 209 164 
5-14y - - - - - - - 56 49 55 56 50 52 46 62 60 
15-64y - - - - - - - 43 37 41 41 40 41 28 36 26 
65+ - - - - - - - 30 30 35 34 36 44 28 33 26 
Total 0-59m - - - - - - - 391 361 391 346 335 357 232 328 284 
